Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017

 

 Permissions and Reprints

Abstract

Therapeutic drug monitoring (TDM) is the quantification and interpretation of drug concentrations in blood to optimize pharmacotherapy. It considers the interindividual variability of pharmacokinetics and thus enables personalized pharmacotherapy. In psychiatry and neurology, patient populations that may particularly benefit from TDM are children and adolescents, pregnant women, elderly patients, individuals with intellectual disabilities, patients with substance abuse disorders, forensic psychiatric patients or patients with known or suspected pharmacokinetic abnormalities. Non-response at therapeutic doses, uncertain drug adherence, suboptimal tolerability, or pharmacokinetic drug-drug interactions are typical indications for TDM. However, the potential benefits of TDM to optimize pharmacotherapy can only be obtained if the method is adequately integrated in the clinical treatment process. To supply treating physicians and laboratories with valid information on TDM, the TDM task force of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP) issued their first guidelines for TDM in psychiatry in 2004. After an update in 2011, it was time for the next update. Following the new guidelines holds the potential to improve neuropsychopharmacotherapy, accelerate the recovery of many patients, and reduce health care costs.

• References

• 1 Abanades S, van der Aart J, Barletta JA. et al. Prediction of repeat-dose occupancy from single-dose data: Characterisation of the relationship between plasma pharmacokinetics and brain target occupancy. J Cereb Blood Flow Metab 2011; 31: 944-952
  CrossrefPubMedGoogle Scholar
• 2 Abdelbary A, Bendas ER, Ramadan AA. et al. Pharmaceutical and pharmacokinetic evaluation of a novel fast dissolving film formulation of flupentixol dihydrochloride. AAPS PharmSciTech 2014; 15: 1603-1610
  CrossrefPubMedGoogle Scholar
• 3 Abernethy DR, Greenblatt DJ, Shader RI. Imipramine and desipramine disposition in the elderly. J Pharmacol Exp Ther 1985; 232: 183-188
  PubMedGoogle Scholar
• 4 Adam K, Oswald I. Effects of lormetazepam and of flurazepam on sleep. Br J Clin Pharmacol 1984; 17: 531-538
  CrossrefPubMedGoogle Scholar
• 5 Adamiak U, Kaldonska M, Klodowska-Duda G. et al. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease. Clin Neuropharmacol 2010; 33: 135-141
  CrossrefPubMedGoogle Scholar
• 6 Addington D. Best practices: Improving quality of care for patients with first-episode psychosis. Psychiatr Serv 2009; 60: 1164-1166
  CrossrefPubMedGoogle Scholar
• 7 Adjei A, Teuscher NS, Kupper RJ. et al. Single-dose pharmacokinetics of methylphenidate extended-release multiple layer beads administered as intact capsule or sprinkles versus methylphenidate immediate-release tablets (Ritalin((R))) in healthy adult volunteers. J Child Adolesc Psychopharmacol 2014; 24: 570-578
  CrossrefPubMedGoogle Scholar
• 8 Adli M, Baethge C, Heinz A. et al. Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review. Eur Arch Psychiatry Clin Neurosci 2005; 255: 387-400
  CrossrefPubMedGoogle Scholar
• 9 Aichhorn W, Marksteiner J, Walch T. et al. Influence of age, gender, body weight and valproate comedication on quetiapine plasma concentrations. Int Clin Psychopharmacol 2006; 21: 81-85
  CrossrefPubMedGoogle Scholar
• 10 Aichhorn W, Weiss U, Marksteiner J. et al. Influence of age and gender on risperidone plasma concentrations. J Psychopharmacol 2005; 19: 395-401
  CrossrefPubMedGoogle Scholar
• 11 Aichhorn W, Whitworth AB, Weiss EM. et al. Second-generation antipsychotics: Is there evidence for sex differences in pharmacokinetic and adverse effect profiles?. Drug Saf 2006; 29: 587-598
  CrossrefPubMedGoogle Scholar
• 12 Akamine Y, Uehara H, Miura M. et al. Multiple inductive effects of carbamazepine on combined therapy with paliperidone and amlodipine. J Clin Pharm Ther 2015; 40: 480-482
  CrossrefPubMedGoogle Scholar
• 13 Akerblad AC, Bengtsson F, Ekselius L. et al. Effects of an educational compliance enhancement programme and therapeutic drug monitoring on treatment adherence in depressed patients managed by general practitioners. Int Clin Psychopharmacol 2003; 18: 347-354
  CrossrefPubMedGoogle Scholar
• 14 Akerblad AC, Bengtsson F, Holgersson M. et al. Identification of primary care patients at risk of nonadherence to antidepressant treatment. Patient Prefer Adherence 2008; 2: 379-386
  PubMedGoogle Scholar
• 15 Aklillu E, Djordjevic N, Carrillo JA. et al. High CYP2A6 enzyme activity as measured by a caffeine test and unique distribution of CYP2A6 variant alleles in Ethiopian population. OMICS 2014; 18: 446-453
  CrossrefPubMedGoogle Scholar
• 16 Aklillu E, Kalow W, Endrenyi L. et al. CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics 2007; 17: 989-993
  CrossrefPubMedGoogle Scholar
• 17 Akutsu T, Kobayashi K, Sakurada K. et al. Identification of human cytochrome p450 isozymes involved in diphenhydramine N-demethylation. Drug Metab Dispos 2007; 35: 72-78
  CrossrefPubMedGoogle Scholar
• 18 Al-Janabi I, Arranz MJ, Blakemore AI. et al. Association study of serotonergic gene variants with antipsychotic-induced adverse reactions. Psychiatr Genet 2009; 19: 305-311
  CrossrefPubMedGoogle Scholar
• 19 Al Hadithy AF, Ivanova SA, Pechlivanoglou P. et al. Tardive dyskinesia and DRD3, HTR2A and HTR2C gene polymorphisms in Russian psychiatric inpatients from Siberia. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33: 475-481
  CrossrefPubMedGoogle Scholar
• 20 Alderman J, Wolkow R, Fogel IM. Drug concentration monitoring with tolerability and efficacy assessments during open-label, long-term sertraline treatment of children and adolescents. J Child Adolesc Psychopharmacol 2006; 16: 117-129
  CrossrefPubMedGoogle Scholar
• 21 Alexanderson B. Prediction of steady-state plasma levels of nortriptyline from single oral dose kinetics: A study in twins. Eur J Clin Pharmacol 1973; 6: 44-53
  CrossrefPubMedGoogle Scholar
• 22 Allen MD, Greenblatt DJ, Harmatz JS. et al. Desmethyldiazepam kinetics in the elderly after oral prazepam. Clin Pharmacol Ther 1980; 28: 196-202
  CrossrefPubMedGoogle Scholar
• 23 Allen MH, Hirschfeld RM, Wozniak PJ. et al. Linear relationship of valproate serum concentration to response and optimal serum levels for acute mania. Am J Psychiatry 2006; 163: 272-275
  CrossrefPubMedGoogle Scholar
• 24 Allqvist A, Miura J, Bertilsson L. et al. Inhibition of CYP3A4 and CYP3A5 catalyzed metabolism of alprazolam and quinine by ketoconazole as racemate and four different enantiomers. Eur J Clin Pharmacol 2007; 63: 173-179
  CrossrefPubMedGoogle Scholar
• 25 Altamura AC, Moliterno D, Paletta S. et al. Effect of quetiapine and norquetiapine on anxiety and depression in major psychoses using a pharmacokinetic approach: A prospective observational study. Clin Drug Investig 2012; 32: 213-219
  CrossrefPubMedGoogle Scholar
• 26 Altamura AC, Moliterno D, Paletta S. et al. Understanding the pharmacokinetics of anxiolytic drugs. Expert Opin Drug Metab Toxicol 2013; 9: 423-440
  CrossrefPubMedGoogle Scholar
• 27 Altamura AC, Moro AR, Percudani M. Clinical pharmacokinetics of fluoxetine. Clin Pharmacokinet 1994; 26: 201-214
  CrossrefPubMedGoogle Scholar
• 28 Altamura AC, Sassella F, Santini A. et al. Intramuscular preparations of antipsychotics: uses and relevance in clinical practice. Drugs 2003; 63: 493-512
  CrossrefPubMedGoogle Scholar
• 29 Althaus M, Retzow A, Castell JV. et al. In vitro identification of the cytochrome P450 isoform responsible for the metabolism of alpha-dihydroergocryptine. Xenobiotica 2000; 30: 1033-1045
  CrossrefPubMedGoogle Scholar
• 30 Aman MG, Vinks AA, Remmerie B. et al. Plasma pharmacokinetic characteristics of risperidone and their relationship to saliva concentrations in children with psychiatric or neurodevelopmental disorders. Clin Ther 2007; 29: 1476-1486
  CrossrefPubMedGoogle Scholar
• 31 Amdisen A. Serum level monitoring and clinical pharmacokinetics of lithium. Clin Pharmacokinet 1977; 2: 73-92
  CrossrefPubMedGoogle Scholar
• 32 American Geriatrics Society Beers Criteria Update Expert P. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2012; 60: 616-631
  CrossrefPubMedGoogle Scholar
• 33 Anderson D, Reed S, Lintemoot J. et al. A first look at duloxetine (Cymbalta) in a postmortem laboratory. J Anal Toxicol 2006; 30: 576-580
  CrossrefPubMedGoogle Scholar
• 34 Anderson GD. Pharmacogenetics and enzyme induction/inhibition properties of antiepileptic drugs. Neurology 2004; 63: S3-S8
  PubMedGoogle Scholar
• 35 Anderson IM, Ferrier IN, Baldwin RC. et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol 2008; 22: 343-396
  CrossrefPubMedGoogle Scholar
• 36 Ansermot N, Albayrak O, Schlapfer J. et al. Substitution of (R,S)-methadone by (R)-methadone: Impact on QTc interval. Arch Intern Med 2010; 170: 529-536
  CrossrefPubMedGoogle Scholar
• 37 Ansermot N, Brawand-Amey M, Eap CB. Simultaneous quantification of selective serotonin reuptake inhibitors and metabolites in human plasma by liquid chromatography-electrospray mass spectrometry for therapeutic drug monitoring. J Chromatogr B Analyt Technol Biomed Life Sci 2012; 885-886: 117-130
  CrossrefPubMedGoogle Scholar
• 38 Aoki FY, Sitar DS. Clinical pharmacokinetics of amantadine hydrochloride. Clin Pharmacokinet 1988; 14: 35-51
  CrossrefPubMedGoogle Scholar
• 39 Aps JK, Martens LC. Review: The physiology of saliva and transfer of drugs into saliva. Forensic Sci Int 2005; 150: 119-131
  CrossrefPubMedGoogle Scholar
• 40 Arakawa R, Ito H, Takano A. et al. Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia. Psychopharmacology (Berl) 2008; 197: 229-235
  CrossrefPubMedGoogle Scholar
• 41 Arango C, Bombin I, Gonzalez-Salvador T. et al. Randomised clinical trial comparing oral versus depot formulations of zuclopenthixol in patients with schizophrenia and previous violence. Eur Psychiatry 2006; 21: 34-40
  CrossrefPubMedGoogle Scholar
• 42 Aravagiri M, Marder SR, Yuwiler A. et al. Distribution of fluphenazine and its metabolites in brain regions and other tissues of the rat. Neuropsychopharmacology 1995; 13: 235-247
  CrossrefPubMedGoogle Scholar
• 43 Aravagiri M, Teper Y, Marder SR. Pharmacokinetics and tissue distribution of olanzapine in rats. Biopharm Drug Dispos 1999; 20: 369-377
  CrossrefPubMedGoogle Scholar
• 44 Aravagiri M, Yuwiler A, Marder SR. Distribution after repeated oral administration of different dose levels of risperidone and 9-hydroxy-risperidone in the brain and other tissues of rat. Psychopharmacology (Berl) 1998; 139: 356-363
  CrossrefPubMedGoogle Scholar
• 45 Arbus C, Benyamina A, Llorca PM. et al. Characterization of human cytochrome P450 enzymes involved in the metabolism of cyamemazine. Eur J Pharm Sci 2007; 32: 357-366
  CrossrefPubMedGoogle Scholar
• 46 Areberg J, Luntang-Jensen M, Sogaard B. et al. Occupancy of the serotonin transporter after administration of Lu AA21004 and its relation to plasma concentration in healthy subjects. Basic Clin Pharmacol Toxicol 2012; 110: 401-404
  CrossrefPubMedGoogle Scholar
• 47 Areberg J, Petersen KB, Chen G. et al. Population pharmacokinetic meta-analysis of vortioxetine in healthy individuals. Basic Clin Pharmacol Toxicol 2014; 115: 552-559
  CrossrefPubMedGoogle Scholar
• 48 Armijo JA, Cuadrado A, Bravo J. et al. Vigabatrin serum concentration to dosage ratio: Influence of age and associated antiepileptic drugs. Ther Drug Monit 1997; 19: 491-498
  CrossrefPubMedGoogle Scholar
• 49 Aronson JK. Compliance, concordance, adherence. Br J Clin Pharmacol 2007; 63: 383-384
  CrossrefPubMedGoogle Scholar
• 50 Aronson JK, Ferner RE. The law of mass action and the pharmacological concentration-effect curve: Resolving the paradox of apparently non-dose-related adverse drug reactions. Br J Clin Pharmacol 2016; 81: 56-61
  CrossrefPubMedGoogle Scholar
• 51 Asberg M, Cronholm B, Sjoqvist F. et al. Correlation of subjective side effects with plasma concentrations of nortriptyline. Br Med J 1970; 4: 18-21
  CrossrefPubMedGoogle Scholar
• 52 Asberg M, Cronholm B, Sjoqvist F. et al. Relationship between plasma level and therapeutic effect of nortriptyline. Br Med J 1971; 3: 331-334
  CrossrefPubMedGoogle Scholar
• 53 Ashby M, Fleming B, Wood M. et al. Plasma morphine and glucuronide (M3G and M6G) concentrations in hospice inpatients. J Pain Symptom Manage 1997; 14: 157-167
  CrossrefPubMedGoogle Scholar
• 54 Athanasoulia AP, Sievers C, Ising M. et al. Polymorphisms of the drug transporter gene ABCB1 predict side effects of treatment with cabergoline in patients with PRL adenomas. Eur J Endocrinol 2012; 167: 327-335
  CrossrefPubMedGoogle Scholar
• 55 Bach MV, Coutts RT, Baker GB. Involvement of CYP2D6 in the in vitro metabolism of amphetamine, two N-alkylamphetamines and their 4-methoxylated derivatives. Xenobiotica 1999; 29: 719-732
  CrossrefPubMedGoogle Scholar
• 56 Bachmann CJ, Haberhausen M, Heinzel-Gutenbrunner M. et al. Large intraindividual variability of olanzapine serum concentrations in adolescent patients. Ther Drug Monit 2008; 30: 108-112
  CrossrefPubMedGoogle Scholar
• 57 Bachmann CJ, Rieger-Gies A, Heinzel-Gutenbrunner M. et al. Large variability of aripiprazole and dehydroaripiprazole serum concentrations in adolescent patients with schizophrenia. Ther Drug Monit 2008; 30: 462-466
  PubMedGoogle Scholar
• 58 Bachus R, Bickel U, Thomsen T. et al. The O-demethylation of the antidementia drug galanthamine is catalysed by cytochrome P450 2D6. Pharmacogenetics 1999; 9: 661-668
  CrossrefPubMedGoogle Scholar
• 59 Backman JT, Filppula AM, Niemi M. et al. Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions. Pharmacol Rev 2016; 68: 168-241
  CrossrefPubMedGoogle Scholar
• 60 Backman JT, Olkkola KT, Ojala M. et al. Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin. Epilepsia 1996; 37: 253-257
  CrossrefPubMedGoogle Scholar
• 61 Bagli M, Hoflich G, Rao ML. et al. Bioequivalence and absolute bioavailability of oblong and coated levomepromazine tablets in CYP2D6 phenotyped subjects. Int J. Clin Pharmacol Ther 1995; 33: 646-652
  PubMedGoogle Scholar
• 62 Bagli M, Rao ML, Hoflich G. et al. Pharmacokinetics of chlorprothixene after single intravenous and oral administration of three galenic preparations. Arzneimittelforschung 1996; 46: 247-250
  PubMedGoogle Scholar
• 63 Baird-Bellaire S, Behrle JA, Parker VD. et al. An open-label, single-dose, parallel-group study of the effects of chronic hepatic impairment on the safety and pharmacokinetics of desvenlafaxine. Clin Ther 2013; 35: 782-794
  CrossrefPubMedGoogle Scholar
• 64 Baker GB, Urichuk LJ, McKenna KF. et al. Metabolism of monoamine oxidase inhibitors. Cell Mol Neurobiol 1999; 19: 411-426
  CrossrefPubMedGoogle Scholar
• 65 Bakken GV, Rudberg I, Christensen H. et al. Metabolism of quetiapine by CYP3A4 and CYP3A5 in presence or absence of cytochrome B5. Drug Metab Dispos 2009; 37: 254-258
  CrossrefPubMedGoogle Scholar
• 66 Bakken GV, Rudberg I, Molden E. et al. Pharmacokinetic variability of quetiapine and the active metabolite N-desalkylquetiapine in psychiatric patients. Ther Drug Monit 2011; 33: 222-226
  PubMedGoogle Scholar
• 67 Balant-Gorgia AE, Eisele R, Aeschlimann JM. et al. Plasma flupentixol concentrations and clinical response in acute schizophrenia. Ther Drug Monit 1985; 7: 411-414
  CrossrefPubMedGoogle Scholar
• 68 Balant LP, Balant-Gorgia AE, Eisele R. et al. Clinical and pharmacokinetic evaluation of zuclopenthixol acetate in Viscoleo. Pharmacopsychiatry 1989; 22: 250-254
  Article in Thieme ConnectPubMedGoogle Scholar
• 69 Baldinger P, Kranz GS, Haeusler D. et al. Regional differences in SERT occupancy after acute and prolonged SSRI intake investigated by brain PET. Neuroimage 2014; 88: 252-262
  CrossrefPubMedGoogle Scholar
• 70 Barbhaiya RH, Shukla UA, Pfeffer M. et al. Disposition kinetics of buspirone in patients with renal or hepatic impairment after administration of single and multiple doses. Eur J Clin Pharmacol 1994; 46: 41-47
  PubMedGoogle Scholar
• 71 Bareggi SR, Bianchi L, Cavallaro R. et al. Citalopram concentrations and response in obsessive-compulsive disorder. Preliminary results. CNS Drugs 2004; 18: 329-335
  CrossrefPubMedGoogle Scholar
• 72 Barry M, Mulcahy F, Merry C. et al. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Clin Pharmacokinet 1999; 36: 289-304
  CrossrefPubMedGoogle Scholar
• 73 Barski OA, Tipparaju SM, Bhatnagar A. The aldo-keto reductase superfamily and its role in drug metabolism and detoxification. Drug Metab Rev 2008; 40: 553-624
  CrossrefPubMedGoogle Scholar
• 74 Baruzzi A, Bordo B, Bossi L. et al. Plasma levels of di-no-propylacetate and clonazepam in epileptic patients. Int J Clin Pharmacol Biopharm 1977; 15: 403-408
  PubMedGoogle Scholar
• 75 Bates DW, Gawande AA. Improving safety with information technology. N Engl J Med 2003; 348: 2526-2534
  CrossrefPubMedGoogle Scholar
• 76 Batty KT, Davis TM, Ilett KF. et al. The effect of ciprofloxacin on theophylline pharmacokinetics in healthy subjects. Br J Clin Pharmacol 1995; 39: 305-311
  CrossrefPubMedGoogle Scholar
• 77 Bauer LA. Applied Clinical Pharmacokinetics. 3rd ed. New York: McGraw-Hill Education; 2014
  Google Scholar
• 78 Bauer S, David Rudd G, Mylius V. et al. Lacosamide intoxication in attempted suicide. Epilepsy Behav 2010; 17: 549-551
  CrossrefPubMedGoogle Scholar
• 79 Baumann P. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet 1996; 31: 444-469
  CrossrefPubMedGoogle Scholar
• 80 Baumann P, Barbe R, Vabre-Bogdalova A. et al. Epileptiform seizure after sertraline treatment in an adolescent experiencing obsessive-compulsive disorder and presenting a rare pharmacogenetic status. J Clin Psychopharmacol 2006; 26: 679-681
  CrossrefPubMedGoogle Scholar
• 81 Baumann P, Hiemke C. Central nervous system drugs.In: Metabolism of drugs and other xenobiotics. 1st ed. Anzenbacher P, Zanger UM. (eds)Wiley-VCH; 2012: Chapter 11: 301–329
  PubMed
• 82 Baumann P, Hiemke C, Ulrich S. et al. The AGNP-TDM expert group consensus guidelines: Therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 2004; 37: 243-265
  Article in Thieme ConnectPubMedGoogle Scholar
• 83 Baumann P, Kirchherr H, Berney P. et al. Flupentixol: Relevance of stereoselective therapeutic drug monitoring. Psychopharmacology (Berl) 2012; 221: 719-720
  CrossrefPubMedGoogle Scholar
• 84 Baumann P, Meyer JW, Amey M. et al. Dextromethorphan and mephenytoin phenotyping of patients treated with thioridazine or amitriptyline. Ther Drug Monit 1992; 14: 1-8
  CrossrefPubMedGoogle Scholar
• 85 Baumann P, Rougemont M, Corruble E. et al. Recommendations for therapeutic monitoring of antidepressants. Rev Med Suisse 2013; 9: 577-586
  PubMedGoogle Scholar
• 86 Baumann P, Spies M, Moller HJ. et al. A proposal for a psychopharmacology-pharmacotherapy catalogue of learning objectives and a curriculum in Europe. World J Biol Psychiatry 2017; 18: 29-38
  CrossrefPubMedGoogle Scholar
• 87 Baumann P, Tinguely D, Koeb L. et al. On the relationship between free plasma and saliva amitriptyline and nortriptyline. Int Pharmacopsychiatry 1982; 17: 136-146
  CrossrefPubMedGoogle Scholar
• 88 Baumann P, Zullino DF, Eap CB. Enantiomers’ potential in psychopharmacology–a critical analysis with special emphasis on the antidepressant escitalopram. Eur Neuropsychopharmacol 2002; 12: 433-444
  PubMedGoogle Scholar
• 89 Bazire S. Psychotropic Drug Directory. 2016. Aberdeen: Lloyd-Reinhold Publications Ltd;
  Google Scholar
• 90 Beasley Jr. CM, Stauffer VL, Liu-Seifert H. et al. All-cause treatment discontinuation in schizophrenia during treatment with olanzapine relative to other antipsychotics: An integrated analysis. J Clin Psychopharmacol 2007; 27: 252-258
  CrossrefPubMedGoogle Scholar
• 91 Bech P, Gex-Fabry M, Aubry JM. et al. Olanzapine plasma level in relation to antimanic effect in the acute therapy of manic states. Nord J Psychiatry 2006; 60: 181-182
  CrossrefPubMedGoogle Scholar
• 92 Becquemont L, Mouajjah S, Escaffre O. et al. Cytochrome P-450 3A4 and 2C8 are involved in zopiclone metabolism. Drug Metab Dispos 1999; 27: 1068-1073
  PubMedGoogle Scholar
• 93 Beedham C, Miceli JJ, Obach RS. Ziprasidone metabolism, aldehyde oxidase, and clinical implications. J Clin Psychopharmacol 2003; 23: 229-232
  PubMedGoogle Scholar
• 94 Benedetti MS, Whomsley R, Poggesi I. et al. Drug metabolism and pharmacokinetics. Drug Metab Rev 2009; 41: 344-390
  CrossrefPubMedGoogle Scholar
• 95 Benetton SA, Fang C, Yang YO. et al. P450 phenotyping of the metabolism of selegiline to desmethylselegiline and methamphetamine. Drug Metab Pharmacokinet 2007; 22: 78-87
  CrossrefPubMedGoogle Scholar
• 96 Bengtsson F. Therapeutic drug monitoring of psychotropic drugs. TDM "nouveau”. Ther Drug Monit 2004; 26: 145-151
  CrossrefPubMedGoogle Scholar
• 97 Bennett Jr. JP, Piercey MF. Pramipexole–a new dopamine agonist for the treatment of Parkinson’s disease. J Neurol Sci 1999; 163: 25-31
  CrossrefPubMedGoogle Scholar
• 98 Bentue-Ferrer D, Tribut O, Verdier MC. Therapeutic drug monitoring of ethosuximide. Therapie 2012; 67: 391-396
  CrossrefPubMedGoogle Scholar
• 99 Bentue-Ferrer D, Tribut O, Verdier MC. Therapeutic drug monitoring of lacosamide. Therapie 2012; 67: 151-155
  CrossrefPubMedGoogle Scholar
• 100 Bentue-Ferrer D, Tribut O, Verdier MC. Therapeutic drug monitoring of rufinamide. Therapie 2012; 67: 161-165
  CrossrefPubMedGoogle Scholar
• 101 Bergemann N, Frick A, Parzer P. et al. Olanzapine plasma concentration, average daily dose, and interaction with co-medication in schizophrenic patients. Pharmacopsychiatry 2004; 37: 63-68
  Article in Thieme ConnectPubMedGoogle Scholar
• 102 Bergemann N, Kopitz J, Kress KR. et al. Plasma amisulpride levels in schizophrenia or schizoaffective disorder. Eur Neuropsychopharmacol 2004; 14: 245-250
  CrossrefPubMedGoogle Scholar
• 103 Bergemann N, Rommel F, Conca A. Therapeutisches drug-monitoring von psychopharmaka in der schwangerschaft. J Neurol Neurochir Psychiatr 2009; 10: 38-40
  PubMedGoogle Scholar
• 104 Bergen AW, Michel M, Nishita D. et al. Drug metabolizing enzyme and transporter gene variation, nicotine metabolism, prospective abstinence, and cigarette consumption. PLoS One 2015; 10: e0126113
  CrossrefPubMedGoogle Scholar
• 105 Bergmann TK, Bathum L, Brosen K. Duplication of CYP2D6 predicts high clearance of desipramine but high clearance does not predict duplication of CYP2D6. Eur J Clin Pharmacol 2001; 57: 123-127
  CrossrefPubMedGoogle Scholar
• 106 Bergstrom RF, Cerimele BJ. Olanzapine in subjects with and without renal failure (data on file). Lilly Laboratory for Clinical Research. Eli Lilly and Co; 1996
  Google Scholar
• 107 Berry D, Millington C. Analysis of pregabalin at therapeutic concentrations in human plasma/serum by reversed-phase HPLC. Ther Drug Monit 2005; 27: 451-456
  CrossrefPubMedGoogle Scholar
• 108 Bertelsen KM, Venkatakrishnan K, Von Moltke LL. et al. Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. Drug Metab Dispos 2003; 31: 289-293
  CrossrefPubMedGoogle Scholar
• 109 Bertilsson L, Tomson T, Tybring G. Pharmacokinetics: Time-dependent changes--autoinduction of carbamazepine epoxidation. J Clin Pharmacol 1986; 26: 459-462
  CrossrefPubMedGoogle Scholar
• 110 Berwaerts J, Cleton A, Rossenu S. et al. A comparison of serum prolactin concentrations after administration of paliperidone extended-release and risperidone tablets in patients with schizophrenia. J Psychopharmacol 2010; 24: 1011-1018
  CrossrefPubMedGoogle Scholar
• 111 Bet PM, Verbeek EC, Milaneschi Y. et al. A common polymorphism in the ABCB1 gene is associated with side effects of PGP-dependent antidepressants in a large naturalistic Dutch cohort. Pharmacogenomics J 2016; 16: 202-208
  CrossrefPubMedGoogle Scholar
• 112 Biernacka JM, Sangkuhl K, Jenkins G. et al. The International SSRI Pharmacogenomics Consortium (ISPC): A genome-wide association study of antidepressant treatment response. Transl Psychiatry 2016; 6: e937
  CrossrefPubMedGoogle Scholar
• 113 Bigliani V, Mulligan RS, Acton PD. et al. Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo: A [123I]epidepride single photon emission tomography (SPET) study. Psychopharmacology (Berl) 2000; 150: 132-140
  CrossrefPubMedGoogle Scholar
• 114 Bigos KL, Bies RR, Pollock BG. et al. Genetic variation in CYP3A43 explains racial difference in olanzapine clearance. Mol Psychiatry 2011; 16: 620-625
  CrossrefPubMedGoogle Scholar
• 115 Birkenhager TK, van den Broek WW, Moleman P. et al. Imipramine dose in relation to therapeutic plasma level: Are clinical trials using imipramine as a positive control flawed?. Psychopharmacology (Berl) 2005; 181: 595-599
  CrossrefPubMedGoogle Scholar
• 116 Bishara D, Olofinjana O, Sparshatt A. et al. Olanzapine: A systematic review and meta-regression of the relationships between dose, plasma concentration, receptor occupancy, and response. J Clin Psychopharmacol 2013; 33: 329-335
  CrossrefPubMedGoogle Scholar
• 117 Bjerkenstedt L, Flyckt L, Overo KF. et al. Relationship between clinical effects, serum drug concentration and serotonin uptake inhibition in depressed patients treated with citalopram. A double-blind comparison of three dose levels. Eur J Clin Pharmacol 1985; 28: 553-557
  CrossrefPubMedGoogle Scholar
• 118 Bjorndal N, Bjerre M, Gerlach J. et al. High dosage haloperidol therapy in chronic schizophrenic patients: A double-blind study of clinical response, side effects, serum haloperidol, and serum prolactin. Psychopharmacology (Berl) 1980; 67: 17-23
  CrossrefPubMedGoogle Scholar
• 119 Bland TM, Haining RL, Tracy TS. et al. CYP2C-catalyzed delta9-tetrahydrocannabinol metabolism: Kinetics, pharmacogenetics and interaction with phenytoin. Biochem Pharmacol 2005; 70: 1096-1103
  CrossrefPubMedGoogle Scholar
• 120 Blazquez A, Mas S, Plana MT. et al. Plasma fluoxetine concentrations and clinical improvement in an adolescent sample diagnosed with major depressive disorder, obsessive-compulsive disorder, or generalized anxiety disorder. J Clin Psychopharmacol 2014; 34: 318-326
  CrossrefPubMedGoogle Scholar
• 121 Bockbrader HN. Clinical pharmacokinetics of gabapentin. Drugs Today 1995; 31: 613-619
  PubMedGoogle Scholar
• 122 Bockbrader HN, Burger P, Knapp L. et al. Population pharmacokinetics of pregabalin in healthy subjects and patients with chronic pain or partial seizures. Epilepsia 2011; 52: 248-257
  PubMedGoogle Scholar
• 123 Bockbrader HN, Wesche D, Miller R. et al. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet 2010; 49: 661-669
  CrossrefPubMedGoogle Scholar
• 124 Boden R, Brandt L, Kieler H. et al. Early non-adherence to medication and other risk factors for rehospitalization in schizophrenia and schizoaffective disorder. Schizophr Res 2011; 133: 36-41
  CrossrefPubMedGoogle Scholar
• 125 Boellner SW, Stark JG, Krishnan S. et al. Pharmacokinetics of lisdexamfetamine dimesylate and its active metabolite, d-amphetamine, with increasing oral doses of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: A single-dose, randomized, open-label, crossover study. Clin Ther 2010; 32: 252-264
  CrossrefPubMedGoogle Scholar
• 126 Bogaards JJ, Hissink EM, Briggs M. et al. Prediction of interindividual variation in drug plasma levels in vivo from individual enzyme kinetic data and physiologically based pharmacokinetic modeling. Eur J Pharm Sci 2000; 12: 117-124
  CrossrefPubMedGoogle Scholar
• 127 Boinpally R, Alcorn H, Adams MH. et al. Pharmacokinetics of vilazodone in patients with mild or moderate renal impairment. Clin Drug Investig 2013; 33: 199-206
  CrossrefPubMedGoogle Scholar
• 128 Boinpally R, Gad N, Gupta S. et al. Influence of CYP3A4 induction/inhibition on the pharmacokinetics of vilazodone in healthy subjects. Clin Ther 2014; 36: 1638-1649
  CrossrefPubMedGoogle Scholar
• 129 Bomsien S, Aderjan R, Mattern R. et al. Effect of psychotropic medication on the in vitro metabolism of buprenorphine in human cDNA-expressed cytochrome P450 enzymes. Eur J Clin Pharmacol 2006; 62: 639-643
  CrossrefPubMedGoogle Scholar
• 130 Bond A, Seijas D, Dawling S. et al. Systemic absorption and abuse liability of snorted flunitrazepam. Addiction 1994; 89: 821-830
  CrossrefPubMedGoogle Scholar
• 131 Bond AJ, Reed KD, Beavan P. et al. After the randomised injectable opiate treatment trial: Post-trial investigation of slow-release oral morphine as an alternative opiate maintenance medication. Drug Alcohol Rev 2012; 31: 492-498
  CrossrefPubMedGoogle Scholar
• 132 Bondareva IB, Jelliffe RW, Gusev EI. et al. Population pharmacokinetic modelling of carbamazepine in epileptic elderly patients: implications for dosage. J Clin Pharm Ther 2006; 31: 211-221
  CrossrefPubMedGoogle Scholar
• 133 Bondolfi G, Morel F, Crettol S. et al. Increased clozapine plasma concentrations and side effects induced by smoking cessation in 2 CYP1A2 genotyped patients. Ther Drug Monit 2005; 27: 539-543
  CrossrefPubMedGoogle Scholar
• 134 Bont L, Bosker HA, Brus F. et al. Torsade de pointes after pipamperone intoxication. Pharm World Sci 1998; 20: 137
  CrossrefPubMedGoogle Scholar
• 135 Borgstrom L, Larsson H, Molander L. Pharmacokinetics of parenteral and oral melperone in man. Eur J Clin Pharmacol 1982; 23: 173-176
  CrossrefPubMedGoogle Scholar
• 136 Borys DJ, Setzer SC, Ling LJ. et al. Acute fluoxetine overdose: a report of 234 cases. Am J Emerg Med 1992; 10: 115-120
  CrossrefPubMedGoogle Scholar
• 137 Bosse GM, Spiller HA, Collins AM. A fatal case of venlafaxine overdose. J Med Toxicol 2008; 4: 18-20
  CrossrefPubMedGoogle Scholar
• 138 Bowskill SV, Patel MX, Handley SA. et al. Plasma amisulpride in relation to prescribed dose, clozapine augmentation, and other factors: data from a therapeutic drug monitoring service, 2002-2010. Hum Psychopharmacol 2012; 27: 507-513
  CrossrefPubMedGoogle Scholar
• 139 Bozik ME, Mather JL, Kramer WG. et al. Safety, tolerability, and pharmacokinetics of KNS-760704 (dexpramipexole) in healthy adult subjects. J Clin Pharmacol 2011; 51: 1177-1185
  CrossrefPubMedGoogle Scholar
• 140 Brachtendorf L, Jetter A, Beckurts KT. et al. Cytochrome P450 enzymes contributing to demethylation of maprotiline in man. Pharmacol Toxicol 2002; 90: 144-149
  CrossrefPubMedGoogle Scholar
• 141 Brahmi N, Kouraichi N, Abderrazek H. et al. Clinical experience with carbamazepine overdose: Relationship between serum concentration and neurological severity. J Clin Psychopharmacol 2008; 28: 241-243
  CrossrefPubMedGoogle Scholar
• 142 Branch RA, Adedoyin A, Frye RF. et al. In vivo modulation of CYP enzymes by quinidine and rifampin. Clin Pharmacol Ther 2000; 68: 401-411
  CrossrefPubMedGoogle Scholar
• 143 Brandl EJ, Kennedy JL, Müller DJ. Pharmacogenetics of antipsychotics. Can J Psychiatry 2014; 59: 76-88
  CrossrefPubMedGoogle Scholar
• 144 Brandt C, Baumann P, Eckermann G. et al. [Therapeutic drug monitoring in epileptology and psychiatry]. Nervenarzt 2008; 79: 167-174
  CrossrefPubMedGoogle Scholar
• 145 Brandt C, May TW. Therapeutic drug monitoring of newer antiepileptic drugs. J Lab Med 2011; 35: 161-169
  PubMedGoogle Scholar
• 146 Breitenstein B, Bruckl TM, Ising M. et al. ABCB1 gene variants and antidepressant treatment outcome: A meta-analysis. Am J Med Genet B Neuropsychiatr Genet 2015; 168B: 274-283
  PubMedGoogle Scholar
• 147 Breitenstein B, Scheuer S, Bruckl TM. et al. Association of ABCB1 gene variants, plasma antidepressant concentration, and treatment response: Results from a randomized clinical study. J Psychiatr Res 2016; 73: 86-95
  CrossrefPubMedGoogle Scholar
• 148 Bressan RA, Erlandsson K, Jones HM. et al. Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? an in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients. Am J Psychiatry 2003; 160: 1413-1420
  CrossrefPubMedGoogle Scholar
• 149 Bressolle F, Bres J, Faure-Jeantis A. Absolute bioavailability, rate of absorption, and dose proportionality of sulpiride in humans. J Pharm Sci 1992; 81: 26-32
  CrossrefPubMedGoogle Scholar
• 150 Breyer-Pfaff U. The metabolic fate of amitriptyline, nortriptyline and amitriptylinoxide in man. Drug Metab Rev 2004; 36: 723-746
  CrossrefPubMedGoogle Scholar
• 151 Breyer-Pfaff U, Brinkschulte M, Rein W. et al. Prediction and evaluation criteria in perazine therapy of acute schizophrenics. Pharmacokinetic data. Pharmacopsychiatria 1983; 16: 160-165
  Article in Thieme ConnectPubMedGoogle Scholar
• 152 Breyer-Pfaff U, Nill K. Carbonyl reduction of naltrexone and dolasetron by oxidoreductases isolated from human liver cytosol. J Pharm Pharmacol 2004; 56: 1601-1606
  CrossrefPubMedGoogle Scholar
• 153 Breyer-Pfaff U, Nill K, Schied HW. et al. Single-dose kinetics of the neuroleptic drug perazine in psychotic patients. Psychopharmacology (Berl) 1988; 95: 374-377
  PubMedGoogle Scholar
• 154 Brockmoller J, Kirchheiner J, Schmider J. et al. The impact of the CYP2D6 polymorphism on haloperidol pharmacokinetics and on the outcome of haloperidol treatment. Clin Pharmacol Ther 2002; 72: 438-452
  CrossrefPubMedGoogle Scholar
• 155 Brocks DR. Anticholinergic drugs used in Parkinson’s disease: An overlooked class of drugs from a pharmacokinetic perspective. J Pharm Pharm Sci 1999; 2: 39-46
  PubMedGoogle Scholar
• 156 Brosen K, Gram LF, Klysner R. et al. Steady-state levels of imipramine and its metabolites: significance of dose-dependent kinetics. Eur J Clin Pharmacol 1986; 30: 43-49
  CrossrefPubMedGoogle Scholar
• 157 Brosen K, Klysner R, Gram LF. et al. Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism. Eur J Clin Pharmacol 1986; 30: 679-684
  CrossrefPubMedGoogle Scholar
• 158 Brosen K, Naranjo CA. Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram. Eur Neuropsychopharmacol 2001; 11: 275-283
  CrossrefPubMedGoogle Scholar
• 159 Browne JL, Perry PJ, Alexander B. et al. Pharmacokinetic protocol for predicting plasma nortriptyline levels. J Clin Psychopharmacol 1983; 3: 351-356
  PubMedGoogle Scholar
• 160 Bruckl TM, Uhr M. ABCB1 genotyping in the treatment of depression. Pharmacogenomics 2016; 17: 2039-2069
  CrossrefPubMedGoogle Scholar
• 161 Bruhn O, Cascorbi I. Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance. Expert Opin Drug Metab Toxicol 2014; 10: 1337-1354
  CrossrefPubMedGoogle Scholar
• 162 Bruijn JA, Moleman P, Mulder PG. et al. A double-blind, fixed blood-level study comparing mirtazapine with imipramine in depressed in-patients. Psychopharmacology (Berl) 1996; 127: 231-237
  CrossrefPubMedGoogle Scholar
• 163 Brunen S, Vincent PD, Baumann P. et al. Therapeutic drug monitoring for drugs used in the treatment of substance-related disorders: literature review using a therapeutic drug monitoring appropriateness rating scale. Ther Drug Monit 2011; 33: 561-572
  PubMedGoogle Scholar
• 164 Buckinx F, Rolland Y, Reginster JY. et al. Burden of frailty in the elderly population: Perspectives for a public health challenge. Arch Public Health 2015; 73: 19
  CrossrefPubMedGoogle Scholar
• 165 Buckley NA, Dawson AH, Whyte IM. et al. Greater toxicity in overdose of dothiepin than of other tricyclic antidepressants. Lancet 1994; 343: 159-162
  CrossrefPubMedGoogle Scholar
• 166 Bundgaard C, Eneberg E, Sanchez C. P-glycoprotein differentially affects escitalopram, levomilnacipran, vilazodone and vortioxetine transport at the mouse blood-brain barrier in vivo. Neuropharmacology 2016; 103: 104-111
  CrossrefPubMedGoogle Scholar
• 167 Bunten H, Liang WJ, Pounder DJ. et al. OPRM1 and CYP2B6 gene variants as risk factors in methadone-related deaths. Clin Pharmacol Ther 2010; 88: 383-389
  CrossrefPubMedGoogle Scholar
• 168 Burke MJ, Preskorn SH. Therapeutic drug monitoring of antidepressants: cost implications and relevance to clinical practice. Clin Pharmacokinet 1999; 37: 147-165
  CrossrefPubMedGoogle Scholar
• 169 Burns ML, Baftiu A, Opdal MS. et al. Therapeutic drug monitoring of clobazam and its metabolite-impact of age and comedication on pharmacokinetic variability. Ther Drug Monit 2016; 38: 350-357
  CrossrefPubMedGoogle Scholar
• 170 Busardo FP, Jones AW. GHB pharmacology and toxicology: acute intoxication, concentrations in blood and urine in forensic cases and treatment of the withdrawal syndrome. Curr Neuropharmacol 2015; 13: 47-70
  CrossrefPubMedGoogle Scholar
• 171 Byerly MJ, Thompson A, Carmody T. et al. Validity of electronically monitored medication adherence and conventional adherence measures in schizophrenia. Psychiatr Serv 2007; 58: 844-847
  CrossrefPubMedGoogle Scholar
• 172 Cabaleiro T, Ochoa D, Lopez-Rodriguez R. et al. Effect of polymorphisms on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers. Hum Psychopharmacol 2014; 29: 459-469
  CrossrefPubMedGoogle Scholar
• 173 Caccia S, Garattini S. Pharmacokinetic and pharmacodynamic significance of antidepressant drug metabolites. Pharmacol Res 1992; 26: 317-329
  PubMedGoogle Scholar
• 174 Caccia S, Invernizzi RW, Nobili A. et al. A new generation of antipsychotics: pharmacology and clinical utility of cariprazine in schizophrenia. Ther Clin Risk Manag 2013; 9: 319-328
  PubMedGoogle Scholar
• 175 Caccia S, Pasina L, Nobili A. New atypical antipsychotics for schizophrenia: iloperidone. Drug Des Devel Ther 2010; 4: 33-48
  PubMedGoogle Scholar
• 176 Callaghan JT, Bergstrom RF, Ptak LR. et al. Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet 1999; 37: 177-193
  CrossrefPubMedGoogle Scholar
• 177 Canal-Raffin M, Deridet E, Titier K. et al. Simplified ultraviolet liquid chromatographic method for determination of sertindole, dehydrosertindole and norsertindole, in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 814: 61-67
  CrossrefPubMedGoogle Scholar
• 178 Canal-Raffin M, Titier K, Deridet E. et al. Myocardium distribution of sertindole and its metabolite dehydrosertindole in guinea-pigs. Biopharm Drug Dispos 2006; 27: 171-179
  CrossrefPubMedGoogle Scholar
• 179 Capone D, Tarantino G, Gentile A. et al. Effects of voriconazole on tacrolimus metabolism in a kidney transplant recipient. J Clin Pharm Ther 2010; 35: 121-124
  CrossrefPubMedGoogle Scholar
• 180 Carlsson B, Olsson G, Reis M. et al. Enantioselective analysis of citalopram and metabolites in adolescents. Ther Drug Monit 2001; 23: 658-664
  CrossrefPubMedGoogle Scholar
• 181 Carnovale C, Pellegrino P, Beretta S. et al. A case of tinnitus induced by chlorpromazine in a pediatric patient. J Pharmacol Pharmacother 2014; 5: 163-165
  CrossrefPubMedGoogle Scholar
• 182 Carrillo JA, Benitez J. Clinically significant pharmacokinetic interactions between dietary caffeine and medications. Clin Pharmacokinet 2000; 39: 127-153
  CrossrefPubMedGoogle Scholar
• 183 Castberg I, Skogvoll E, Spigset O. Quetiapine and drug interactions: evidence from a routine therapeutic drug monitoring service. J Clin Psychiatry 2007; 68: 1540-1545
  CrossrefPubMedGoogle Scholar
• 184 Castberg I, Spigset O. Prescribing patterns and the use of therapeutic drug monitoring of psychotropic medication in a psychiatric high-security unit. Ther Drug Monit 2008; 30: 597-603
  CrossrefPubMedGoogle Scholar
• 185 Causon R. Validation of chromatographic methods in biomedical analysis. Viewpoint and discussion. J Chromatogr B Biomed Sci Appl 1997; 689: 175-180
  CrossrefPubMedGoogle Scholar
• 186 Cawello W. Clinical pharmacokinetic and pharmacodynamic profile of lacosamide. Clin Pharmacokinet 2015; 54: 901-914
  CrossrefPubMedGoogle Scholar
• 187 Cawello W, Braun M, Boekens H. Absorption, disposition, metabolic fate, and elimination of the dopamine agonist rotigotine in man: administration by intravenous infusion or transdermal delivery. Drug Metab Dispos 2009; 37: 2055-2060
  CrossrefPubMedGoogle Scholar
• 188 Cawello W, Fichtner A, Boekens H. et al. Influence of hepatic impairment on the pharmacokinetics of the dopamine agonist rotigotine. Eur J Drug Metab Pharmacokinet 2014; 39: 155-163
  CrossrefPubMedGoogle Scholar
• 189 Centerholt C, Ekblom M, Odergren T. et al. Pharmacokinetics and sedative effects in healthy subjects and subjects with impaired liver function after continuous infusion of clomethiazole. Eur J Clin Pharmacol 2003; 59: 117-122
  CrossrefPubMedGoogle Scholar
• 190 Ceskova E. The need to improve current psychopharmacotherapy before developing new drugs. Expert Opin Pharmacother 2014; 15: 1969-1973
  CrossrefPubMedGoogle Scholar
• 191 Chakraborty BS, Midha KK, McKay G. et al. Single dose kinetics of thioridazine and its two psychoactive metabolites in healthy humans: A dose proportionality study. J Pharm Sci 1989; 78: 796-801
  CrossrefPubMedGoogle Scholar
• 192 Chamorro AJ, Marcos M, Miron-Canelo JA. et al. Association of micro-opioid receptor (OPRM1) gene polymorphism with response to naltrexone in alcohol dependence: a systematic review and meta-analysis. Addict Biol 2012; 17: 505-512
  CrossrefPubMedGoogle Scholar
• 193 Chan LN, Anderson GD. Pharmacokinetic and pharmacodynamic drug interactions with ethanol (alcohol). Clin Pharmacokinet 2014; 53: 1115-1136
  CrossrefPubMedGoogle Scholar
• 194 Chan V, Morris RG, Ilett KF. et al. Population pharmacokinetics of lamotrigine. Ther Drug Monit 2001; 23: 630-635
  CrossrefPubMedGoogle Scholar
• 195 Chang M, Tybring G, Dahl ML. et al. Impact of cytochrome P450 2C19 polymorphisms on citalopram/escitalopram exposure: A systematic review and meta-analysis. Clin Pharmacokinet 2014; 53: 801-811
  CrossrefPubMedGoogle Scholar
• 196 Chang YC, Lane HY, Yang KH. et al. Optimizing early prediction for antipsychotic response in schizophrenia. J Clin Psychopharmacol 2006; 26: 554-559
  CrossrefPubMedGoogle Scholar
• 197 Chapel S, Hutmacher MM, Haig G. et al. Exposure-response analysis in patients with schizophrenia to assess the effect of asenapine on QTc prolongation. J Clin Pharmacol 2009; 49: 1297-1308
  CrossrefPubMedGoogle Scholar
• 198 Chappell JC, Eisenhofer G, Owens MJ. et al. Effects of duloxetine on norepinephrine and serotonin transporter activity in healthy subjects. J Clin Psychopharmacol 2014; 34: 9-16
  CrossrefPubMedGoogle Scholar
• 199 Chawarski MC, Schottenfeld RS, O’Connor PG. et al. Plasma concentrations of buprenorphine 24 to 72 hours after dosing. Drug Alcohol Depend 1999; 55: 157-163
  CrossrefPubMedGoogle Scholar
• 200 Chen G, Lee R, Hojer AM. et al. Pharmacokinetic drug interactions involving vortioxetine (Lu AA21004), a multimodal antidepressant. Clin Drug Investig 2013; 33: 727-736
  CrossrefPubMedGoogle Scholar
• 201 Chen H, Grover S, Yu L. et al. Bioactivation of lamotrigine in vivo in rat and in vitro in human liver microsomes, hepatocytes, and epidermal keratinocytes: characterization of thioether conjugates by liquid chromatography/mass spectrometry and high field nuclear magnetic resonance spectroscopy. Chem Res Toxicol 2010; 23: 159-170
  CrossrefPubMedGoogle Scholar
• 202 Chen L, Greenberg WM, Brand-Schieber E. et al. Effect of renal impairment on the pharmacokinetics of levomilnacipran following a single oral dose of levomilnacipran extended-release capsule in humans. Drug Des Devel Ther 2015; 9: 3293-3300
  PubMedGoogle Scholar
• 203 Chen L, Greenberg WM, Gommoll C. et al. Levomilnacipran pharmacokinetics in healthy volunteers versus patients with major depressive disorder and implications for norepinephrine and serotonin reuptake inhibition. Clin Ther 2015; 37: 2059-2070
  CrossrefPubMedGoogle Scholar
• 204 Chen P, Tanasijevic MJ, Schoenenberger RA. et al. A computer-based intervention for improving the appropriateness of antiepileptic drug level monitoring. Am J Clin Pathol 2003; 119: 432-438
  CrossrefPubMedGoogle Scholar
• 205 Cheng YF, Paalzow LK, Bondesson U. et al. Pharmacokinetics of haloperidol in psychotic patients. Psychopharmacology (Berl) 1987; 91: 410-414
  CrossrefPubMedGoogle Scholar
• 206 Chenu F, Batten LA, Zernig G. et al. Comparison of pharmacokinetic profiles of brand-name and generic formulations of citalopram and venlafaxine: a crossover study. J Clin Psychiatry 2009; 70: 958-966
  CrossrefPubMedGoogle Scholar
• 207 Cherma MD, Lofgren UB, Almkvist G. et al. Assessment of the prescription of antidepressant drugs in elderly nursing home patients: a clinical and laboratory follow-up investigation. J Clin Psychopharmacol 2008; 28: 424-431
  CrossrefPubMedGoogle Scholar
• 208 Cherma MD, Reis M, Hagg S. et al. Therapeutic drug monitoring of ziprasidone in a clinical treatment setting. Ther Drug Monit 2008; 30: 682-688
  CrossrefPubMedGoogle Scholar
• 209 Cherubini A, Nistico G, Rozzini R. et al. Subthreshold depression in older subjects: an unmet therapeutic need. J Nutr Health Aging 2012; 16: 909-913
  CrossrefPubMedGoogle Scholar
• 210 Chetty M, Gouws E, Miller R. et al. The use of a side effect as a qualitative indicator of plasma chlorpromazine levels. Eur Neuropsychopharmacol 1999; 9: 77-82
  CrossrefPubMedGoogle Scholar
• 211 Chew ML, Alvey CW, Plotka A. et al. Pregabalin controlled-release pharmacokinetics in healthy volunteers: Analysis of four multiple-dose randomized clinical pharmacology studies. Clin Drug Investig 2014; 34: 627-637
  CrossrefPubMedGoogle Scholar
• 212 Chew ML, Mulsant BH, Pollock BG. et al. Anticholinergic activity of 107 medications commonly used by older adults. J Am Geriatr Soc 2008; 56: 1333-1341
  CrossrefPubMedGoogle Scholar
• 213 Chiu YY, Ereshefsky L, Preskorn SH. et al. Lurasidone drug-drug interaction studies: A comprehensive review. Drug Metabol Drug Interact 2014; 29: 191-202
  PubMedGoogle Scholar
• 214 Cho HY, Yoo HD, Lee YB. Influence of ABCB1 genetic polymorphisms on the pharmacokinetics of levosulpiride in healthy subjects. Neuroscience 2010; 169: 378-387
  CrossrefPubMedGoogle Scholar
• 215 Cho JY, Yu KS, Jang IJ. et al. Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic EM genotype for CYP2C19. Br J Clin Pharmacol 2002; 53: 393-397
  CrossrefPubMedGoogle Scholar
• 216 Choc MG, Hsuan F, Honigfeld G. et al. Single- vs multiple-dose pharmacokinetics of clozapine in psychiatric patients. Pharm Res 1990; 7: 347-351
  CrossrefPubMedGoogle Scholar
• 217 Choi CI, Bae JW, Lee YJ. et al. Effects of CYP2C19 genetic polymorphisms on atomoxetine pharmacokinetics. J Clin Psychopharmacol 2014; 34: 139-142
  CrossrefPubMedGoogle Scholar
• 218 Christensen M, Andersson K, Dalen P. et al. The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes. Clin Pharmacol Ther 2003; 73: 517-528
  CrossrefPubMedGoogle Scholar
• 219 Chu XM, Zhang LF, Wang GJ. et al. Influence of UDP-glucuronosyltransferase polymorphisms on valproic acid pharmacokinetics in Chinese epilepsy patients. Eur J Clin Pharmacol 2012; 68: 1395-1401
  CrossrefPubMedGoogle Scholar
• 220 Ciraulo DA, Hitzemann RJ, Somoza E. et al. Pharmacokinetics and pharmacodynamics of multiple sublingual buprenorphine tablets in dose-escalation trials. J Clin Pharmacol 2006; 46: 179-192
  CrossrefPubMedGoogle Scholar
• 221 Ciszowski K, Szpak D, Wilimowska J. et al. Sulpiride poisoning--case report confirmed with the quantitative determination of the xenobiotic serum level. Przegl Lek 2011; 68: 506-509
  PubMedGoogle Scholar
• 222 Citrome L. Asenapine review, part I: Chemistry, receptor affinity profile, pharmacokinetics and metabolism. Expert Opin Drug Metab Toxicol 2014; 10: 893-903
  CrossrefPubMedGoogle Scholar
• 223 Citrome L. Brexpiprazole: A new dopamine D(2)receptor partial agonist for the treatment of schizophrenia and major depressive disorder. Drugs Today (Barc). 2015: 51: 397–414
  PubMed
• 224 Citrome L. Paliperidone palmitate – review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication. Int J Clin Pract 2010; 64: 216-239
  CrossrefPubMedGoogle Scholar
• 225 Citrome L. A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: An evidence-based medicine approach. CNS Drugs 2013; 27: 879-911
  CrossrefPubMedGoogle Scholar
• 226 Citrome L, Stauffer VL, Chen L. et al. Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg/d in patients with schizophrenia: An analysis of correlations with efficacy, weight gain, and prolactin concentration. J Clin Psychopharmacol 2009; 29: 278-283
  CrossrefPubMedGoogle Scholar
• 227 Coghill D, Banaschewski T, Zuddas A. et al. Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: A systematic review of head-to-head studies. BMC Psychiatry 2013; 13: 237
  CrossrefPubMedGoogle Scholar
• 228 Coller JK, Somogyi AA, Bochner F. Flunitrazepam oxidative metabolism in human liver microsomes: Involvement of CYP2C19 and CYP3A4. Xenobiotica 1999; 29: 973-986
  CrossrefPubMedGoogle Scholar
• 229 Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med 2015; 372: 793-795
  CrossrefPubMedGoogle Scholar
• 230 Collins N, Barnes TR, Shingleton-Smith A. et al. Standards of lithium monitoring in mental health trusts in the UK. BMC Psychiatry 2010; 10: 80
  CrossrefPubMedGoogle Scholar
• 231 Conca A, Schmidt E, Pastore M. et al. Therapeutic drug monitoring in Italian psychiatry. Pharmacopsychiatry 2011; 44: 259-262
  Article in Thieme ConnectPubMedGoogle Scholar
• 232 Connarn JN, Zhang X, Babiskin A. et al. Metabolism of bupropion by carbonyl reductases in liver and intestine. Drug Metab Dispos 2015; 43: 1019-1027
  CrossrefPubMedGoogle Scholar
• 233 Citrome L. Brexpiprazole: A new dopamine D(2)receptor partial agonist for the treatment of schizophrenia and major depressive disorder. Drugs Today (Barc). 2015: 51: 397–414
  PubMed
• 234 Contin M, Albani F, Riva R. et al. Lacosamide therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs. Ther Drug Monit 2013; 35: 849-852
  CrossrefPubMedGoogle Scholar
• 235 Contin M, Mohamed S, Albani F. et al. Levetiracetam clinical pharmacokinetics in elderly and very elderly patients with epilepsy. Epilepsy Res 2012; 98: 130-134
  CrossrefPubMedGoogle Scholar
• 236 Contin M, Riva R, Martinelli P. et al. Effect of meal timing on the kinetic-dynamic profile of levodopa/carbidopa controlled release [corrected] in parkinsonian patients. Eur J Clin Pharmacol 1998; 54: 303-308
  CrossrefPubMedGoogle Scholar
• 237 Cooper TB. Plasma level monitoring of antipsychotic drugs. Clin Pharmacokinet 1978; 3: 14-38
  CrossrefPubMedGoogle Scholar
• 238 Coppen A, Kopera H. Workshop on the clinical pharmacology and efficacy of mianserin. Br J Clin Pharmacol 1978; 5 (Suppl. 01) 91S-99S
  PubMedGoogle Scholar
• 239 Correll CU, Malhotra AK, Kaushik S. et al. Early prediction of antipsychotic response in schizophrenia. Am J Psychiatry 2003; 160: 2063-2065
  CrossrefPubMedGoogle Scholar
• 240 Couchman L, Bowskill SV, Handley S. et al. Plasma clozapine and norclozapine in relation to prescribed dose and other factors in patients aged<18 years: Data from a therapeutic drug monitoring service, 1994-2010. Early Interv Psychiatry 2013; 7: 122-130
  CrossrefPubMedGoogle Scholar
• 241 Couchman L, Morgan PE, Spencer EP. et al. Plasma clozapine, norclozapine, and the clozapine: Norclozapine ratio in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1993-2007. Ther Drug Monit 2010; 32: 438-447
  CrossrefPubMedGoogle Scholar
• 242 Couchman L, Morgan PE, Spencer EP. et al. Plasma clozapine and norclozapine in patients prescribed different brands of clozapine (Clozaril, Denzapine, and Zaponex). Ther Drug Monit 2010; 32: 624-627
  CrossrefPubMedGoogle Scholar
• 243 Coulomb F, Ducret F, Laneury JP. et al. Pharmacokinetics of single-dose reboxetine in volunteers with renal insufficiency. J Clin Pharmacol 2000; 40: 482-487
  CrossrefPubMedGoogle Scholar
• 244 Cournoyer G, de Montigny C, Ouellette J. et al. A comparative double-blind controlled study of trimipramine and amitriptyline in major depression: Lack of correlation with 5-hydroxytryptamine reuptake blockade. J Clin Psychopharmacol 1987; 7: 385-393
  PubMedGoogle Scholar
• 245 Court MH. Interindividual variability in hepatic drug glucuronidation: studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system. Drug Metab Rev 2010; 42: 209-224
  CrossrefPubMedGoogle Scholar
• 246 Court MH, Duan SX, Guillemette C. et al. Stereoselective conjugation of oxazepam by human UDP-glucuronosyltransferases (UGTs): S-oxazepam is glucuronidated by UGT2B15, while R-oxazepam is glucuronidated by UGT2B7 and UGT1A9. Drug Metab Dispos 2002; 30: 1257-1265
  CrossrefPubMedGoogle Scholar
• 247 Crettol S, Besson J, Croquette-Krokar M. et al. Association of dopamine and opioid receptor genetic polymorphisms with response to methadone maintenance treatment. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32: 1722-1727
  CrossrefPubMedGoogle Scholar
• 248 Crettol S, de Leon J, Hiemke C. et al. Pharmacogenomics in psychiatry: From therapeutic drug monitoring to genomic medicine. Clin Pharmacol Ther 2014; 95: 254-257
  CrossrefPubMedGoogle Scholar
• 249 Crettol S, Deglon JJ, Besson J. et al. ABCB1 and cytochrome P450 genotypes and phenotypes: Influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther 2006; 80: 668-681
  CrossrefPubMedGoogle Scholar
• 250 Crettol S, Deglon JJ, Besson J. et al. Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clin Pharmacol Ther 2005; 78: 593-604
  CrossrefPubMedGoogle Scholar
• 251 Csajka C, Crettol S, Guidi M. et al. Population Genetic-Based Pharmacokinetic Modeling of Methadone and its Relationship with the QTc Interval in Opioid-Dependent Patients. Clin Pharmacokinet 2016; 55: 1521-1533
  CrossrefPubMedGoogle Scholar
• 252 Cummings J, Lefevre G, Small G. et al. Pharmacokinetic rationale for the rivastigmine patch. Neurology 2007; 69: S10-S13
  PubMedGoogle Scholar
• 253 Cutler NR, Polinsky RJ, Sramek JJ. et al. Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer’s disease. Acta Neurol Scand 1998; 97: 244-250
  PubMedGoogle Scholar
• 254 Dahl SG. Active metabolites of neuroleptic drugs: possible contribution to therapeutic and toxic effects. Ther Drug Monit 1982; 4: 33-40
  CrossrefPubMedGoogle Scholar
• 255 Dahl SG, Strandjord RE, Sigfusson S. Pharmacokinetics and relative bioavailability of levomepromazine after repeated administration of tablets and syrup. Eur J Clin Pharmacol 1977; 11: 305-310
  CrossrefPubMedGoogle Scholar
• 256 Damoiseaux VA, Proost JH, Jiawan VC. et al. Sex differences in the pharmacokinetics of antidepressants: Influence of female sex hormones and oral contraceptives. Clin Pharmacokinet 2014; 53: 509-519
  CrossrefPubMedGoogle Scholar
• 257 Darby JK, Pasta DJ, Wilson MG. et al. Long-term therapeutic drug monitoring of risperidone and olanzapine identifies altered steady-state pharmacokinetics: A clinical, two-group, naturalistic study. Clin Drug Investig 2008; 28: 553-564
  CrossrefPubMedGoogle Scholar
• 258 Davies SJ, Westin AA, Castberg I. et al. Characterisation of zuclopenthixol metabolism by in vitro and therapeutic drug monitoring studies. Acta Psychiatr Scand 2010; 122: 444-453
  CrossrefPubMedGoogle Scholar
• 259 Daviss WB, Perel JM, Birmaher B. et al. Steady-state clinical pharmacokinetics of bupropion extended-release in youths. J Am Acad Child Adolesc Psychiatry 2006; 45: 1503-1509
  CrossrefPubMedGoogle Scholar
• 260 Daviss WB, Perel JM, Brent DA. et al. Acute antidepressant response and plasma levels of bupropion and metabolites in a pediatric-aged sample: an exploratory study. Ther Drug Monit 2006; 28: 190-198
  CrossrefPubMedGoogle Scholar
• 261 Dawling S. Monitoring of tricyclic antidepressant therapy. Clin Biochem 1982; 15: 56-61
  CrossrefPubMedGoogle Scholar
• 262 De Gregori S, De Gregori M, Ranzani GN. et al. Morphine metabolism, transport and brain disposition. Metab Brain Dis 2012; 27: 1-5
  CrossrefPubMedGoogle Scholar
• 263 de Klerk OL, Nolte IM, Bet PM. et al. ABCB1 gene variants influence tolerance to selective serotonin reuptake inhibitors in a large sample of Dutch cases with major depressive disorder. Pharmacogenomics J 2013; 13: 349-353
  CrossrefPubMedGoogle Scholar
• 264 De las Cuevas C, Penate W, Sanz EJ. Risk factors for non-adherence to antidepressant treatment in patients with mood disorders. Eur J Clin Pharmacol 2014; 70: 89-98
  CrossrefPubMedGoogle Scholar
• 265 de Leon J. The crucial role of the therapeutic window in understanding the clinical relevance of the poor versus the ultrarapid metabolizer phenotypes in subjects taking drugs metabolized by CYP2D6 or CYP2C19. J Clin Psychopharmacol 2007; 27: 241-245
  CrossrefPubMedGoogle Scholar
• 266 de Leon J. The effects of antiepileptic inducers in neuropsychopharmacology, a neglected issue. Part I: A summary of the current state for clinicians. Rev Psiquiatr Salud Ment 2015; 8: 97-115
  CrossrefPubMedGoogle Scholar
• 267 de J. Focusing on drug versus disease mechanisms and on clinical subgrouping to advance personalised medicine in psychiatry. Acta Neuropsychiatr 2014; 26: 327-333
  CrossrefPubMedGoogle Scholar
• 268 de Leon J. Glucuronidation enzymes, genes and psychiatry. Int J Neuropsychopharmacol 2003; 6: 57-72
  CrossrefPubMedGoogle Scholar
• 269 de Leon J. Incorporating pharmacogenetics into clinical practice: reality of a new tool in psychiatry. Current issues in clinical implementation. CNS Spectr 2006; 11: 8-12
  CrossrefPubMedGoogle Scholar
• 270 de Leon J, Greenlee B, Barber J. et al. Practical guidelines for the use of new generation antipsychotic drugs (except clozapine) in adult individuals with intellectual disabilities. Res Dev Disabil 2009; 30: 613-669
  CrossrefPubMedGoogle Scholar
• 271 de Leon J, Spina E, Diaz FJ. Clobazam therapeutic drug monitoring: A comprehensive review of the literature with proposals to improve future studies. Ther Drug Monit 2013; 35: 30-47
  PubMedGoogle Scholar
• 272 de Leon J, Susce MT, Pan RM. et al. The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation. J Clin Psychiatry 2005; 66: 15-27
  CrossrefPubMedGoogle Scholar
• 273 de Leon J, Wynn G, Sandson NB. The pharmacokinetics of paliperidone versus risperidone. Psychosomatics 2010; 51: 80-88
  CrossrefPubMedGoogle Scholar
• 274 de Mey C, Althaus M, Ezan E. et al. Erythromycin increases plasma concentrations of alpha-dihydroergocryptine in humans. Clin Pharmacol Ther 2001; 70: 142-148
  CrossrefPubMedGoogle Scholar
• 275 de Wit M, Best AM, Epstein SK. et al. Lorazepam concentrations, pharmacokinetics and pharmacodynamics in a cohort of mechanically ventilated ICU patients. Int J Clin Pharmacol Ther 2006; 44: 466-473
  CrossrefPubMedGoogle Scholar
• 276 Degen J, Wolke E, Seiberling M. et al. Comparative study of the pharmacokinetics of amitriptyline oxide and trimipramine after single administration in healthy male probands and patients with renal failure. Med Klin (Munich) 1993; 88: 129-133 171
  PubMedGoogle Scholar
• 277 Degner D, Grohmann R, Kropp S. et al. Severe adverse drug reactions of antidepressants: results of the German multicenter drug surveillance program AMSP. Pharmacopsychiatry 2004; 37 (Suppl. 01) S39-S45
  Article in Thieme ConnectPubMedGoogle Scholar
• 278 Del Dotto P, Bonuccelli U. Clinical pharmacokinetics of cabergoline. Clin Pharmacokinet 2003; 42: 633-645
  CrossrefPubMedGoogle Scholar
• 279 Deleu D, Northway MG, Hanssens Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson’s disease. Clin Pharmacokinet 2002; 41: 261-309
  CrossrefPubMedGoogle Scholar
• 280 Deligiannidis KM. Therapeutic drug monitoring in pregnant and postpartum women: Recommendations for SSRIs, lamotrigine, and lithium. J Clin Psychiatry 2010; 71: 649-650
  CrossrefPubMedGoogle Scholar
• 281 Delva NJ, Hawken ER. Preventing lithium intoxication. Guide for physicians. Can Fam Physician 2001; 47: 1595-1600
  PubMedGoogle Scholar
• 282 Dempsey St DA, Helen G, Jacob 3rd P. et al. Genetic and pharmacokinetic determinants of response to transdermal nicotine in white, black, and Asian nonsmokers. Clin Pharmacol Ther 2013; 94: 687-694
  CrossrefPubMedGoogle Scholar
• 283 Derungs A, Donzelli M, Berger B. et al. Effects of Cytochrome P450 Inhibition and Induction on the phenotyping metrics of the basel cocktail: A randomized crossover study. Clin Pharmacokinet 2016; 55: 79-91
  CrossrefPubMedGoogle Scholar
• 284 Desta Z, Kerbusch T, Flockhart DA. Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6). Clin Pharmacol Ther 1999; 65: 10-20
  CrossrefPubMedGoogle Scholar
• 285 Desta Z, Kerbusch T, Soukhova N. et al. Identification and characterization of human cytochrome P450 isoforms interacting with pimozide. J Pharmacol Exp Ther 1998; 285: 428-437
  PubMedGoogle Scholar
• 286 Deuschle M, Härtter S, Hiemke C. et al. Doxepin and its metabolites in plasma and cerebrospinal fluid in depressed patients. Psychopharmacology (Berl) 1997; 131: 19-22
  CrossrefPubMedGoogle Scholar
• 287 DeVane CL, Boulton DW, Miller LF. et al. Pharmacokinetics of trazodone and its major metabolite m-chlorophenylpiperazine in plasma and brain of rats. Int J Neuropsychopharmacol 1999; 2: 17-23
  CrossrefPubMedGoogle Scholar
• 288 DeVane CL, Liston HL, Markowitz JS. Clinical pharmacokinetics of sertraline. Clin Pharmacokinet 2002; 41: 1247-1266
  CrossrefPubMedGoogle Scholar
• 289 DeVane CL, Stowe ZN, Donovan JL. et al. Therapeutic drug monitoring of psychoactive drugs during pregnancy in the genomic era: challenges and opportunities. J Psychopharmacol 2006; 20: 54-59
  CrossrefPubMedGoogle Scholar
• 290 Diaz FJ, de Leon J, Josiassen RC. et al. Plasma clozapine concentration coefficients of variation in a long-term study. Schizophr Res 2005; 72: 131-135
  CrossrefPubMedGoogle Scholar
• 291 Diaz FJ, Eap CB, Ansermot N. et al. Can valproic acid be an inducer of clozapine metabolism?. Pharmacopsychiatry 2014; 47: 89-96
  Article in Thieme ConnectPubMedGoogle Scholar
• 292 Diaz FJ, Santoro V, Spina E. et al. Estimating the size of the effects of co-medications on plasma clozapine concentrations using a model that controls for clozapine doses and confounding variables. Pharmacopsychiatry 2008; 41: 81-91
  Article in Thieme ConnectPubMedGoogle Scholar
• 293 Dilmaghanian S, Gerber JG, Filler SG. et al. Enantioselectivity of inhibition of cytochrome P450 3A4 (CYP3A4) by ketoconazole: Testosterone and methadone as substrates. Chirality 2004; 16: 79-85
  CrossrefPubMedGoogle Scholar
• 294 Dingemanse J, Jorga K, Zurcher G. et al. Multiple-dose clinical pharmacology of the catechol-O-methyl-transferase inhibitor tolcapone in elderly subjects. Eur J Clin Pharmacol 1996; 50: 47-55
  CrossrefPubMedGoogle Scholar
• 295 Dingemanse J, Wood N, Guentert T. et al. Clinical pharmacology of moclobemide during chronic administration of high doses to healthy subjects. Psychopharmacology (Berl) 1998; 140: 164-172
  CrossrefPubMedGoogle Scholar
• 296 Dinger J, Meyer MR, Maurer HH. Development of an in vitro cytochrome P450 cocktail inhibition assay for assessing the inhibition risk of drugs of abuse. Toxicol Lett 2014; 230: 28-35
  CrossrefPubMedGoogle Scholar
• 297 Dixon R, Gentile J, Hsu HB. et al. Nalmefene: Safety and kinetics after single and multiple oral doses of a new opioid antagonist. J Clin Pharmacol 1987; 27: 233-239
  CrossrefPubMedGoogle Scholar
• 298 Dockens RC, Salazar DE, Fulmor IE. et al. Pharmacokinetics of a newly identified active metabolite of buspirone after administration of buspirone over its therapeutic dose range. J Clin Pharmacol 2006; 46: 1308-1312
  CrossrefPubMedGoogle Scholar
• 299 Dockens RC, Tran AQ, Zeng J. et al. Pharmacokinetics of 6-hydroxybuspirone and its enantiomers administered individually or following buspirone administration in humans. Biopharm Drug Dispos 2007; 28: 393-402
  CrossrefPubMedGoogle Scholar
• 300 Domschke K, Tidow N, Schwarte K. et al. Serotonin transporter gene hypomethylation predicts impaired antidepressant treatment response. Int J Neuropsychopharmacol 2014; 17: 1167-1176
  CrossrefPubMedGoogle Scholar
• 301 Dong C, Wong ML, Licinio J. Sequence variations of ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1 and NTRK2: Association with major depression and antidepressant response in Mexican-Americans. Mol Psychiatry 2009; 14: 1105-1118
  CrossrefPubMedGoogle Scholar
• 302 Doose DR, Brodie MJ, Wilson EA. et al. Topiramate and lamotrigine pharmacokinetics during repetitive monotherapy and combination therapy in epilepsy patients. Epilepsia 2003; 44: 917-922
  CrossrefPubMedGoogle Scholar
• 303 Doran A, Obach RS, Smith BJ. et al. The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: Evaluation using the MDR1A/1B knockout mouse model. Drug Metab Dispos 2005; 33: 165-174
  CrossrefPubMedGoogle Scholar
• 304 Dormann H, Sonst A, Müller F. et al. Adverse drug events in older patients admitted as an emergency: The role of potentially inappropriate medication in elderly people (PRISCUS). Dtsch Arztebl Int 2013; 110: 213-219
  PubMedGoogle Scholar
• 305 dos Santos FM, Goncalves JC, Caminha R. et al. Pharmacokinetic/pharmacodynamic modeling of psychomotor impairment induced by oral clonazepam in healthy volunteers. Ther Drug Monit 2009; 31: 566-574
  CrossrefPubMedGoogle Scholar
• 306 Dost FH. Der Blutspiegel- Kinetik der Konzentrationsabläufe in der Kreislaufkörperflüssigkeit. Leipzig: Georg Thieme; 1953
  Google Scholar
• 307 Dresse A, Rosen JM, Brems H. et al. Influence of food on tianeptine and its main metabolite kinetics. J Clin Pharmacol 1988; 28: 1115-1119
  CrossrefPubMedGoogle Scholar
• 308 Drouet-Coassolo C, Iliadis A, Coassolo P. et al. Pharmacokinetics of flunitrazepam following single dose oral administration in liver disease patients compared with healthy volunteers. Fundam Clin Pharmacol 1990; 4: 643-651
  CrossrefPubMedGoogle Scholar
• 309 Drover D, Lemmens H, Naidu S. et al. Pharmacokinetics, pharmacodynamics, and relative pharmacokinetic/pharmacodynamic profiles of zaleplon and zolpidem. Clin Ther 2000; 22: 1443-1461
  CrossrefPubMedGoogle Scholar
• 310 Dubois N, Demaret I, Ansseau M. et al. Plasma level monitoring of the major metabolites of diacetylmorphine (heroin) by the "chasing the dragon" route in severe heroin addicts. Acta Clin Belg 2013; 68: 359-367
  CrossrefPubMedGoogle Scholar
• 311 Dubois N, Hallet C, Seidel L. et al. Estimation of the Time Interval between the Administration of Heroin and the Sampling of Blood in Chronic Inhalers. J Anal Toxicol 2015; 39: 300-305
  CrossrefPubMedGoogle Scholar
• 312 Dubovsky SL, Frobose C, Phiri P. et al. Short-term safety and pharmacokinetic profile of asenapine in older patients with psychosis. Int J Geriatr Psychiatry 2012; 27: 472-482
  CrossrefPubMedGoogle Scholar
• 313 Dunbar JL, Turncliff RZ, Hayes SC. et al. Population pharmacokinetics of extended-release injectable naltrexone (XR-NTX) in patients with alcohol dependence. J Stud Alcohol Drugs 2007; 68: 862-870
  CrossrefPubMedGoogle Scholar
• 314 Dvorchik BH, Vesell ES. Pharmacokinetic interpretation of data gathered during therapeutic drug monitoring. Clin Chem 1976; 22: 868-878
  CrossrefPubMedGoogle Scholar
• 315 Dwivedi R, Gupta YK, Singh M. et al. Correlation of saliva and serum free valproic acid concentrations in persons with epilepsy. Seizure 2015; 25: 187-190
  CrossrefPubMedGoogle Scholar
• 316 Dwivedi R, Singh M, Kaleekal T. et al. Concentration of antiepileptic drugs in persons with epilepsy: A comparative study in serum and saliva. Int J Neurosci 2016; 126: 972-978
  CrossrefPubMedGoogle Scholar
• 317 Eagles JM, McCann I, MacLeod TN. et al. Lithium monitoring before and after the distribution of clinical practice guidelines. Acta Psychiatr Scand 2000; 101: 349-353
  CrossrefPubMedGoogle Scholar
• 318 Eap CB, Baumann P. Analytical methods for the quantitative determination of selective serotonin reuptake inhibitors for therapeutic drug monitoring purposes in patients. J Chromatogr B Biomed Appl 1996; 686: 51-63
  CrossrefPubMedGoogle Scholar
• 319 Eap CB, Bender S, Gastpar M. et al. Steady state plasma levels of the enantiomers of trimipramine and of its metabolites in CYP2D6-, CYP2C19- and CYP3A4/5-phenotyped patients. Ther Drug Monit 2000; 22: 209-214
  CrossrefPubMedGoogle Scholar
• 320 Eap CB, Bertschy G, Baumann P. et al. High interindividual variability of methadone enantiomer blood levels to dose ratios. Arch Gen Psychiatry 1998; 55: 89-90
  CrossrefPubMedGoogle Scholar
• 321 Eap CB, Bourquin M, Martin J. et al. Plasma concentrations of the enantiomers of methadone and therapeutic response in methadone maintenance treatment. Drug Alcohol Depend 2000; 61: 47-54
  CrossrefPubMedGoogle Scholar
• 322 Eap CB, Buclin T, Baumann P. Interindividual variability of the clinical pharmacokinetics of methadone: Implications for the treatment of opioid dependence. Clin Pharmacokinet 2002; 41: 1153-1193
  CrossrefPubMedGoogle Scholar
• 323 Eap CB, Finkbeiner T, Gastpar M. et al. Replacement of (R)-methadone by a double dose of (R,S)-methadone in addicts: Interindividual variability of the (R)/(S) ratios and evidence of adaptive changes in methadone pharmacokinetics. Eur J Clin Pharmacol 1996; 50: 385-389
  CrossrefPubMedGoogle Scholar
• 324 Eap CB, Guentert TW, Schaublin-Loidl M. et al. Plasma levels of the enantiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone, and thioridazine 5-sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin. Clin Pharmacol Ther 1996; 59: 322-331
  CrossrefPubMedGoogle Scholar
• 325 Eap CB, Koeb L, Baumann P. Determination of trimipramine and its demethylated and hydroxylated metabolites in plasma by gas chromatography-mass spectrometry. J Chromatogr 1994; 652: 97-103
  CrossrefPubMedGoogle Scholar
• 326 Eap CB, Lima CA, Macciardi F. et al. Steady state concentrations of the enantiomers of mianserin and desmethylmianserin in poor and in homozygous and heterozygous extensive metabolizers of debrisoquine. Ther Drug Monit 1998; 20: 7-13
  CrossrefPubMedGoogle Scholar
• 327 Egberts K, Karwautz A, Plener PL. et al. Pharmacovigilance in child and adolescent psychiatry. Z Kinder Jugendpsychiatr Psychother 2015; 43: 21-28
  CrossrefPubMedGoogle Scholar
• 328 Egberts KM, Mehler-Wex C, Gerlach M. Therapeutic drug monitoring in child and adolescent psychiatry. Pharmacopsychiatry 2011; 44: 249-253
  Article in Thieme ConnectPubMedGoogle Scholar
• 329 Eggart V, Hiemke C, Zernig G. "There is no dose-response relationship in psychopharmacotherapy" vs "pharmacotherapy in psychiatry is based on ligand-receptor interaction": A unifying hypothesis and the need for plasma concentration based clinical trials. Psychopharmacology (Berl) 2011; 217: 297-300
  CrossrefPubMedGoogle Scholar
• 330 Eggert Hansen C, Rosted Christensen T, Elley J. et al. Clinical pharmacokinetic studies of perphenazine. Br J Clin Pharmacol 1976; 3: 915-923
  CrossrefPubMedGoogle Scholar
• 331 Ehmann F, Caneva L, Prasad K. et al. Pharmacogenomic information in drug labels: European medicines agency perspective. Pharmacogenomics J 2015; 15: 201-210
  CrossrefPubMedGoogle Scholar
• 332 Eichelbaum M, Ingelman-Sundberg M, Evans WE. Pharmacogenomics and individualized drug therapy. Annu Rev Med 2006; 57: 119-137
  CrossrefPubMedGoogle Scholar
• 333 El Desoky ES, Sabarinath SN, Hamdi MM. et al. Population pharmacokinetics of steady-state carbamazepine in Egyptian epilepsy patients. J Clin Pharm Ther 2012; 37: 352-355
  CrossrefPubMedGoogle Scholar
• 334 Ellinwood Jr. EH, Heatherly DG, Nikaido AM. et al. Comparative pharmacokinetics and pharmacodynamics of lorazepam, alprazolam and diazepam. Psychopharmacology (Berl) 1985; 86: 392-399
  CrossrefPubMedGoogle Scholar
• 335 Elshoff JP, Cawello W, Andreas JO. et al. An update on pharmacological, pharmacokinetic properties and drug-drug interactions of rotigotine transdermal system in Parkinson’s disease and restless legs syndrome. Drugs 2015; 75: 487-501
  CrossrefPubMedGoogle Scholar
• 336 Ereshefsky L, Jann MW, Saklad SR. et al. Effects of smoking on fluphenazine clearance in psychiatric inpatients. Biol Psychiatry 1985; 20: 329-332
  CrossrefPubMedGoogle Scholar
• 337 Erickson-Ridout KK, Zhu J, Lazarus P. Olanzapine metabolism and the significance of UGT1A448V and UGT2B1067Y variants. Pharmacogenet Genomics 2011; 21: 539-551
  CrossrefPubMedGoogle Scholar
• 338 Ermer J, Corcoran M, Lasseter K. et al. Relative bioavailabilities of lisdexamfetamine dimesylate and d-amphetamine in healthy adults in an open-label, randomized, crossover study after mixing lisdexamfetamine dimesylate with food or drink. Ther Drug Monit 2016; 38: 769-776
  CrossrefPubMedGoogle Scholar
• 339 Ermer J, Haffey MB, Richards C. et al. An open-label investigation of the pharmacokinetic profiles of lisdexamfetamine dimesylate and venlafaxine extended-release, administered alone and in combination, in healthy adults. Clin Drug Investig 2013; 33: 243-254
  CrossrefPubMedGoogle Scholar
• 340 Evans LE, Bett JH, Cox JR. et al. The bioavailability of oral and parenteral chlorimipramine (Anafranil). Prog Neuropsychopharmacol 1980; 4: 293-302
  CrossrefPubMedGoogle Scholar
• 341 Evans WE, Relling MV. Pharmacogenomics: Translating functional genomics into rational therapeutics. Science 1999; 286: 487-491
  CrossrefPubMedGoogle Scholar
• 342 Faber MS, Fuhr U. Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. Clin Pharmacol Ther 2004; 76: 178-184
  CrossrefPubMedGoogle Scholar
• 343 Faber MS, Jetter A, Fuhr U. Assessment of CYP1A2 activity in clinical practice: Why, how, and when?. Basic Clin Pharmacol Toxicol 2005; 97: 125-134
  CrossrefPubMedGoogle Scholar
• 344 Faessel HM, Gibbs MA, Clark DJ. et al. Multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy smokers. J Clin Pharmacol 2006; 46: 1439-1448
  CrossrefPubMedGoogle Scholar
• 345 Faiman MD, Jensen JC, Lacoursiere RB. Elimination kinetics of disulfiram in alcoholics after single and repeated doses. Clin Pharmacol Ther 1984; 36: 520-526
  CrossrefPubMedGoogle Scholar
• 346 Fanton L, Bevalot F, Grait H. et al. Fatal intoxication with milnacipran. J Forensic Leg Med 2008; 15: 388-390
  CrossrefPubMedGoogle Scholar
• 347 Farde L, Nordstrom AL, Wiesel FA. et al. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 1992; 49: 538-544
  CrossrefPubMedGoogle Scholar
• 348 Fasano A, Bove F, Gabrielli M. et al. Liquid melevodopa versus standard levodopa in patients with Parkinson disease andsmall intestinal bacterial overgrowth. Clin Neuropharmacol 2014; 37: 91-95
  CrossrefPubMedGoogle Scholar
• 349 Fellows L, Ahmad F, Castle DJ. et al. Investigation of target plasma concentration-effect relationships for olanzapine in schizophrenia. Ther Drug Monit 2003; 25: 682-689
  CrossrefPubMedGoogle Scholar
• 350 Feng Y, Pollock BG, Coley K. et al. Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study. Br J Clin Pharmacol 2008; 66: 629-639
  PubMedGoogle Scholar
• 351 Feng Y, Pollock BG, Ferrell RE. et al. Paroxetine: Population pharmacokinetic analysis in late-life depression using sparse concentration sampling. Br J Clin Pharmacol 2006; 61: 558-569
  CrossrefPubMedGoogle Scholar
• 352 Fernandez C, Martin C, Gimenez F. et al. Clinical pharmacokinetics of zopiclone. Clin Pharmacokinet 1995; 29: 431-441
  CrossrefPubMedGoogle Scholar
• 353 Ferrari A, Bertolotti M, Dell’Utri A. et al. Serum time course of naltrexone and 6 beta-naltrexol levels during long-term treatment in drug addicts. Drug Alcohol Depend 1998; 52: 211-220
  CrossrefPubMedGoogle Scholar
• 354 Ferrell Jr. PB, McLeod HL. Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics 2008; 9: 1543-1546
  CrossrefPubMedGoogle Scholar
• 355 Ferron GM, Paul J, Fruncillo R. et al. Multiple-dose, linear, dose-proportional pharmacokinetics of retigabine in healthy volunteers. J Clin Pharmacol 2002; 42: 175-182
  CrossrefPubMedGoogle Scholar
• 356 Figueroa C, Brecher M, Hamer-Maansson JE. et al. Pharmacokinetic profiles of extended release quetiapine fumarate compared with quetiapine immediate release. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33: 199-204
  CrossrefPubMedGoogle Scholar
• 357 Filser JG, Kaumeier S, Brand T. et al. Pharmacokinetics of amitriptyline and amitriptylinoxide after intravenous or oral administration in humans. Pharmacopsychiatry 1988; 21: 381-383
  Article in Thieme ConnectPubMedGoogle Scholar
• 358 Findling RL, Goldman R, Chiu YY. et al. Pharmacokinetics and Tolerability of Lurasidone in Children and Adolescents With Psychiatric Disorders. Clin Ther 2015; 37: 2788-2797
  CrossrefPubMedGoogle Scholar
• 359 Findling RL, Nucci G, Piergies AA. et al. Multiple dose pharmacokinetics of paroxetine in children and adolescents with major depressive disorder or obsessive-compulsive disorder. Neuropsychopharmacology 2006; 31: 1274-1285
  CrossrefPubMedGoogle Scholar
• 360 Fischer M, Unterecker S, Deckert J. et al. Elevated clozapine serum levels in combination with perazine. Psychopharmacology (Berl) 2013; 226: 623-625
  CrossrefPubMedGoogle Scholar
• 361 Fisher DS, Handley SA, Flanagan RJ. et al. Plasma concentrations of quetiapine, N-desalkylquetiapine, o-desalkylquetiapine, 7-hydroxyquetiapine, and quetiapine sulfoxide in relation to quetiapine dose, formulation, and other factors. Ther Drug Monit 2012; 34: 415-421
  PubMedGoogle Scholar
• 362 Fisher DS, van Schalkwyk GI, Seedat S. et al. Plasma, oral fluid, and whole-blood distribution of antipsychotics and metabolites in clinical samples. Ther Drug Monit 2013; 35: 345-351
  CrossrefPubMedGoogle Scholar
• 363 Fitzgerald PB, Kapur S, Remington G. et al. Predicting haloperidol occupancy of central dopamine D2 receptors from plasma levels. Psychopharmacology (Berl) 2000; 149: 1-5
  CrossrefPubMedGoogle Scholar
• 364 Flanagan RJ. Developing an analytical toxicology service: principles and guidance. Toxicol Rev 2004; 23: 251-263
  CrossrefPubMedGoogle Scholar
• 365 Fleischhacker WW, Sanchez R, Perry PP. et al. Aripiprazole once-monthly for treatment of schizophrenia: Double-blind, randomised, non-inferiority study. Br J Psychiatry 2014; 205: 135-144
  CrossrefPubMedGoogle Scholar
• 366 Fleming J, Chetty M. Therapeutic monitoring of valproate in psychiatry: how far have we progressed?. Clin Neuropharmacol 2006; 29: 350-360
  CrossrefPubMedGoogle Scholar
• 367 Fogelman SM, Schmider J, Venkatakrishnan K. et al. O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: Effect of metabolic inhibitors and SSRI antidepressants. Neuropsychopharmacology 1999; 20: 480-490
  CrossrefPubMedGoogle Scholar
• 368 Foisy MM, Yakiwchuk EM, Hughes CA. Induction effects of ritonavir: implications for drug interactions. Ann Pharmacother 2008; 42: 1048-1059
  CrossrefPubMedGoogle Scholar
• 369 Fontaine R, Mercier P, Beaudry P. et al. Bromazepam and lorazepam in generalized anxiety: a placebo-controlled study with measurement of drug plasma concentrations. Acta Psychiatr Scand 1986; 74: 451-458
  CrossrefPubMedGoogle Scholar
• 370 Food and Drug Administration. Guidance for industry: bioanalytical method validation. 2001; http://www.fda.gov/cvm
  PubMed
• 371 Foster DJ, Somogyi AA, Dyer KR. et al. Steady-state pharmacokinetics of (R)- and (S)-methadone in methadone maintenance patients. Br J Clin Pharmacol 2000; 50: 427-440
  CrossrefPubMedGoogle Scholar
• 372 Foti RS, Rock DA, Wienkers LC. et al. Selection of alternative CYP3A4 probe substrates for clinical drug interaction studies using in vitro data and in vivo simulation. Drug Metab Dispos 2010; 38: 981-987
  CrossrefPubMedGoogle Scholar
• 373 Frank D, Jaehde U, Fuhr U. Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping. Eur J Clin Pharmacol 2007; 63: 321-333
  CrossrefPubMedGoogle Scholar
• 374 Freeman MP, Nolan Jr. PE, Davis MF. et al. Pharmacokinetics of sertraline across pregnancy and postpartum. J Clin Psychopharmacol 2008; 28: 646-653
  CrossrefPubMedGoogle Scholar
• 375 Fric M, Pfuhlmann B, Laux G. et al. The influence of smoking on the serum level of duloxetine. Pharmacopsychiatry 2008; 41: 151-155
  Article in Thieme ConnectPubMedGoogle Scholar
• 376 Friden M, Winiwarter S, Jerndal G. et al. Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids. J Med Chem 2009; 52: 6233-6243
  CrossrefPubMedGoogle Scholar
• 377 Frieboes RM, Sonntag A, Yassouridis A. et al. Clinical outcome after trimipramine in patients with delusional depression – a pilot study. Pharmacopsychiatry 2003; 36: 12-17
  Article in Thieme ConnectPubMedGoogle Scholar
• 378 Friedman H, Greenblatt DJ, Peters GR. et al. Pharmacokinetics and pharmacodynamics of oral diazepam: Effect of dose, plasma concentration, and time. Clin Pharmacol Ther 1992; 52: 139-150
  CrossrefPubMedGoogle Scholar
• 379 Friedrich ME, Akimova E, Huf W et al. Drug-induced liver injury during antidepressant treatment: Results of AMSP, a drug surveillance program. Int J Neuropsychopharmacol 2016; 19:
  PubMed
• 380 Fritze J, Laux G, Sofic E. et al. Plasma moclobemide and metabolites: Lack of correlation with clinical response and biogenic amines. Psychopharmacology (Berl) 1989; 99: 252-256
  CrossrefPubMedGoogle Scholar
• 381 Froemming JS, Lam YW, Jann MW. et al. Pharmacokinetics of haloperidol. Clin Pharmacokinet 1989; 17: 396-423
  CrossrefPubMedGoogle Scholar
• 382 Froscher W, Schier KR, Hoffmann M. et al. Topiramate: A prospective study on the relationship between concentration, dosage and adverse events in epileptic patients on combination therapy. Epileptic Disord 2005; 7: 237-248
  PubMedGoogle Scholar
• 383 Frye RF, Matzke GR, Jallad NS. et al. The effect of age on the pharmacokinetics of the opioid antagonist nalmefene. Br J Clin Pharmacol 1996; 42: 301-306
  CrossrefPubMedGoogle Scholar
• 384 Fudio S, Borobia AM, Pinana E. et al. Evaluation of the influence of sex and CYP2C19 and CYP2D6 polymorphisms in the disposition of citalopram. Eur J Pharmacol 2010; 626: 200-204
  CrossrefPubMedGoogle Scholar
• 385 Fuhr U, Anders EM, Mahr G. et al. Inhibitory potency of quinolone antibacterial agents against cytochrome P450IA2 activity in vivo and in vitro. Antimicrob Agents Chemother 1992; 36: 942-948
  CrossrefPubMedGoogle Scholar
• 386 Fuhr U, Rost KL, Engelhardt R. et al. Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations. Pharmacogenetics 1996; 6: 159-176
  CrossrefPubMedGoogle Scholar
• 387 Fukasawa T, Suzuki A, Otani K. Effects of genetic polymorphism of cytochrome P450 enzymes on the pharmacokinetics of benzodiazepines. J Clin Pharm Ther 2007; 32: 333-341
  CrossrefPubMedGoogle Scholar
• 388 Furukori H, Kondo T, Yasui N. et al. Effects of itraconazole on the steady-state plasma concentrations of bromperidol and reduced bromperidol in schizophrenic patients. Psychopharmacology (Berl) 1999; 145: 189-192
  CrossrefPubMedGoogle Scholar
• 389 Gaedigk A, Simon SD, Pearce RE. et al. The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther 2008; 83: 234-242
  CrossrefPubMedGoogle Scholar
• 390 Gaertner HJ, Golfinopoulos G, Breyer-Pfaff U. Response to maprotiline treatment in depressive patients relationship to urinary MHPG excretion and plasma drug level. Pharmacopsychiatria 1982; 15: 170-174
  Article in Thieme ConnectPubMedGoogle Scholar
• 391 Gaertner I, Gaertner HJ, Vonthein R. et al. Therapeutic drug monitoring of clozapine in relapse prevention: A five-year prospective study. J Clin Psychopharmacol 2001; 21: 305-310
  CrossrefPubMedGoogle Scholar
• 392 Gafni I, Busto UE, Tyndale RF. et al. The role of cytochrome P450 2C19 activity in flunitrazepam metabolism in vivo. J Clin Psychopharmacol 2003; 23: 169-175
  CrossrefPubMedGoogle Scholar
• 393 Gallagher P, O’Mahony D. STOPP (Screening Tool of Older Persons’ potentially inappropriate Prescriptions): application to acutely ill elderly patients and comparison with Beers’ criteria. Age Ageing 2008; 37: 673-679
  CrossrefPubMedGoogle Scholar
• 394 Garg V, Chandorkar G, Farmer HF. et al. Effect of telaprevir on the pharmacokinetics of midazolam and digoxin. J Clin Pharmacol 2012; 52: 1566-1573
  CrossrefPubMedGoogle Scholar
• 395 Garnock-Jones KP, Keating GM. Atomoxetine: A review of its use in attention-deficit hyperactivity disorder in children and adolescents. Paediatr Drugs 2009; 11: 203-226
  CrossrefPubMedGoogle Scholar
• 396 Gastpar M, Heinz W, Poehlke T et al. Substitutionstherapie bei Drogenabhängigkeit. 2. überarbeitete AuflageBerlin, Heidelberg, New York: Springer Verlag; 2002
  PubMed
• 397 Genton P, Guerrini R, Perucca E. Tiagabine in clinical practice. Epilepsia 2001; 42 (Suppl. 03) 42-45
  CrossrefPubMedGoogle Scholar
• 398 Geretsegger C. Psychopharmaka-Spiegel bei Gutachten in Pensionsverfahren. Proc DGPPN 2006; P0169
  PubMedGoogle Scholar
• 399 Gerlach M, Egberts K, Dang SY. et al. Therapeutic drug monitoring as a measure of proactive pharmacovigilance in child and adolescent psychiatry. Expert Opin Drug Saf 2016; 15: 1477-1482
  CrossrefPubMedGoogle Scholar
• 400 Gerlach M, Hunnerkopf R, Rothenhofer S. et al. Therapeutic drug monitoring of quetiapine in adolescents with psychotic disorders. Pharmacopsychiatry 2007; 40: 72-76
  Article in Thieme ConnectPubMedGoogle Scholar
• 401 Gerstenberg G, Aoshima T, Fukasawa T. et al. Relationship between clinical effects of fluvoxamine and the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients. Psychopharmacology (Berl) 2003; 167: 443-448
  CrossrefPubMedGoogle Scholar
• 402 Gervasini G, Carrillo JA, Benitez J. Potential role of cerebral cytochrome P450 in clinical pharmacokinetics: Modulation by endogenous compounds. Clin Pharmacokinet 2004; 43: 693-706
  CrossrefPubMedGoogle Scholar
• 403 Gex-Fabry M, Balant-Gorgia AE, Balant LP. Clomipramine concentration as a predictor of delayed response: A naturalistic study. Eur J Clin Pharmacol 1999; 54: 895-902
  CrossrefPubMedGoogle Scholar
• 404 Gex-Fabry M, Balant-Gorgia AE, Balant LP. Therapeutic drug monitoring of olanzapine: The combined effect of age, gender, smoking, and comedication. Ther Drug Monit 2003; 25: 46-53
  CrossrefPubMedGoogle Scholar
• 405 Gex-Fabry M, Balant-Gorgia AE, Balant LP. et al. Time course of clinical response to venlafaxine: Relevance of plasma level and chirality. Eur J Clin Pharmacol 2004; 59: 883-891
  CrossrefPubMedGoogle Scholar
• 406 Gex-Fabry M, Gervasoni N, Eap CB. et al. Time course of response to paroxetine: Influence of plasma level. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 892-900
  CrossrefPubMedGoogle Scholar
• 407 Ghosal A, Yuan Y, Tong W. et al. Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor. Drug Metab Dispos 2011; 39: 510-521
  CrossrefPubMedGoogle Scholar
• 408 Gidal BE, Majid O, Ferry J. et al. The practical impact of altered dosing on perampanel plasma concentrations: Pharmacokinetic modeling from clinical studies. Epilepsy Behav 2014; 35: 6-12
  CrossrefPubMedGoogle Scholar
• 409 Giessmann T, May K, Modess C. et al. Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans. Clin Pharmacol Ther 2004; 76: 192-200
  CrossrefPubMedGoogle Scholar
• 410 Gilles M, Deuschle M, Kellner S. et al. Paroxetine serum concentrations in depressed patients and response to treatment. Pharmacopsychiatry 2005; 38: 118-121
  Article in Thieme ConnectPubMedGoogle Scholar
• 411 Gillman PK. Advances pertaining to the pharmacology and interactions of irreversible nonselective monoamine oxidase inhibitors. J Clin Psychopharmacol 2011; 31: 66-74
  CrossrefPubMedGoogle Scholar
• 412 Gillman PK. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol 2007; 151: 737-748
  CrossrefPubMedGoogle Scholar
• 413 Gjestad C, Westin AA, Skogvoll E. et al. Effect of proton pump inhibitors on the serum concentrations of the selective serotonin reuptake inhibitors citalopram, escitalopram, and sertraline. Ther Drug Monit 2015; 37: 90-97
  CrossrefPubMedGoogle Scholar
• 414 Glassman AH, Perel JM, Shostak M. et al. Clinical implications of imipramine plasma levels for depressive illness. Arch Gen Psychiatry 1977; 34: 197-204
  CrossrefPubMedGoogle Scholar
• 415 Glauser TA, Pippenger CE. Controversies in blood-level monitoring: Reexamining its role in the treatment of epilepsy. Epilepsia 2000; 41 (Suppl. 08) S6-15
  CrossrefPubMedGoogle Scholar
• 416 Gleason MM, Egger HL, Emslie GJ. et al. Psychopharmacological treatment for very young children: Contexts and guidelines. J Am Acad Child Adolesc Psychiatry 2007; 46: 1532-1572
  CrossrefPubMedGoogle Scholar
• 417 Glotzbach RK, Preskorn SH. Brain concentrations of tricyclic antidepressants: Single-dose kinetics and relationship to plasma concentrations in chronically dosed rats. Psychopharmacology (Berl) 1982; 78: 25-27
  CrossrefPubMedGoogle Scholar
• 418 Glue P, Cape G, Tunnicliff D. et al. Switching opioid-dependent patients from methadone to morphine: Safety, tolerability, and methadone pharmacokinetics. J Clin Pharmacol 2016; 56: 960-965
  CrossrefPubMedGoogle Scholar
• 419 Gomolin IH, Smith C, Jeitner TM. Once-daily memantine: Pharmacokinetic and clinical considerations. J Am Geriatr Soc 2010; 58: 1812-1813
  CrossrefPubMedGoogle Scholar
• 420 Gonzalez JP, Brogden RN. Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs 1988; 35: 192-213
  CrossrefPubMedGoogle Scholar
• 421 Goodnick PJ, Dominguez RA, DeVane CL. et al. Bupropion slow-release response in depression: Diagnosis and biochemistry. Biol Psychiatry 1998; 44: 629-632
  CrossrefPubMedGoogle Scholar
• 422 Goole J, Van Gansbeke B, Pilcer G. et al. Pharmacoscintigraphic and pharmacokinetic evaluation on healthy human volunteers of sustained-release floating minitablets containing levodopa and carbidopa. Int J Pharm 2008; 364: 54-63
  CrossrefPubMedGoogle Scholar
• 423 Gram LF, Guentert TW, Grange S. et al. Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: A panel study. Clin Pharmacol Ther 1995; 57: 670-677
  CrossrefPubMedGoogle Scholar
• 424 Grandjean EM, Aubry JM. Lithium: Updated human knowledge using an evidence-based approach. Part II: Clinical pharmacology and therapeutic monitoring. CNS Drugs 2009; 23: 331-349
  CrossrefPubMedGoogle Scholar
• 425 Grangeon A, Gravel S, Gaudette F. et al. Highly sensitive LC-MS/MS methods for the determination of seven human CYP450 activities using small oral doses of probe-drugs in human. J Chromatogr B Analyt Technol Biomed Life Sci 2017; 1040: 144-158
  CrossrefPubMedGoogle Scholar
• 426 Granneman GR, Braeckman RA, Locke CS. et al. Effect of zileuton on theophylline pharmacokinetics. Clin Pharmacokinet 1995; 29 (Suppl. 02) 77-83
  CrossrefPubMedGoogle Scholar
• 427 Grasela TH, Fiedler-Kelly JB, Salvadori C. et al. Predictive performance of population pharmacokinetic parameters of tianeptine as applied to plasma concentrations from a post-marketing study. Eur J Clin Pharmacol 1993; 45: 123-128
  CrossrefPubMedGoogle Scholar
• 428 Grasmader K, Verwohlt PL, Kuhn KU. et al. Relationship between mirtazapine dose, plasma concentration, response, and side effects in clinical practice. Pharmacopsychiatry 2005; 38: 113-117
  Article in Thieme ConnectPubMedGoogle Scholar
• 429 Greenbaum L, Smith RC, Rigbi A. et al. Further evidence for association of the RGS2 gene with antipsychotic-induced parkinsonism: protective role of a functional polymorphism in the 3’-untranslated region. Pharmacogenomics J 2009; 9: 103-110
  CrossrefPubMedGoogle Scholar
• 430 Greenbaum L, Strous RD, Kanyas K. et al. Association of the RGS2 gene with extrapyramidal symptoms induced by treatment with antipsychotic medication. Pharmacogenet Genomics 2007; 17: 519-528
  CrossrefPubMedGoogle Scholar
• 431 Greenblatt DJ, Abernethy DR, Divoll M. et al. Pharmacokinetic properties of benzodiazepine hypnotics. J Clin Psychopharmacol 1983; 3: 129-132
  PubMedGoogle Scholar
• 432 Greenblatt DJ, Blaskovich PD, Nuwayser ES. et al. Clonazepam pharmacokinetics: Comparison of subcutaneous microsphere injection with multiple-dose oral administration. J Clin Pharmacol 2005; 45: 1288-1293
  CrossrefPubMedGoogle Scholar
• 433 Greenblatt DJ, Divoll M, Harmatz JS. et al. Kinetics and clinical effects of flurazepam in young and elderly noninsomniacs. Clin Pharmacol Ther 1981; 30: 475-486
  CrossrefPubMedGoogle Scholar
• 434 Greenblatt DJ, Divoll M, Harmatz JS. et al. Oxazepam kinetics: Effects of age and sex. J Pharmacol Exp Ther 1980; 215: 86-91
  PubMedGoogle Scholar
• 435 Greenblatt DJ, Ehrenberg BL, Gunderman J. et al. Pharmacokinetic and electroencephalographic study of intravenous diazepam, midazolam, and placebo. Clin Pharmacol Ther 1989; 45: 356-365
  CrossrefPubMedGoogle Scholar
• 436 Greenblatt DJ, Gan L, Harmatz JS. et al. Pharmocokinetics and pharmacodynamics of single-dose triazolam: Electroencephalography compared with the Digit-Symbol Substitution Test. Br J Clin Pharmacol 2005; 60: 244-248
  CrossrefPubMedGoogle Scholar
• 437 Greenblatt DJ, Harmatz JS, Friedman H. et al. A large-sample study of diazepam pharmacokinetics. Ther Drug Monit 1989; 11: 652-657
  CrossrefPubMedGoogle Scholar
• 438 Greenblatt DJ, Harmatz JS, von Moltke LL. et al. Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo. Clin Pharmacol Ther 1998; 64: 553-561
  CrossrefPubMedGoogle Scholar
• 439 Greenblatt DJ, Harmatz JS, von Moltke LL. et al. Age and gender effects on the pharmacokinetics and pharmacodynamics of triazolam, a cytochrome P450 3A substrate. Clin Pharmacol Ther 2004; 76: 467-479
  CrossrefPubMedGoogle Scholar
• 440 Greenblatt DJ, Shader RI, Franke K. et al. Pharmacokinetics and bioavailability of intravenous, intramuscular, and oral lorazepam in humans. J Pharm Sci 1979; 68: 57-63
  CrossrefPubMedGoogle Scholar
• 441 Greenblatt DJ, von Moltke LL, Ehrenberg BL. et al. Kinetics and dynamics of lorazepam during and after continuous intravenous infusion. Crit Care Med 2000; 28: 2750-2757
  CrossrefPubMedGoogle Scholar
• 442 Greenblatt DJ, von Moltke LL, Harmatz JS. et al. Short-term exposure to low-dose ritonavir impairs clearance and enhances adverse effects of trazodone. J Clin Pharmacol 2003; 43: 414-422
  CrossrefPubMedGoogle Scholar
• 443 Greig SL. Brexpiprazole First Global Approval. Drugs 2015; 75: 1687-1697
  CrossrefPubMedGoogle Scholar
• 444 Greil W, Haberle A, Haueis P. et al. Pharmacotherapeutic trends in 2231 psychiatric inpatients with bipolar depression from the International AMSP Project between 1994 and 2009. J Affect Disord 2012; 136: 534-542
  CrossrefPubMedGoogle Scholar
• 445 Greil W, Haberle A, Schuhmann T. et al. Age and adverse drug reactions from psychopharmacological treatment: Data from the AMSP drug surveillance programme in Switzerland. Swiss Med Wkly 2013; 143: w13772
  PubMedGoogle Scholar
• 446 Greiner C, Hiemke C, Bader W. et al. Determination of citalopram and escitalopram together with their active main metabolites desmethyl(es-)citalopram in human serum by column-switching high performance liquid chromatography (HPLC) and spectrophotometric detection. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 848: 391-394
  CrossrefPubMedGoogle Scholar
• 447 Gressier F, Porcelli S, Calati R. et al. Pharmacogenetics of clozapine response and induced weight gain: A comprehensive review and meta-analysis. Eur Neuropsychopharmacol 2016; 26: 163-185
  CrossrefPubMedGoogle Scholar
• 448 Grimaldi R, Perucca E, Ruberto G. et al. Pharmacokinetic and pharmacodynamic studies following the intravenous and oral administration of the antiparkinsonian drug biperiden to normal subjects. Eur J Clin Pharmacol 1986; 29: 735-737
  CrossrefPubMedGoogle Scholar
• 449 Grislain L, Gele P, Bertrand M. et al. The metabolic pathways of tianeptine, a new antidepressant, in healthy volunteers. Drug Metab Dispos 1990; 18: 804-808
  PubMedGoogle Scholar
• 450 Grohmann R, Engel RR, Ruther E. et al. The AMSP drug safety program: methods and global results. Pharmacopsychiatry 2004; 37 (Suppl. 01) S4-11
  Article in Thieme ConnectPubMedGoogle Scholar
• 451 Grover CA, Flaherty B, Lung D. et al. Significant toxicity in a young female after low-dose tricyclic antidepressant ingestion. Pediatr Emerg Care 2012; 28: 1066-1069
  CrossrefPubMedGoogle Scholar
• 452 Grözinger M, Härtter S, Hiemke C. et al. Oxybutynin enhances the metabolism of clomipramine and dextrorphan possibly by induction of a cytochrome P450 isoenzyme. J Clin Psychopharmacol 1999; 19: 287-289
  CrossrefPubMedGoogle Scholar
• 453 Gründer G, Baumann P, Conca A. et al. Therapeutic drug monitoring in psychiatry. A brief summary of the new consensus paper by the task force on TDM of the AGNP. Nervenarzt 2014; 85: 847-855
  CrossrefPubMedGoogle Scholar
• 454 Gründer G, Carlsson A, Wong DF. Mechanism of new antipsychotic medications: Occupancy is not just antagonism. Arch Gen Psychiatry 2003; 60: 974-977
  CrossrefPubMedGoogle Scholar
• 455 Gründer G, Fellows C, Janouschek H. et al. Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: An [18F]fallypride PET study. Am J Psychiatry 2008; 165: 988-995
  CrossrefPubMedGoogle Scholar
• 456 Gründer G, Hiemke C, Paulzen M. et al. Therapeutic plasma concentrations of antidepressants and antipsychotics: Lessons from PET imaging. Pharmacopsychiatry 2011; 44: 236-248
  Article in Thieme ConnectPubMedGoogle Scholar
• 457 Gründer G, Hippius H, Carlsson A. The ’atypicality’ of antipsychotics: A concept re-examined and re-defined. Nat Rev Drug Discov 2009; 8: 197-202
  CrossrefPubMedGoogle Scholar
• 458 Guay DR. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson’s disease. Am J Geriatr Pharmacother 2006; 4: 330-346
  CrossrefPubMedGoogle Scholar
• 459 Guberman A, Couture M, Blaschuk K. et al. Add-on trial of clobazam in intractable adult epilepsy with plasma level correlations. Can J Neurol Sci 1990; 17: 311-316
  CrossrefPubMedGoogle Scholar
• 460 Gunes A, Bilir E, Zengil H. et al. Inhibitory effect of valproic acid on cytochrome P450 2C9 activity in epilepsy patients. Basic Clin Pharmacol Toxicol 2007; 100: 383-386
  CrossrefPubMedGoogle Scholar
• 461 Gunes A, Spina E, Dahl ML. et al. ABCB1 polymorphisms influence steady-state plasma levels of 9-hydroxyrisperidone and risperidone active moiety. Ther Drug Monit 2008; 30: 628-633
  CrossrefPubMedGoogle Scholar
• 462 Guo W, Guo GX, Sun C. et al. Therapeutic drug monitoring of psychotropic drugs in China: a nationwide survey. Ther Drug Monit 2013; 35: 816-822
  CrossrefPubMedGoogle Scholar
• 463 Gupta N. Guidelines for lithium monitoring: Are they ideal?. Acta Psychiatr Scand 2001; 104: 76-77
  PubMedGoogle Scholar
• 464 Gupta RN, Dziurdzy SA. Therapeutic monitoring of sertraline. Clin Chem 1994; 40: 498-499
  CrossrefPubMedGoogle Scholar
• 465 Gupta SK, Shah JC, Hwang SS. Pharmacokinetic and pharmacodynamic characterization of OROS and immediate-release amitriptyline. Br J Clin Pharmacol 1999; 48: 71-78
  CrossrefPubMedGoogle Scholar
• 466 Gutmann H, Poller B, Buter KB. et al. Hypericum perforatum: which constituents may induce intestinal MDR1 and CYP3A4 mRNA expression?. Planta Med 2006; 72: 685-690
  Article in Thieme ConnectPubMedGoogle Scholar
• 467 Guy W. editor. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD: U.S. Department of Health, Education, and Welfare; 1976
  Google Scholar
• 468 Haberstroh J, Hampel H, Pantel J. Optimal management of Alzheimer’s disease patients: Clinical guidelines and family advice. Neuropsychiatr Dis Treat 2010; 6: 243-253
  PubMedGoogle Scholar
• 469 Haen E. Der TDM-Befund. Psychopharmakotherapie 2012; 19: 129-134
  PubMedGoogle Scholar
• 470 Haen E. Therapeutic drug monitoring in pharmacovigilance and pharmacotherapy safety. Pharmacopsychiatry 2011; 44: 254-258
  Article in Thieme ConnectPubMedGoogle Scholar
• 471 Haen E, Greiner C, Bader W. et al. Expanding therapeutic reference ranges using dose-related reference ranges. Nervenarzt 2008; 79: 558-566
  CrossrefPubMedGoogle Scholar
• 472 Haen E, Koeber R, Klunemann HH. et al. Implementation of a cost-effective HPLC/UV approach for routine medical quantification of memantine in human serum. Ther Drug Monit 2012; 34: 702-712
  CrossrefPubMedGoogle Scholar
• 473 Haider B, Schmidt R, Schweiger C. et al. Medication adherence in patients with dementia: An Austrian cohort study. Alzheimer Dis Assoc Disord 2014; 28: 128-133
  CrossrefPubMedGoogle Scholar
• 474 Hailey DM, Baird ES. Plasma concentrations of medazepam and its metabolites after oral administration. Br J Anaesth 1979; 51: 493-496
  CrossrefPubMedGoogle Scholar
• 475 Hakooz NM. Caffeine metabolic ratios for the in vivo evaluation of CYP1A2, N-acetyltransferase 2, xanthine oxidase and CYP2A6 enzymatic activities. Curr Drug Metab 2009; 10: 329-338
  CrossrefPubMedGoogle Scholar
• 476 Hallett C, Dean BC. Bromazepam: acute benefit-risk assessment in general practice. Curr Med Res Opin 1984; 8: 683-688
  CrossrefPubMedGoogle Scholar
• 477 Hallinan R, Crettol S, Agho K. et al. Cannabis and benzodiazepines as determinants of methadone trough plasma concentration variability in maintenance treatment: a transnational study. Eur J Clin Pharmacol 2009; 65: 1113-1120
  CrossrefPubMedGoogle Scholar
• 478 Hamelin BA, Allard S, Laplante L. et al. The effect of timing of a standard meal on the pharmacokinetics and pharmacodynamics of the novel atypical antipsychotic agent ziprasidone. Pharmacotherapy 1998; 18: 9-15
  PubMedGoogle Scholar
• 479 Hammarberg A, Beck O, Eksborg S. et al. Acamprosate determinations in plasma and cerebrospinal fluid after multiple dosing measured by liquid chromatography-mass spectroscopy: A pharmacokinetic study in healthy volunteers. Ther Drug Monit 2010; 32: 489-496
  CrossrefPubMedGoogle Scholar
• 480 Hammarberg A, Jayaram-Lindstrom N, Beck O. et al. The effects of acamprosate on alcohol-cue reactivity and alcohol priming in dependent patients: A randomized controlled trial. Psychopharmacology (Berl) 2009; 205: 53-62
  CrossrefPubMedGoogle Scholar
• 481 Hammarlund-Udenaes M. Pharmacokinetic concepts in brain drug delivery. In: Hammarlund-Udenaes M et al. (eds.) Drug Delivery to the Brain, APS Advances in the Pharmaceutical Sciences Series. 10:2014: 127–161
  PubMed
• 482 Handley SA, Bowskill SV, Patel MX. et al. Plasma quetiapine in relation to prescribed dose and other factors: Data from a therapeutic drug monitoring service, 2000-2011. Ther Adv Psychopharmacol 2013; 3: 129-137
  CrossrefPubMedGoogle Scholar
• 483 Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143: 29-36
  CrossrefPubMedGoogle Scholar
• 484 Harden CL, Trifiletti R, Kutt H. Felbamate levels in patients with epilepsy. Epilepsia 1996; 37: 280-283
  CrossrefPubMedGoogle Scholar
• 485 Härtter S, Dingemanse J, Baier D. et al. The role of cytochrome P450 2D6 in the metabolism of moclobemide. Eur Neuropsychopharmacol 1996; 6: 225-230
  PubMedGoogle Scholar
• 486 Härtter S, Hermes B, Szegedi A. et al. Automated determination of paroxetine and its main metabolite by column switching and on-line high-performance liquid chromatography. Ther Drug Monit 1994; 16: 400-406
  CrossrefPubMedGoogle Scholar
• 487 Härtter S, Hiemke C. Column switching and high-performance liquid chromatography in the analysis of amitriptyline, nortriptyline and hydroxylated metabolites in human plasma or serum. J Chromatogr 1992; 578: 273-282
  CrossrefPubMedGoogle Scholar
• 488 Härtter S, Tybring G, Friedberg T. et al. The N-demethylation of the doxepin isomers is mainly catalyzed by the polymorphic CYP2C19. Pharm Res 2002; 19: 1034-1037
  CrossrefPubMedGoogle Scholar
• 489 Härtter S, Wang X, Weigmann H. et al. Differential effects of fluvoxamine and other antidepressants on the biotransformation of melatonin. J Clin Psychopharmacol 2001; 21: 167-174
  CrossrefPubMedGoogle Scholar
• 490 Härtter S, Weigmann H, Hiemke C. Automated determination of reboxetine by high-performance liquid chromatography with column-switching and ultraviolet detection. J Chromatogr B Biomed Sci Appl 2000; 740: 135-140
  CrossrefPubMedGoogle Scholar
• 491 Härtter S, Wetzel H, Hiemke C. Automated determination of fluvoxamine in plasma by column-switching high-performance liquid chromatography. Clin Chem 1992; 38: 2082-2086
  CrossrefPubMedGoogle Scholar
• 492 Hasselstrom J, Linnet K. Quetiapine serum concentrations in psychiatric patients: The influence of comedication. Ther Drug Monit 2004; 26: 486-491
  CrossrefPubMedGoogle Scholar
• 493 Hassler F, Glaser T, Pap AF. et al. A double-blind placebo-controlled discontinuation study of zuclopenthixol for the treatment of aggressive disruptive behaviours in adults with mental retardation – secondary parameter analyses. Pharmacopsychiatry 2008; 41: 232-239
  Article in Thieme ConnectPubMedGoogle Scholar
• 494 Hassler F, Reis O. Pharmacotherapy of disruptive behavior in mentally retarded subjects: A review of the current literature. Dev Disabil Res Rev 2010; 16: 265-272
  CrossrefPubMedGoogle Scholar
• 495 Hattori N, Hasegawa K, Sakamoto T. Pharmacokinetics and effect of food after oral administration of prolonged-release tablets of ropinirole hydrochloride in Japanese patients with Parkinson’s disease. J Clin Pharm Ther 2012; 37: 571-577
  CrossrefPubMedGoogle Scholar
• 496 Havemann-Reinecke U, Küfner H, Schneider U et al. Postakutbehandlung bei Störungen durch Opioide. In: Schmidt LG, Gastpar M, Falkai P et al.(Eds.) Evidenzbasierte Suchtmedizin. AWMF S2 Behandungsleitlinie Suchtbezogene Störungen. Köln: Dt. Ärzte-Verlag; 2006: 193–239
  PubMed
• 497 Haymond J, Ensom MH. Does valproic acid warrant therapeutic drug monitoring in bipolar affective disorder?. Ther Drug Monit 2010; 32: 19-29
  CrossrefPubMedGoogle Scholar
• 498 Hazell P, Becker K, Nikkanen EA. et al. Relationship between atomoxetine plasma concentration, treatment response and tolerability in attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. Atten Defic Hyperact Disord 2009; 1: 201-210
  CrossrefPubMedGoogle Scholar
• 499 Hefner G, Brueckner A, Hiemke C. et al. Therapeutic drug monitoring for patients with Alzheimer dementia to improve treatment with donepezil. Ther Drug Monit 2015; 37: 353-361
  CrossrefPubMedGoogle Scholar
• 500 Hefner G, Laib AK, Sigurdsson H. et al. The value of drug and metabolite concentration in blood as a biomarker of psychopharmacological therapy. Int Rev Psychiatry 2013; 25: 494-508
  CrossrefPubMedGoogle Scholar
• 501 Hefner G, Shams ME, Unterecker S. et al. Inflammation and psychotropic drugs: The relationship between C-reactive protein and antipsychotic drug levels. Psychopharmacology (Berl) 2016; 233: 1695-1705
  CrossrefPubMedGoogle Scholar
• 502 Hefner G, Unterecker S, Shams ME. et al. Melperone but not bisoprolol or metoprolol is a clinically relevant inhibitor of CYP2D6: evidence from a therapeutic drug monitoring survey. J Neural Transm (Vienna) 2015; 122: 1609-1617
  CrossrefPubMedGoogle Scholar
• 503 Hegerl U, Bottlender R, Gallinat J. et al. The serotonin syndrome scale: first results on validity. Eur Arch Psychiatry Clin Neurosci 1998; 248: 96-103
  CrossrefPubMedGoogle Scholar
• 504 Heikkinen H, Saraheimo M, Antila S. et al. Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique. Eur J Clin Pharmacol 2001; 56: 821-826
  CrossrefPubMedGoogle Scholar
• 505 Hejna P, Ublova M, Vorisek V. Black esophagus: acute esophageal necrosis in fatal haloperidol intoxication. J Forensic Sci 2013; 58: 1367-1369
  CrossrefPubMedGoogle Scholar
• 506 Heller S, Hiemke C, Stroba G. et al. Assessment of storage and transport stability of new antidepressant and antipsychotic drugs for a nationwide TDM service. Ther Drug Monit 2004; 26: 459-461
  CrossrefPubMedGoogle Scholar
• 507 Hellriegel ET, Arora S, Nelson M. et al. Steady-state pharmacokinetics and tolerability of modafinil administered alone or in combination with dextroamphetamine in healthy volunteers. J Clin Pharmacol 2002; 42: 450-460
  CrossrefPubMedGoogle Scholar
• 508 Hendershot CS. Pharmacogenetic approaches in the treatment of alcohol use disorders: Addressing clinical utility and implementation thresholds. Addict Sci Clin Pract 2014; 9: 20
  CrossrefPubMedGoogle Scholar
• 509 Hendset M, Hermann M, Lunde H. et al. Impact of the CYP2D6 genotype on steady-state serum concentrations of aripiprazole and dehydroaripiprazole. Eur J Clin Pharmacol 2007; 63: 1147-1151
  CrossrefPubMedGoogle Scholar
• 510 Herman BD, Fleishaker JC, Brown MT. Ketoconazole inhibits the clearance of the enantiomers of the antidepressant reboxetine in humans. Clin Pharmacol Ther 1999; 66: 374-379
  CrossrefPubMedGoogle Scholar
• 511 Herman RJ, Wilkinson GR. Disposition of diazepam in young and elderly subjects after acute and chronic dosing. Br J Clin Pharmacol 1996; 42: 147-155
  CrossrefPubMedGoogle Scholar
• 512 Hermann M, Hendset M, Fosaas K. et al. Serum concentrations of venlafaxine and its metabolites O-desmethylvenlafaxine and N-desmethylvenlafaxine in heterozygous carriers of the CYP2D6*3, *4 or *5 allele. Eur J Clin Pharmacol 2008; 64: 483-487
  CrossrefPubMedGoogle Scholar
• 513 Hermida J, Paz E, Tutor JC. Clozapine and norclozapine concentrations in serum and plasma samples from schizophrenic patients. Ther Drug Monit 2008; 30: 41-45
  CrossrefPubMedGoogle Scholar
• 514 Hesse LM, He P, Krishnaswamy S. et al. Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. Pharmacogenetics 2004; 14: 225-238
  CrossrefPubMedGoogle Scholar
• 515 Hicks JK, Bishop JR, Sangkuhl K. et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther 2015; 98: 127-134
  CrossrefPubMedGoogle Scholar
• 516 Hicks JK, Sangkuhl K, Swen JJ et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther 2017; 102: 37–44
  PubMed
• 517 Hicks JK, Swen JJ, Thorn CF. et al. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther 2013; 93: 402-408
  CrossrefPubMedGoogle Scholar
• 518 Hiemke C. Clinical utility of drug measurement and pharmacokinetics: therapeutic drug monitoring in psychiatry. Eur J Clin Pharmacol 2008; 64: 159-166
  CrossrefPubMedGoogle Scholar
• 519 Hiemke C. Consensus Guideline Based Therapeutic Drug Monitoring (TDM) in Psychiatry and Neurology. Curr Drug Deliv 2016; 13: 353-361
  CrossrefPubMedGoogle Scholar
• 520 Hiemke C. Therapeutic drug monitoring in neuropsychopharmacology: does it hold its promises?. Eur Arch Psychiatry Clin Neurosci 2008; 258 (Suppl. 01) 21-27
  CrossrefPubMedGoogle Scholar
• 521 Hiemke C, Baumann P, Bergemann N. et al. AGNP-Konsensus-Leitlinie für therapeutisches Drug-Monitoring in der Psychiatrie. Update 2011. Psychopharmakotherapie 2012; 19: 91-122
  PubMedGoogle Scholar
• 522 Hiemke C, Baumann P, Bergemann N. et al. Linee guida della consensus conference dell’ANGP per il monitoraggio plasmatico dei farmaci (TDM) in psichiatria. Aggiornamento 2011. Journal of Psychopathology 2014; 20: 286-321
  PubMedGoogle Scholar
• 523 Hiemke C, Baumann P, Bergemann N. et al. The TDM group of the AGNP Az AGNP konszenzuson alapuló irányelvei a terápiás gyógyszerszint montorozásához a pszichiátriában. Psychiatria Hungarica 2012; 27 (Suppl. 01) 7-64
  PubMedGoogle Scholar
• 524 Hiemke C, Baumann P, Bergemann N. et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: Update 2011. Pharmacopsychiatry 2011; 44: 195-235
  Article in Thieme ConnectPubMedGoogle Scholar
• 525 Hiemke C, Dragicevic A, Gründer G. et al. Therapeutic monitoring of new antipsychotic drugs. Ther Drug Monit 2004; 26: 156-160
  CrossrefPubMedGoogle Scholar
• 526 Hiemke C, Härtter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther 2000; 85: 11-28
  CrossrefPubMedGoogle Scholar
• 527 Hiemke C, Shams M. Phenotyping and genotyping of drug metabolism to guide pharmacotherapy in psychiatry. Curr Drug Deliv 2013; 10: 46-53
  CrossrefPubMedGoogle Scholar
• 528 Higuchi H, Yoshida K, Takahashi H. et al. Milnacipran plasma levels and antidepressant response in Japanese major depressive patients. Hum Psychopharmacol 2003; 18: 255-259
  CrossrefPubMedGoogle Scholar
• 529 Hildebrand M, Hellstern A, Humpel M. et al. Plasma levels and urinary excretion of lormetazepam in patients with liver cirrhosis and in healthy volunteers. Eur J Drug Metab Pharmacokinet 1990; 15: 19-26
  CrossrefPubMedGoogle Scholar
• 530 Hirsch LJ, Arif H, Buchsbaum R. et al. Effect of age and comedication on levetiracetam pharmacokinetics and tolerability. Epilepsia 2007; 48: 1351-1359
  CrossrefPubMedGoogle Scholar
• 531 Hirsch LJ, Weintraub D, Du Y. et al. Correlating lamotrigine serum concentrations with tolerability in patients with epilepsy. Neurology 2004; 63: 1022-1026
  CrossrefPubMedGoogle Scholar
• 532 Hodge LS, Tracy TS. Alterations in drug disposition during pregnancy: implications for drug therapy. Expert Opin Drug Metab Toxicol 2007; 3: 557-571
  CrossrefPubMedGoogle Scholar
• 533 Hohmann N, Haefeli WE, Mikus G. Use of microdose phenotyping to individualise dosing of patients. Clin Pharmacokinet 2015; 54: 893-900
  CrossrefPubMedGoogle Scholar
• 534 Hoiseth G, Haslemo T, Uthus LH. et al. Effect of CYP2B6*6 on Steady-state serum concentrations of bupropion and hydroxybupropion in psychiatric patients: A study based on therapeutic drug monitoring data. Ther Drug Monit 2015; 37: 589-593
  CrossrefPubMedGoogle Scholar
• 535 Hojer J, Hulting J, Salmonson H. Fatal cardiotoxicity induced by venlafaxine overdosage. Clin Toxicol (Phila) 2008; 46: 336-337
  CrossrefPubMedGoogle Scholar
• 536 Holbrook JM, Parks-Veal P, Mimbs J. Clinical monitoring guidelines for neuroleptic and antidepressant drugs. Central State Hospital, Milledgeville, Georgia. Hosp Pharm 1991; 26 (783/784) 787-793
  PubMedGoogle Scholar
• 537 Holt S, Schmiedl S, Thurmann PA. Potentially inappropriate medications in the elderly: The PRISCUS list. Dtsch Arztebl Int 2010; 107: 543-551
  PubMedGoogle Scholar
• 538 Holzer L, Preuss U, Baumgartner L. et al. Quetiapine in adolescents with non-affective psychotic disorders: An open-label trial. Pharmacopsychiatry 2011; 44: 87-95
  Article in Thieme ConnectPubMedGoogle Scholar
• 539 Hooper WD, Dickinson RG, Dunstan PR. et al. Oxcarbazepine: preliminary clinical and pharmacokinetic studies on a new anticonvulsant. Clin Exp Neurol 1987; 24: 105-112
  PubMedGoogle Scholar
• 540 Horadam VW, Sharp JG, Smilack JD. et al. Pharmacokinetics of amantadine hydrochloride in subjects with normal and impaired renal function. Ann Intern Med 1981; 94: 454-458
  CrossrefPubMedGoogle Scholar
• 541 Hou L, Heilbronner U, Degenhardt F. et al. Genetic variants associated with response to lithium treatment in bipolar disorder: A genome-wide association study. Lancet 2016; 387: 1085-1093
  PubMedGoogle Scholar
• 542 Hrdina PD, Lapierre YD. Plasma levels of maprotiline and zimelidine and their relationship to clinical response in depressed patients. Ther Drug Monit 1986; 8: 400-406
  CrossrefPubMedGoogle Scholar
• 543 Hsieh YH, Yang YH, Yeh HH. et al. Simultaneous determination of galantamine, rivastigmine and NAP 226-90 in plasma by MEKC and its application in Alzheimer’s disease. Electrophoresis 2009; 30: 644-653
  CrossrefPubMedGoogle Scholar
• 544 Huezo-Diaz P, Perroud N, Spencer EP. et al. CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP. J Psychopharmacol 2012; 26: 398-407
  CrossrefPubMedGoogle Scholar
• 545 Hughes J, Gill AM, Mulhearn H. et al. Steady-state plasma concentrations of midazolam in critically ill infants and children. Ann Pharmacother 1996; 30: 27-30
  CrossrefPubMedGoogle Scholar
• 546 Hui WK, Mitchell LB, Kavanagh KM. et al. Melperone: Electrophysiologic and antiarrhythmic activity in humans. J Cardiovasc Pharmacol 1990; 15: 144-149
  CrossrefPubMedGoogle Scholar
• 547 Huttunen KM, Raunio H, Rautio J. Prodrugs–from serendipity to rational design. Pharmacol Rev 2011; 63: 750-771
  CrossrefPubMedGoogle Scholar
• 548 Hvenegaard MG, Bang-Andersen B, Pedersen H. et al. Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. Drug Metab Dispos 2012; 40: 1357-1365
  CrossrefPubMedGoogle Scholar
• 549 Ignjatovic AR, Miljkovic B, Todorovic D. et al. Evaluation of single-point sampling strategies for the estimation of moclobemide exposure in depressive patients. J Clin Pharmacol 2011; 51: 661-671
  CrossrefPubMedGoogle Scholar
• 550 Ilett KF, Blythe TH, Hackett LP. et al. Plasma concentrations of dothiepin and its metabolites are not correlated with clinical efficacy in major depressive illness. Ther Drug Monit 1993; 15: 351-357
  CrossrefPubMedGoogle Scholar
• 551 Ingman K, Hagelberg N, Aalto S. et al. Prolonged central mu-opioid receptor occupancy after single and repeated nalmefene dosing. Neuropsychopharmacology 2005; 30: 2245-2253
  CrossrefPubMedGoogle Scholar
• 552 Inui N, Akamatsu T, Uchida S. et al. Chronological effects of rifampicin discontinuation on cytochrome P450 activity in healthy Japanese volunteers, using the cocktail method. Clin Pharmacol Ther 2013; 94: 702-708
  CrossrefPubMedGoogle Scholar
• 553 Hohmann N, Haefeli WE, Mikus G. Use of microdose phenotyping to individualise dosing of patients. Clin Pharmacokinet 2015; 54: 893–900
  PubMed
• 554 Isacsson G, Holmgren P, Druid H. et al. The utilization of antidepressants--a key issue in the prevention of suicide: An analysis of 5281 suicides in Sweden during the period 1992-1994. Acta Psychiatr Scand 1997; 96: 94-100
  CrossrefPubMedGoogle Scholar
• 555 Isbister GK, Hackett LP, Dawson AH. et al. Moclobemide poisoning: toxicokinetics and occurrence of serotonin toxicity. Br J Clin Pharmacol 2003; 56: 441-450
  CrossrefPubMedGoogle Scholar
• 556 Ishida M, Otani K, Kaneko S. et al. Effects of various factors on steady state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine. Int Clin Psychopharmacol 1995; 10: 143-146
  CrossrefPubMedGoogle Scholar
• 557 Iwamoto K, Kawamura Y, Takahashi M. et al. Plasma amitriptyline level after acute administration, and driving performance in healthy volunteers. Psychiatry Clin Neurosci 2008; 62: 610-616
  CrossrefPubMedGoogle Scholar
• 558 Iwersen S, Schmoldt A. One fatal and one nonfatal intoxication with tranylcypromine. Absence of amphetamines as metabolites. J Anal Toxicol 1996; 20: 301-304
  CrossrefPubMedGoogle Scholar
• 559 Jaanson P, Marandi T, Kiivet RA. et al. Maintenance therapy with zuclopenthixol decanoate: associations between plasma concentrations, neurological side effects and CYP2D6 genotype. Psychopharmacology (Berl) 2002; 162: 67-73
  CrossrefPubMedGoogle Scholar
• 560 Jackson A. Impact of release mechanism on the pharmacokinetic performance of PAUC metrics for three methylphenidate products with complex absorption. Pharm Res 2014; 31: 173-181
  CrossrefPubMedGoogle Scholar
• 561 Jackson SH, Jansen PA, Mangoni AA. Off-label prescribing in older patients. Drugs Aging 2012; 29: 427-434
  CrossrefPubMedGoogle Scholar
• 562 Jacob S, Nair AB. An Updated Overview on Therapeutic Drug Monitoring of Recent Antiepileptic Drugs. Drugs R D 2016; 16: 303-316
  CrossrefPubMedGoogle Scholar
• 563 Jacqmin P, Ansseau M. Comparison of sublingual and oral prazepam in normal subjects. II. Pharmacokinetic and pharmacodynamic data. Neuropsychobiology 1988; 19: 186-191
  CrossrefPubMedGoogle Scholar
• 564 Jakubovski E, Varigonda AL, Freemantle N. et al. Systematic review and meta-analysis: dose-response relationship of selective serotonin reuptake inhibitors in major depressive disorder. Am J Psychiatry 2016; 173: 174-183
  CrossrefPubMedGoogle Scholar
• 565 Jang SH, Yan Z, Lazor JA. Therapeutic drug monitoring: A patient management tool for precision medicine. Clin Pharmacol Ther 2016; 99: 148-150
  CrossrefPubMedGoogle Scholar
• 566 Jann MW, Shirley KL, Small GW. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet 2002; 41: 719-739
  CrossrefPubMedGoogle Scholar
• 567 Jaquenoud Sirot E, Harenberg S, Vandel P. et al. Multicenter study on the clinical effectiveness, pharmacokinetics, and pharmacogenetics of mirtazapine in depression. J Clin Psychopharmacol 2012; 32: 622-629
  CrossrefPubMedGoogle Scholar
• 568 Jaquenoud Sirot E, Knezevic B, Morena GP. et al. ABCB1 and cytochrome P450 polymorphisms: Clinical pharmacogenetics of clozapine. J Clin Psychopharmacol 2009; 29: 319-326
  CrossrefPubMedGoogle Scholar
• 569 Jaquenoud Sirot E, van der Velden JW, Rentsch K. et al. Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance. Drug Saf 2006; 29: 735-768
  CrossrefPubMedGoogle Scholar
• 570 Jefferson JW, Pradko JF, Muir KT. Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations. Clin Ther 2005; 27: 1685-1695
  CrossrefPubMedGoogle Scholar
• 571 Jenner P, Konen-Bergmann M, Schepers C. et al. Pharmacokinetics of a once-daily extended-release formulation of pramipexole in healthy male volunteers: three studies. Clin Ther 2009; 31: 2698-2711
  CrossrefPubMedGoogle Scholar
• 572 Jeppesen U, Gram LF, Vistisen K. et al. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol 1996; 51: 73-78
  CrossrefPubMedGoogle Scholar
• 573 Jerling M, Bertilsson L, Sjoqvist F. The use of therapeutic drug monitoring data to document kinetic drug interactions: An example with amitriptyline and nortriptyline. Ther Drug Monit 1994; 16: 1-12
  CrossrefPubMedGoogle Scholar
• 574 Jerling M, Dahl ML, Aberg-Wistedt A. et al. The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol. Clin Pharmacol Ther 1996; 59: 423-428
  CrossrefPubMedGoogle Scholar
• 575 Jerling M, Merle Y, Mentre F. et al. Population pharmacokinetics of clozapine evaluated with the nonparametric maximum likelihood method. Br J Clin Pharmacol 1997; 44: 447-453
  CrossrefPubMedGoogle Scholar
• 576 Jerling M, Merle Y, Mentre F. et al. Population pharmacokinetics of nortriptyline during monotherapy and during concomitant treatment with drugs that inhibit CYP2D6--an evaluation with the nonparametric maximum likelihood method. Br J Clin Pharmacol 1994; 38: 453-462
  CrossrefPubMedGoogle Scholar
• 577 Ji P, Damle B, Xie J. et al. Pharmacokinetic interaction between efavirenz and carbamazepine after multiple-dose administration in healthy subjects. J Clin Pharmacol 2008; 48: 948-956
  CrossrefPubMedGoogle Scholar
• 578 Ji Y, Schaid DJ, Desta Z. et al. Citalopram and escitalopram plasma drug and metabolite concentrations: genome-wide associations. Br J Clin Pharmacol 2014; 78: 373-383
  CrossrefPubMedGoogle Scholar
• 579 Jia C, Luo L, Kurogi K. et al. Identification of the Human SULT enzymes involved in the metabolism of rotigotine. J Clin Pharmacol 2016; 56: 754-760
  CrossrefPubMedGoogle Scholar
• 580 Jiang F, Kim HD, Na HS. et al. The influences of CYP2D6 genotypes and drug interactions on the pharmacokinetics of venlafaxine: Exploring predictive biomarkers for treatment outcomes. Psychopharmacology (Berl) 2015; 232: 1899-1909
  CrossrefPubMedGoogle Scholar
• 581 Jimmink A, Caminada K, Hunfeld NG. et al. Clinical toxicology of citalopram after acute intoxication with the sole drug or in combination with other drugs: Overview of 26 cases. Ther Drug Monit 2008; 30: 365-371
  CrossrefPubMedGoogle Scholar
• 582 Jin Y, Pollock BG, Coley K. et al. Population pharmacokinetics of perphenazine in schizophrenia patients from CATIE: Impact of race and smoking. J Clin Pharmacol 2010; 50: 73-80
  CrossrefPubMedGoogle Scholar
• 583 Jin Y, Pollock BG, Frank E. et al. Effect of age, weight, and CYP2C19 genotype on escitalopram exposure. J Clin Pharmacol 2010; 50: 62-72
  CrossrefPubMedGoogle Scholar
• 584 Jin Y, Pollock BG, Frank E. et al. The effect of reporting methods for dosing times on the estimation of pharmacokinetic parameters of escitalopram. J Clin Pharmacol 2009; 49: 176-184
  CrossrefPubMedGoogle Scholar
• 585 Jochemsen R, Wesselman JG, Hermans J. et al. Pharmacokinetics of brotizolam in healthy subjects following intravenous and oral administration. Br J Clin Pharmacol 1983; 16 (Suppl. 02) 285S-290S
  CrossrefPubMedGoogle Scholar
• 586 Johannessen Landmark C, Svendsen T, Dinarevic J. et al. The impact of pharmacokinetic interactions with eslicarbazepine acetate versus oxcarbazepine and carbamazepine in clinical practice. Ther Drug Monit 2016; 38: 499-505
  CrossrefPubMedGoogle Scholar
• 587 Johannessen SI, Tomson T. Pharmacokinetic variability of newer antiepileptic drugs: When is monitoring needed?. Clin Pharmacokinet 2006; 45: 1061-1075
  CrossrefPubMedGoogle Scholar
• 588 Johansson B. A review of the pharmacokinetics and pharmacodynamics of disulfiram and its metabolites. Acta Psychiatr Scand Suppl 1992; 369: 15-26
  PubMedGoogle Scholar
• 589 Johnston JA, Fiedler-Kelly J, Glover ED. et al. Relationship between drug exposure and the efficacy and safety of bupropion sustained release for smoking cessation. Nicotine Tob Res 2001; 3: 131-140
  CrossrefPubMedGoogle Scholar
• 590 Jones AW. Ultra-rapid rate of ethanol elimination from blood in drunken drivers with extremely high blood-alcohol concentrations. Int J Legal Med 2008; 122: 129-134
  CrossrefPubMedGoogle Scholar
• 591 Jones AW, Holmgren A. Concentrations of diazepam and nordiazepam in 1,000 blood samples from apprehended drivers--therapeutic use or abuse of anxiolytics?. J Pharm Pract 2013; 26: 198-203
  CrossrefPubMedGoogle Scholar
• 592 Jörg J, Pröfrock A. Wirksamkeit und Verträglichkeit der Parkinson-Behandlung mit Amantadinsulfat. Nervenheilkunde 1995; 14: 76-82
  PubMedGoogle Scholar
• 593 Jorga KM, Fotteler B, Heizmann P. et al. Pharmacokinetics and pharmacodynamics after oral and intravenous administration of tolcapone, a novel adjunct to Parkinson’s disease therapy. Eur J Clin Pharmacol 1998; 54: 443-447
  CrossrefPubMedGoogle Scholar
• 594 Jorga KM, Larsen JP, Beiske A. et al. The effect of tolcapone on the pharmacokinetics of benserazide. Eur J Neurol 1999; 6: 211-219
  CrossrefPubMedGoogle Scholar
• 595 Jorgensen A. Pharmacokinetic studies in volunteers of intravenous and oral cis (Z)-flupentixol and intramuscular cis (Z)-flupentixol decanoate in Viscoleo. Eur J Clin Pharmacol 1980; 18: 355-360
  CrossrefPubMedGoogle Scholar
• 596 Jornil J, Jensen KG, Larsen F. et al. Identification of cytochrome P450 isoforms involved in the metabolism of paroxetine and estimation of their importance for human paroxetine metabolism using a population-based simulator. Drug Metab Dispos 2010; 38: 376-385
  CrossrefPubMedGoogle Scholar
• 597 Jornil J, Jensen KG, Larsen F. et al. Risk assessment of accidental nortriptyline poisoning: The importance of cytochrome P450 for nortriptyline elimination investigated using a population-based pharmacokinetic simulator. Eur J Pharm Sci 2011; 44: 265-272
  CrossrefPubMedGoogle Scholar
• 598 Jornil J, Nielsen TS, Rosendal I. et al. A poor metabolizer of both CYP2C19 and CYP2D6 identified by mechanistic pharmacokinetic simulation in a fatal drug poisoning case involving venlafaxine. Forensic Sci Int 2013; 226: e26-e31
  CrossrefPubMedGoogle Scholar
• 599 Jovanovic M, Sokic D, Grabnar I. et al. Population pharmacokinetics of topiramate in adult patients with epilepsy using nonlinear mixed effects modelling. Eur J Pharm Sci 2013; 50: 282-289
  CrossrefPubMedGoogle Scholar
• 600 Kagawa S, Mihara K, Nakamura A. et al. Relationship between plasma concentrations of lamotrigine and its early therapeutic effect of lamotrigine augmentation therapy in treatment-resistant depressive disorder. Ther Drug Monit 2014; 36: 730-733
  CrossrefPubMedGoogle Scholar
• 601 Kajosaari LI, Niemi M, Backman JT. et al. Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide. Clin Pharmacol Ther 2006; 79: 231-242
  CrossrefPubMedGoogle Scholar
• 602 Kandasamy M, Srinivas P, Subramaniam K. et al. Differential outcomes from metabolic ratios in the identification of CYP2D6 phenotypes--focus on venlafaxine and O-desmethylvenlafaxine. Eur J Clin Pharmacol 2010; 66: 879-887
  CrossrefPubMedGoogle Scholar
• 603 Kane JM, Leucht S, Carpenter D. et al. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: Methods, commentary, and summary. J Clin Psychiatry 2003; 64 (Suppl. 12) 5-19
  CrossrefPubMedGoogle Scholar
• 604 Kaplan SA, de Silva JA, Jack ML. et al. Blood level profile in man following chronic oral administration of flurazepam hydrochloride. J Pharm Sci 1973; 62: 1932-1935
  CrossrefPubMedGoogle Scholar
• 605 Kaplan SA, Jack ML, Weinfeld RE. et al. Biopharmaceutical and clinical pharmacokinetic profile of bromazepam. J Pharmacokinet Biopharm 1976; 4: 1-16
  CrossrefPubMedGoogle Scholar
• 606 Karlsson L, Zackrisson AL, Josefsson M. et al. Influence of CYP2D6 and CYP2C19 genotypes on venlafaxine metabolic ratios and stereoselective metabolism in forensic autopsy cases. Pharmacogenomics J 2015; 15: 165-171
  CrossrefPubMedGoogle Scholar
• 607 Karson CN, Newton JE, Livingston R. et al. Human brain fluoxetine concentrations. J Neuropsychiatry Clin Neurosci 1993; 5: 322-329
  CrossrefPubMedGoogle Scholar
• 608 Kasper S, Dotsch M, Kick H. et al. Plasma concentrations of fluvoxamine and maprotiline in major depression: Implications on therapeutic efficacy and side effects. Eur Neuropsychopharmacol 1993; 3: 13-21
  CrossrefPubMedGoogle Scholar
• 609 Katayama Y, Terao T, Kamei K. et al. Therapeutic window of lamotrigine for mood disorders: A naturalistic retrospective study. Pharmacopsychiatry 2014; 47: 111-114
  Article in Thieme ConnectPubMedGoogle Scholar
• 610 Kato M, Serretti A, Nonen S. et al. Genetic variants in combination with early partial improvement as a clinical utility predictor of treatment outcome in major depressive disorder: The result of two pooled RCTs. Transl Psychiatry 2015; 5: e513
  CrossrefPubMedGoogle Scholar
• 611 Katoh Y, Uchida S, Kawai M. et al. Effects of cigarette smoking and cytochrome P450 2D6 genotype on fluvoxamine concentration in plasma of Japanese patients. Biol Pharm Bull 2010; 33: 285-288
  CrossrefPubMedGoogle Scholar
• 612 Katon W, Cantrell CR, Sokol MC. et al. Impact of antidepressant drug adherence on comorbid medication use and resource utilization. Arch Intern Med 2005; 165: 2497-2503
  CrossrefPubMedGoogle Scholar
• 613 Kaufman E, Lamster IB. The diagnostic applications of saliva–a review. Crit Rev Oral Biol Med 2002; 13: 197-212
  CrossrefPubMedGoogle Scholar
• 614 Kaye CM, Nicholls B. Clinical pharmacokinetics of ropinirole. Clin Pharmacokinet 2000; 39: 243-254
  CrossrefPubMedGoogle Scholar
• 615 Kemp DE, Ganocy SJ, Brecher M. et al. Clinical value of early partial symptomatic improvement in the prediction of response and remission during short-term treatment trials in 3369 subjects with bipolar I or II depression. J Affect Disord 2011; 130: 171-179
  CrossrefPubMedGoogle Scholar
• 616 Kennedy MC. Post-mortem drug concentrations. Intern Med J 2010; 40: 183-187
  CrossrefPubMedGoogle Scholar
• 617 Kerbusch-Herben V, Cleton A, Berwaerts J. et al. Effect of carbamazepine on the pharmacokinetics of paliperidone extended-release tablets at steady-state. Clin Pharmacol Drug Dev 2014; 3: 371-377
  PubMedGoogle Scholar
• 618 Kerr BM, Thummel KE, Wurden CJ. et al. Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochem Pharmacol 1994; 47: 1969-1979
  CrossrefPubMedGoogle Scholar
• 619 Kharasch ED, Hankins DC, Jubert C. et al. Lack of single-dose disulfiram effects on cytochrome P-450 2C9, 2C19, 2D6, and 3A4 activities: evidence for specificity toward P-450 2E1. Drug Metab Dispos 1999; 27: 717-723
  PubMedGoogle Scholar
• 620 Kharasch ED, Hoffer C, Whittington D. et al. Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine. Clin Pharmacol Ther 2003; 74: 543-554
  CrossrefPubMedGoogle Scholar
• 621 Kharasch ED, Mitchell D, Coles R. Stereoselective bupropion hydroxylation as an in vivo phenotypic probe for cytochrome P4502B6 (CYP2B6) activity. J Clin Pharmacol 2008; 48: 464-474
  CrossrefPubMedGoogle Scholar
• 622 Kiang TK, Ensom MH, Chang TK. UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ther 2005; 106: 97-132
  CrossrefPubMedGoogle Scholar
• 623 Kiechel JR. Pharmacokinetics and metabolism of guanfacine in man: a review. Br J Clin Pharmacol 1980; 10 (Suppl. 01) 25S-32S
  CrossrefPubMedGoogle Scholar
• 624 Kikkawa H, Maruyama N, Fujimoto Y. et al. Single- and multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy Japanese adult smokers. J Clin Pharmacol 2011; 51: 527-537
  CrossrefPubMedGoogle Scholar
• 625 Kim E, Howes OD, Kim BH. et al. Predicting brain occupancy from plasma levels using PET: Superiority of combining pharmacokinetics with pharmacodynamics while modeling the relationship. J Cereb Blood Flow Metab 2012; 32: 759-768
  CrossrefPubMedGoogle Scholar
• 626 Kim JR, Seo HB, Cho JY. et al. Population pharmacokinetic modelling of aripiprazole and its active metabolite, dehydroaripiprazole, in psychiatric patients. Br J Clin Pharmacol 2008; 66: 802-810
  CrossrefPubMedGoogle Scholar
• 627 Kim KA, Lim JL, Kim C. et al. Pharmacokinetic comparison of orally disintegrating and conventional donepezil formulations in healthy Korean male subjects: A single-dose, randomized, open-label, 2-sequence, 2-period crossover study. Clin Ther 2011; 33: 965-972
  CrossrefPubMedGoogle Scholar
• 628 Kinirons MT, O’Mahony MS. Drug metabolism and ageing. Br J Clin Pharmacol 2004; 57: 540-544
  CrossrefPubMedGoogle Scholar
• 629 Kirby BJ, Collier AC, Kharasch ED. et al. Complex drug interactions of HIV protease inhibitors 1: Inactivation, induction, and inhibition of cytochrome P450 3A by ritonavir or nelfinavir. Drug Metab Dispos 2011; 39: 1070-1078
  CrossrefPubMedGoogle Scholar
• 630 Kirchheiner J. CYP2D6 phenotype prediction from genotype: Which system is the best?. Clin Pharmacol Ther 2008; 83: 225-227
  CrossrefPubMedGoogle Scholar
• 631 Kirchheiner J, Meineke I, Müller G. et al. Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. Pharmacogenetics 2002; 12: 571-580
  CrossrefPubMedGoogle Scholar
• 632 Kirchheiner J, Müller G, Meineke I. et al. Effects of polymorphisms in CYP2D6, CYP2C9, and CYP2C19 on trimipramine pharmacokinetics. J Clin Psychopharmacol 2003; 23: 459-466
  CrossrefPubMedGoogle Scholar
• 633 Kirchheiner J, Nickchen K, Bauer M. et al. Pharmacogenetics of antidepressants and antipsychotics: The contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 2004; 9: 442-473
  CrossrefPubMedGoogle Scholar
• 634 Kirchheiner J, Seeringer A. Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes. Biochim Biophys Acta 2007; 1770: 489-494
  CrossrefPubMedGoogle Scholar
• 635 Kirchherr H, Kuhn-Velten WN. Quantitative determination of forty-eight antidepressants and antipsychotics in human serum by HPLC tandem mass spectrometry: A multi-level, single-sample approach. J Chromatogr B Analyt Technol Biomed Life Sci 2006; 843: 100-113
  CrossrefPubMedGoogle Scholar
• 636 Kirkton C, McIntyre IM. Therapeutic and toxic concentrations of mirtazapine. J Anal Toxicol 2006; 30: 687-691
  CrossrefPubMedGoogle Scholar
• 637 Kirschbaum KM, Müller MJ, Malevani J. et al. Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects. World J Biol Psychiatry 2008; 9: 212-218
  CrossrefPubMedGoogle Scholar
• 638 Kirschbaum KM, Müller MJ, Zernig G. et al. Therapeutic monitoring of aripiprazole by HPLC with column-switching and spectrophotometric detection. Clin Chem 2005; 51: 1718-1721
  CrossrefPubMedGoogle Scholar
• 639 Kirschbaum KM, Uhr M, Holthoewer D. et al. Pharmacokinetics of acute and sub-chronic aripiprazole in P-glycoprotein deficient mice. Neuropharmacology 2010; 59: 474-479
  CrossrefPubMedGoogle Scholar
• 640 Kirson NY, Weiden PJ, Yermakov S. et al. Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: Synthesizing results across different research designs. J Clin Psychiatry 2013; 74: 568-575
  CrossrefPubMedGoogle Scholar
• 641 Kishimoto T, Robenzadeh A, Leucht C. et al. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: A meta-analysis of randomized trials. Schizophr Bull 2014; 40: 192-213
  CrossrefPubMedGoogle Scholar
• 642 Kistrup K, Gerlach J, Aaes-Jorgensen T. et al. Perphenazine decanoate and cis(z)-flupentixol decanoate in maintenance treatment of schizophrenic outpatients. Serum levels at the minimum effective dose. Psychopharmacology (Berl) 1991; 105: 42-48
  CrossrefPubMedGoogle Scholar
• 643 Kitzlerova E, Slavicek J, Pisvejcova K. et al. Plasma levels of dosulepine and heart electric field. Physiol Res 2003; 52: 319-325
  PubMedGoogle Scholar
• 644 Kivisto KT, Kroemer HK. Use of probe drugs as predictors of drug metabolism in humans. J Clin Pharmacol 1997; 37: 40S-48S
  CrossrefPubMedGoogle Scholar
• 645 Kjolbye M, Thomsen K, Rogne T. et al. Search for a therapeutic range for serum zuclopenthixol concentrations in schizophrenic patients. Ther Drug Monit 1994; 16: 541-547
  CrossrefPubMedGoogle Scholar
• 646 Klamerus KJ, Maloney K, Rudolph RL. et al. Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite. J Clin Pharmacol 1992; 32: 716-724
  CrossrefPubMedGoogle Scholar
• 647 Klampfl K, Taurines R, Preuss A. et al. Serum concentrations, therapeutic response and side effects in children and adolescents with impulsive-aggressive symptoms during risperidone therapy. Pharmacopsychiatry 2010; 43: 58-65
  Article in Thieme ConnectPubMedGoogle Scholar
• 648 Kleimann A, Schrader V, Stubner S. et al. Psychopharmacological treatment of 1650 in-patients with acute mania-data from the AMSP study. J Affect Disord 2016; 191: 164-171
  CrossrefPubMedGoogle Scholar
• 649 Klengel T, Binder EB. Gene x environment interactions in the prediction of response to antidepressant treatment. Int J Neuropsychopharmacol 2013; 16: 701-711
  CrossrefPubMedGoogle Scholar
• 650 Klinger G, Stahl B, Fusar-Poli P. et al. Antipsychotic drugs and breastfeeding. Pediatr Endocrinol Rev 2013; 10: 308-317
  PubMedGoogle Scholar
• 651 Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev 2009; 41: 67-76
  CrossrefPubMedGoogle Scholar
• 652 Kodaira H, Kusuhara H, Fujita T. et al. Quantitative evaluation of the impact of active efflux by p-glycoprotein and breast cancer resistance protein at the blood-brain barrier on the predictability of the unbound concentrations of drugs in the brain using cerebrospinal fluid concentration as a surrogate. J Pharmacol Exp Ther 2011; 339: 935-944
  CrossrefPubMedGoogle Scholar
• 653 Koeber R, Kluenemann HH, Waimer R. et al. Implementation of a cost-effective HPLC/UV-approach for medical routine quantification of donepezil in human serum. J Chromatogr B Analyt Technol Biomed Life Sci 2012; 881-882: 1-11
  CrossrefPubMedGoogle Scholar
• 654 Koelch M, Pfalzer AK, Kliegl K. et al. Therapeutic drug monitoring of children and adolescents treated with fluoxetine. Pharmacopsychiatry 2012; 45: 72-76
  Article in Thieme ConnectPubMedGoogle Scholar
• 655 Koepp MJ, Patsalos PN, Sander JW. Sulthiame in adults with refractory epilepsy and learning disability: An open trial. Epilepsy Res 2002; 50: 277-282
  CrossrefPubMedGoogle Scholar
• 656 Kokras N, Dalla C, Papadopoulou-Daifoti Z. Sex differences in pharmacokinetics of antidepressants. Expert Opin Drug Metab Toxicol 2011; 7: 213-226
  CrossrefPubMedGoogle Scholar
• 657 Kondo T, Otani K, Ishida M. et al. Adverse effects of zotepine and their relationship to serum concentrations of the drug and prolactin. Ther Drug Monit 1994; 16: 120-124
  CrossrefPubMedGoogle Scholar
• 658 Kootstra-Ros JE, Van Weelden MJ, Hinrichs JW. et al. Therapeutic drug monitoring of antidepressants and cytochrome p450 genotyping in general practice. J Clin Pharmacol 2006; 46: 1320-1327
  CrossrefPubMedGoogle Scholar
• 659 Kornhuber J, Kennepohl EM, Bleich S. et al. Memantine pharmacotherapy: A naturalistic study using a population pharmacokinetic approach. Clin Pharmacokinet 2007; 46: 599-612
  CrossrefPubMedGoogle Scholar
• 660 Kornhuber J, Quack G, Danysz W. et al. Therapeutic brain concentration of the NMDA receptor antagonist amantadine. Neuropharmacology 1995; 34: 713-721
  CrossrefPubMedGoogle Scholar
• 661 Kosaki K, Tamura K, Sato R. et al. A major influence of CYP2C19 genotype on the steady-state concentration of N-desmethylclobazam. Brain Dev 2004; 26: 530-534
  CrossrefPubMedGoogle Scholar
• 662 Koster M, Grohmann R, Engel RR. et al. Seizures during antidepressant treatment in psychiatric inpatients–results from the transnational pharmacovigilance project "Arzneimittelsicherheit in der Psychiatrie" (AMSP) 1993-2008. Psychopharmacology (Berl) 2013; 230: 191-201
  CrossrefPubMedGoogle Scholar
• 663 Kotlyar M, Brauer LH, Tracy TS. et al. Inhibition of CYP2D6 activity by bupropion. J Clin Psychopharmacol 2005; 25: 226-229
  CrossrefPubMedGoogle Scholar
• 664 Koyama E, Chiba K, Tani M. et al. Identification of human cytochrome P450 isoforms involved in the stereoselective metabolism of mianserin enantiomers. J Pharmacol Exp Ther 1996; 278: 21-30
  PubMedGoogle Scholar
• 665 Kozer E, Parvez S, Minassian BA. et al. How high can we go with phenytoin?. Ther Drug Monit 2002; 24: 386-389
  CrossrefPubMedGoogle Scholar
• 666 Kreuzer P, Landgrebe M, Wittmann M. et al. Hypothermia associated with antipsychotic drug use: A clinical case series and review of current literature. J Clin Pharmacol 2012; 52: 1090-1097
  CrossrefPubMedGoogle Scholar
• 667 Krishna G, Moton A, Ma L. et al. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: A phase I, randomized, open-label, crossover study in healthy volunteers. Clin Ther 2009; 31: 286-298
  CrossrefPubMedGoogle Scholar
• 668 Krishnan S, Moncrief S. An evaluation of the cytochrome p450 inhibition potential of lisdexamfetamine in human liver microsomes. Drug Metab Dispos 2007; 35: 180-184
  CrossrefPubMedGoogle Scholar
• 669 Krska J, Corner DA. Serum drug level monitoring in affective disorders. J Clin Pharm Ther 1992; 17: 357-363
  CrossrefPubMedGoogle Scholar
• 670 Kruithof MK, Bruins NA, van Roon EN. Coma after overdose with duloxetine. Ann Pharmacother 2011; 45: e5
  PubMedGoogle Scholar
• 671 Kugelberg FC, Druid H, Carlsson B. et al. Postmortem redistribution of the enantiomers of citalopram and its metabolites: An experimental study in rats. J Anal Toxicol 2004; 28: 631-637
  CrossrefPubMedGoogle Scholar
• 672 Kuhlman Jr. JJ, Levine B, Johnson RE. et al. Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine. Addiction 1998; 93: 549-559
  CrossrefPubMedGoogle Scholar
• 673 Kurtz DL, Bergstrom RF, Goldberg MJ. et al. The effect of sertraline on the pharmacokinetics of desipramine and imipramine. Clin Pharmacol Ther 1997; 62: 145-156
  CrossrefPubMedGoogle Scholar
• 674 Kuss HJ, Feistenauer E. Quantitative high-performance liquid chromatographic assay for the determination of maprotiline and oxaprotiline in human plasma. J Chromatogr 1981; 204: 349-353
  CrossrefPubMedGoogle Scholar
• 675 Kvist EE, Al-Shurbaji A, Dahl ML. et al. Quantitative pharmacogenetics of nortriptyline: a novel approach. Clin Pharmacokinet 2001; 40: 869-877
  CrossrefPubMedGoogle Scholar
• 676 Kyhl LE, Li S, Faerch KU. et al. Population pharmacokinetics of nalmefene in healthy subjects and its relation to mu-opioid receptor occupancy. Br J Clin Pharmacol 2016; 81: 290-300
  CrossrefPubMedGoogle Scholar
• 677 Labellarte M, Biederman J, Emslie G. et al. Multiple-dose pharmacokinetics of fluvoxamine in children and adolescents. J Am Acad Child Adolesc Psychiatry 2004; 43: 1497-1505
  CrossrefPubMedGoogle Scholar
• 678 Laib AK, Brunen S, Pfeifer P. et al. Serum concentrations of hydroxybupropion for dose optimization of depressed patients treated with bupropion. Ther Drug Monit 2014; 36: 473-479
  CrossrefPubMedGoogle Scholar
• 679 Laje G. Pharmacogenetics of mood disorders: What clinicians need to know. CNS Spectr 2013; 18: 272-284
  CrossrefPubMedGoogle Scholar
• 680 Laje G, McMahon FJ. Genome-wide association studies of antidepressant outcome: A brief review. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 1553-1557
  CrossrefPubMedGoogle Scholar
• 681 Landmark CJ, Johannessen SI, Tomson T. Dosing strategies for antiepileptic drugs: From a standard dose for all to individualised treatment by implementation of therapeutic drug monitoring. Epileptic Disord 2016; 18: 367-383
  PubMedGoogle Scholar
• 682 Langel K, Engblom C, Pehrsson A. et al. Drug testing in oral fluid-evaluation of sample collection devices. J Anal Toxicol 2008; 32: 393-401
  CrossrefPubMedGoogle Scholar
• 683 Langel K, Gjerde H, Favretto D. et al. Comparison of drug concentrations between whole blood and oral fluid. Drug Test Anal 2014; 6: 461-471
  PubMedGoogle Scholar
• 684 Lappenberg-Pelzer M. Identification and determination of opipramol metabolites in plasma and urine. J Anal Toxicol 1998; 22: 215-219
  CrossrefPubMedGoogle Scholar
• 685 Larson ME, Richards TM. Quantification of a methadone metabolite (EDDP) in urine: Assessment of compliance. Clin Med Res 2009; 7: 134-141
  CrossrefPubMedGoogle Scholar
• 686 Launonen E, Wallace I, Kotovirta E. et al. Factors associated with non-adherence and misuse of opioid maintenance treatment medications and intoxicating drugs among Finnish maintenance treatment patients. Drug Alcohol Depend 2016; 162: 227-235
  CrossrefPubMedGoogle Scholar
• 687 Lautala P, Ethell BT, Taskinen J. et al. The specificity of glucuronidation of entacapone and tolcapone by recombinant human UDP-glucuronosyltransferases. Drug Metab Dispos 2000; 28: 1385-1389
  PubMedGoogle Scholar
• 688 Le Bloc’h Y, Woggon B, Weissenrieder H. et al. Routine therapeutic drug monitoring in patients treated with 10-360 mg/day citalopram. Ther Drug Monit 2003; 25: 600-608
  CrossrefPubMedGoogle Scholar
• 689 Leavitt SB, Shinderman M, Maxwell S. et al. When "enough" is not enough: new perspectives on optimal methadone maintenance dose. Mt Sinai J Med 2000; 67: 404-411
  PubMedGoogle Scholar
• 690 Lee SY, Kim YG, Kim HG. et al. Pharmacokinetic parameters of bromperidol in Korean subjects. Hum Psychopharmacol 2006; 21: 409-412
  CrossrefPubMedGoogle Scholar
• 691 Lefevre G, Buche M, Sedek G. et al. Similar rivastigmine pharmacokinetics and pharmacodynamics in Japanese and white healthy participants following the application of novel rivastigmine patch. J Clin Pharmacol 2009; 49: 430-443
  CrossrefPubMedGoogle Scholar
• 692 Lemma GL, Wang Z, Hamman MA. et al. The effect of short- and long-term administration of verapamil on the disposition of cytochrome P450 3A and P-glycoprotein substrates. Clin Pharmacol Ther 2006; 79: 218-230
  CrossrefPubMedGoogle Scholar
• 693 Leon J, Susce MT, Pan RM. et al. A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels. Pharmacopsychiatry 2007; 40: 93-102
  Article in Thieme ConnectPubMedGoogle Scholar
• 694 Lerer B, Segman RH, Tan EC. et al. Combined analysis of 635 patients confirms an age-related association of the serotonin 2A receptor gene with tardive dyskinesia and specificity for the non-orofacial subtype. Int J Neuropsychopharmacol 2005; 8: 411-425
  CrossrefPubMedGoogle Scholar
• 695 Lertxundi U, Domingo-Echaburu S, Hernandez R. et al. Expert-based drug lists to measure anticholinergic burden: similar names, different results. Psychogeriatrics 2013; 13: 17-24
  CrossrefPubMedGoogle Scholar
• 696 Leucht S, Busch R, Kissling W. et al. Early prediction of antipsychotic nonresponse among patients with schizophrenia. J Clin Psychiatry 2007; 68: 352-360
  CrossrefPubMedGoogle Scholar
• 697 Leucht S, Steimer W, Kreuz S. et al. Doxepin plasma concentrations: is there really a therapeutic range?. J Clin Psychopharmacol 2001; 21: 432-439
  CrossrefPubMedGoogle Scholar
• 698 Levine M, Truitt CA, O’Connor AD. Cardiotoxicity and serotonin syndrome complicating a milnacipran overdose. J Med Toxicol 2011; 7: 312-316
  CrossrefPubMedGoogle Scholar
• 699 Levran O, Peles E, Hamon S. et al. CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction. Addict Biol 2013; 18: 709-716
  CrossrefPubMedGoogle Scholar
• 700 Levran O, Peles E, Randesi M. et al. Association of genetic variation in pharmacodynamic factors with methadone dose required for effective treatment of opioid addiction. Pharmacogenomics 2013; 14: 755-768
  CrossrefPubMedGoogle Scholar
• 701 LeWitt PA, Jennings D, Lyons KE. et al. Pharmacokinetic-pharmacodynamic crossover comparison of two levodopa extension strategies. Mov Disord 2009; 24: 1319-1324
  CrossrefPubMedGoogle Scholar
• 702 Li-Bo D, Rong-Hua Z, Huan-De L. et al. Quantitative analysis of trazodone in human plasma by using HPLC-fluorescence detector coupled with strong cation exchange chromatographic column: application to a pharmacokinetic study in Chinese healthy volunteers. J Chromatogr B Analyt Technol Biomed Life Sci 2014; 944: 43-48
  CrossrefPubMedGoogle Scholar
• 703 Li AN, Dong F, He JL. et al. The elimination rate after clozapine overdose in chinese schizophrenia patients: A population pharmacokinetics model study. Pharmacopsychiatry 2015; 48: 150-155
  Article in Thieme ConnectPubMedGoogle Scholar
• 704 Li F, Chin C, Wangsa J. et al. Excretion and metabolism of milnacipran in humans after oral administration of milnacipran hydrochloride. Drug Metab Dispos 2012; 40: 1723-1735
  CrossrefPubMedGoogle Scholar
• 705 Li Q, Su YA, Liu Y. et al. Pharmacokinetics and tolerability of extended-release quetiapine fumarate in Han Chinese patients with schizophrenia. Clin Pharmacokinet 2014; 53: 455-465
  CrossrefPubMedGoogle Scholar
• 706 Li RR, Sheng XY, Ma LY. et al. Saliva and plasma monohydroxycarbamazepine concentrations in pediatric patients with epilepsy. Ther Drug Monit 2016; 38: 365-370
  CrossrefPubMedGoogle Scholar
• 707 Licht RW, Vestergaard P, Kessing LV. et al. Psychopharmacological treatment with lithium and antiepileptic drugs: Suggested guidelines from the Danish Psychiatric Association and the Child and Adolescent Psychiatric Association in Denmark. Acta Psychiatr Scand Suppl 2003; 1-22
  PubMedGoogle Scholar
• 708 Lieber CS. The discovery of the microsomal ethanol oxidizing system and its physiologic and pathologic role. Drug Metab Rev 2004; 36: 511-529
  CrossrefPubMedGoogle Scholar
• 709 Lieberman JA, Stroup TS, McEvoy JP. et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-1223
  CrossrefPubMedGoogle Scholar
• 710 Liechti ME, Quednow BB, Liakoni E. et al. Pharmacokinetics and pharmacodynamics of gamma-hydroxybutyrate in healthy subjects. Br J Clin Pharmacol 2016; 81: 980-988
  CrossrefPubMedGoogle Scholar
• 711 Lin SK, Chen CK, Liu YL. Aripiprazole and dehydroaripiprazole plasma concentrations and clinical responses in patients with schizophrenia. J Clin Psychopharmacol 2011; 31: 758-762
  CrossrefPubMedGoogle Scholar
• 712 Lind AB, Reis M, Bengtsson F. et al. Steady-state concentrations of mirtazapine, N-desmethylmirtazapine, 8-hydroxymirtazapine and their enantiomers in relation to cytochrome P450 2D6 genotype, age and smoking behaviour. Clin Pharmacokinet 2009; 48: 63-70
  CrossrefPubMedGoogle Scholar
• 713 Lindberger M, Luhr O, Johannessen SI. et al. Serum concentrations and effects of gabapentin and vigabatrin: Observations from a dose titration study. Ther Drug Monit 2003; 25: 457-462
  CrossrefPubMedGoogle Scholar
• 714 Lindenmayer JP. Long-acting injectable antipsychotics: Focus on olanzapine pamoate. Neuropsychiatr Dis Treat 2010; 6: 261-267
  PubMedGoogle Scholar
• 715 Linder MW, Keck Jr. PE. Standards of laboratory practice: Antidepressant drug monitoring. National Academy of Clinical Biochemistry. Clin Chem 1998; 44: 1073-1084
  PubMedGoogle Scholar
• 716 Lingam R, Scott J. Treatment non-adherence in affective disorders. Acta Psychiatr Scand 2002; 105: 164-172
  CrossrefPubMedGoogle Scholar
• 717 Lingjaerde O, Ahlfors UG, Bech P. et al. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 1987; 334: 1-100
  PubMedGoogle Scholar
• 718 Linnet K, Ejsing TB. A review on the impact of P-glycoprotein on the penetration of drugs into the brain. Focus on psychotropic drugs. Eur Neuropsychopharmacol 2008; 18: 157-169
  CrossrefPubMedGoogle Scholar
• 719 Lintzeris N, Leung SY, Dunlop AJ. et al. A randomised controlled trial of sublingual buprenorphine-naloxone film versus tablets in the management of opioid dependence. Drug Alcohol Depend 2013; 131: 119-126
  CrossrefPubMedGoogle Scholar
• 720 Liu MY, Meng SN, Wu HZ. et al. Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry. Clin Ther 2008; 30: 641-653
  CrossrefPubMedGoogle Scholar
• 721 Liu X, Lu YF, Guan X. et al. Characterizing novel metabolic pathways of melatonin receptor agonist agomelatine using metabolomic approaches. Biochem Pharmacol 2016; 109: 70-82
  CrossrefPubMedGoogle Scholar
• 722 Liu Y, Jiao J, Zhang C. et al. A simplified method to determine five cytochrome p450 probe drugs by HPLC in a single run. Biol Pharm Bull 2009; 32: 717-720
  CrossrefPubMedGoogle Scholar
• 723 Liu ZQ, Shu Y, Huang SL. et al. Effects of CYP2C19 genotype and CYP2C9 on fluoxetine N-demethylation in human liver microsomes. Acta Pharmacol Sin 2001; 22: 85-90
  PubMedGoogle Scholar
• 724 Livezey MR, Briggs ED, Bolles AK. et al. Metoclopramide is metabolized by CYP2D6 and is a reversible inhibitor, but not inactivator, of CYP2D6. Xenobiotica 2014; 44: 309-319
  CrossrefPubMedGoogle Scholar
• 725 Loayza N, Crettol S, Riquier F. et al. Adherence to antidepressant treatment: what the doctor thinks and what the patient says. Pharmacopsychiatry 2012; 45: 204-207
  Article in Thieme ConnectPubMedGoogle Scholar
• 726 Lobo ED, Bergstrom RF, Reddy S. et al. In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine. Clin Pharmacokinet 2008; 47: 191-202
  CrossrefPubMedGoogle Scholar
• 727 Lobo ED, Quinlan T, O’Brien L. et al. Population pharmacokinetics of orally administered duloxetine in patients: implications for dosing recommendation. Clin Pharmacokinet 2009; 48: 189-197
  CrossrefPubMedGoogle Scholar
• 728 Locatelli I, Kastelic M, Koprivsek J. et al. A population pharmacokinetic evaluation of the influence of CYP2D6 genotype on risperidone metabolism in patients with acute episode of schizophrenia. Eur J Pharm Sci 2010; 41: 289-298
  CrossrefPubMedGoogle Scholar
• 729 Lopez LV, Kane JM. Plasma levels of second-generation antipsychotics and clinical response in acute psychosis: A review of the literature. Schizophr Res 2013; 147: 368-374
  CrossrefPubMedGoogle Scholar
• 730 Loscher W, Luna-Tortos C, Romermann K. et al. Do ATP-binding cassette transporters cause pharmacoresistance in epilepsy? Problems and approaches in determining which antiepileptic drugs are affected. Curr Pharm Des 2011; 17: 2808-2828
  CrossrefPubMedGoogle Scholar
• 731 Lotrich FE, Pollock BG. Aging and clinical pharmacology: implications for antidepressants. J Clin Pharmacol 2005; 45: 1106-1122
  CrossrefPubMedGoogle Scholar
• 732 Lucek R, Dixon R. Chlordiazepoxide concentrations in saliva and plasma measured by radioimmunoassay. Res Commun Chem Pathol Pharmacol 1980; 27: 397-400
  PubMedGoogle Scholar
• 733 Lundberg J, Christophersen JS, Petersen KB. et al. PET measurement of serotonin transporter occupancy: A comparison of escitalopram and citalopram. Int J Neuropsychopharmacol 2007; 10: 777-785
  PubMedGoogle Scholar
• 734 Lundmark J, Bengtsson F, Nordin C. et al. Therapeutic drug monitoring of selective serotonin reuptake inhibitors influences clinical dosing strategies and reduces drug costs in depressed elderly patients. Acta Psychiatr Scand 2000; 101: 354-359
  CrossrefPubMedGoogle Scholar
• 735 Lunell E, Curvall M. Nicotine delivery and subjective effects of Swedish portion snus compared with 4 mg nicotine polacrilex chewing gum. Nicotine Tob Res 2011; 13: 573-578
  CrossrefPubMedGoogle Scholar
• 736 Luo JP, Vashishtha SC, Hawes EM. et al. In vitro identification of the human cytochrome p450 enzymes involved in the oxidative metabolism of loxapine. Biopharm Drug Dispos 2011; 32: 398-407
  CrossrefPubMedGoogle Scholar
• 737 Luthi G, Blangy V, Eap CB. et al. Buprenorphine and norbuprenorphine quantification in human plasma by simple protein precipitation and ultra-high performance liquid chromatography tandem mass spectrometry. J Pharm Biomed Anal 2013; 77: 1-8
  CrossrefPubMedGoogle Scholar
• 738 Luurila H, Olkkola KT. Pharmacokinetic-pharmacodynamic modelling of zopiclone effects on human central nervous system. Pharmacol Toxicol 1996; 78: 348-353
  CrossrefPubMedGoogle Scholar
• 739 Lynch MJ, Woods J, George N. et al. Fatality due to amisulpride toxicity: a case report. Med Sci Law 2008; 48: 173-177
  CrossrefPubMedGoogle Scholar
• 740 Machino A, Jitsuiki H, Okamoto Y. et al. The valproate serum level in maintenance therapy for bipolar disorder in Japan. Hiroshima J Med Sci 2013; 62: 7-12
  PubMedGoogle Scholar
• 741 Mackey TK, Liang BA. Improving global health governance to combat counterfeit medicines: A proposal for a UNODC-WHO-Interpol trilateral mechanism. BMC Med 2013; 11: 233
  CrossrefPubMedGoogle Scholar
• 742 Madan A, Graham RA, Carroll KM. et al. Effects of prototypical microsomal enzyme inducers on cytochrome P450 expression in cultured human hepatocytes. Drug Metab Dispos 2003; 31: 421-431
  CrossrefPubMedGoogle Scholar
• 743 Madan A, Parkinson A, Faiman MD. Identification of the human P-450 enzymes responsible for the sulfoxidation and thiono-oxidation of diethyldithiocarbamate methyl ester: Role of P-450 enzymes in disulfiram bioactivation. Alcohol Clin Exp Res 1998; 22: 1212-1219
  PubMedGoogle Scholar
• 744 Madsen H, Nielsen KK, Brosen K. Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms – a population study. Br J Clin Pharmacol 1995; 39: 433-439
  CrossrefPubMedGoogle Scholar
• 745 Maguire KP, Burrows GD, Norman TR. et al. Metabolism and pharmacokinetics of dothiepin. Br J Clin Pharmacol 1981; 12: 405-409
  CrossrefPubMedGoogle Scholar
• 746 Maguire KP, Norman TR, Burrows GD. et al. An evaluation of maprotiline intravenous kinetics and comparison of two oral doses. Eur J Clin Pharmacol 1980; 18: 249-254
  CrossrefPubMedGoogle Scholar
• 747 Magura S, Laudet AB, Mahmood D. et al. Adherence to medication regimens and participation in dual-focus self-help groups. Psychiatr Serv 2002; 53: 310-316
  CrossrefPubMedGoogle Scholar
• 748 Mahmood I, Sahajwalla C. Clinical pharmacokinetics and pharmacodynamics of buspirone, an anxiolytic drug. Clin Pharmacokinet 1999; 36: 277-287
  CrossrefPubMedGoogle Scholar
• 749 Majumdar AK, McCrea JB, Panebianco DL. et al. Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe. Clin Pharmacol Ther 2003; 74: 150-156
  CrossrefPubMedGoogle Scholar
• 750 Mallaysamy S, Johnson MG, Rao PG. et al. Population pharmacokinetics of lamotrigine in Indian epileptic patients. Eur J Clin Pharmacol 2013; 69: 43-52
  PubMedGoogle Scholar
• 751 Mallikaarjun S, Kane JM, Bricmont P. et al. Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: An open-label, parallel-arm, multiple-dose study. Schizophr Res 2013; 150: 281-288
  CrossrefPubMedGoogle Scholar
• 752 Mallikaarjun S, Salazar DE, Bramer SL. Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. J Clin Pharmacol 2004; 44: 179-187
  CrossrefPubMedGoogle Scholar
• 753 Mallinger AG, Himmelhoch JM, Thase ME. et al. Plasma tranylcypromine: relationship to pharmacokinetic variables and clinical antidepressant actions. J Clin Psychopharmacol 1990; 10: 176-183
  PubMedGoogle Scholar
• 754 Mamo D, Kapur S, Keshavan M. et al. D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: An open-label study in patients with schizophrenia. Neuropsychopharmacology 2008; 33: 298-304
  CrossrefPubMedGoogle Scholar
• 755 Mamo D, Kapur S, Shammi CM. et al. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry 2004; 161: 818-825
  CrossrefPubMedGoogle Scholar
• 756 Mandrioli R, Mercolini L, Saracino MA. et al. Selective serotonin reuptake inhibitors (SSRIs): Therapeutic drug monitoring and pharmacological interactions. Curr Med Chem 2012; 19: 1846-1863
  CrossrefPubMedGoogle Scholar
• 757 Mann K, Hiemke C, Lotz J. et al. Appropriateness of plasma level determinations for lithium and valproate in routine care of psychiatric inpatients with affective disorders. J Clin Psychopharmacol 2006; 26: 671-673
  CrossrefPubMedGoogle Scholar
• 758 Mann K, Hiemke C, Schmidt LG. et al. Appropriateness of therapeutic drug monitoring for antidepressants in routine psychiatric inpatient care. Ther Drug Monit 2006; 28: 83-88
  CrossrefPubMedGoogle Scholar
• 759 Mannheimer B, Haslemo T, Lindh JD. et al. Risperidone and venlafaxine metabolic ratios strongly predict a cyp2d6 poor metabolizing genotype. Ther Drug Monit 2016; 38: 127-134
  CrossrefPubMedGoogle Scholar
• 760 Mannheimer B, Holm J, Koukel L. et al. Risperidone metabolic ratio as a biomarker of individual CYP2D6 genotype in schizophrenic patients. Eur J Clin Pharmacol 2014; 70: 695-699
  CrossrefPubMedGoogle Scholar
• 761 Mao J, Johnson TR, Shen Z. et al. Prediction of crizotinib-midazolam interaction using the Simcyp population-based simulator: comparison of CYP3A time-dependent inhibition between human liver microsomes versus hepatocytes. Drug Metab Dispos 2013; 41: 343-352
  CrossrefPubMedGoogle Scholar
• 762 Marazziti D, Baroni S, Picchetti M. et al. Pharmacokinetics and pharmacodynamics of psychotropic drugs: Effect of sex. CNS Spectr 2013; 18: 118-127
  CrossrefPubMedGoogle Scholar
• 763 Marcus SC, Olfson M, Pincus HA. et al. Therapeutic drug monitoring of mood stabilizers in Medicaid patients with bipolar disorder. Am J Psychiatry 1999; 156: 1014-1018
  PubMedGoogle Scholar
• 764 Markert C, Ngui P, Hellwig R. et al. Influence of St. John’s wort on the steady-state pharmacokinetics and metabolism of bosentan. Int J Clin Pharmacol Ther 2014; 52: 328-336
  CrossrefPubMedGoogle Scholar
• 765 Markoula S, Teotonio R, Ratnaraj N. et al. Lacosamide serum concentrations in adult patients with epilepsy: The influence of gender, age, dose, and concomitant antiepileptic drugs. Ther Drug Monit 2014; 36: 494-498
  CrossrefPubMedGoogle Scholar
• 766 Markowitz JS, Patrick KS. Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: Does chirality matter?. J Clin Psychopharmacol 2008; 28: S54-S61
  CrossrefPubMedGoogle Scholar
• 767 Martin P, Dirks B, Gertsik L. et al. Safety and pharmacokinetics of lisdexamfetamine dimesylate in adults with clinically stable schizophrenia: A randomized, double-blind, placebo-controlled trial of ascending multiple doses. J Clin Psychopharmacol 2014; 34: 682-689
  CrossrefPubMedGoogle Scholar
• 768 Martines C, Gatti G, Sasso E. et al. The disposition of primidone in elderly patients. Br J Clin Pharmacol 1990; 30: 607-611
  CrossrefPubMedGoogle Scholar
• 769 Martinez C, Albet C, Agundez JA. et al. Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists. Clin Pharmacol Ther 1999; 65: 369-376
  CrossrefPubMedGoogle Scholar
• 770 Mas S, Gasso P, Ritter MA. et al. Pharmacogenetic predictor of extrapyramidal symptoms induced by antipsychotics: multilocus interaction in the mTOR pathway. Eur Neuropsychopharmacol 2015; 25: 51-59
  CrossrefPubMedGoogle Scholar
• 771 Mason BJ, Goodman AM, Dixon RM. et al. A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone. Neuropsychopharmacology 2002; 27: 596-606
  CrossrefPubMedGoogle Scholar
• 772 Masson CL, Rainey PM, Moody DE. et al. Effects of HCV seropositive status on buprenorphine pharmacokinetics in opioid-dependent individuals. Am J Addict 2014; 23: 34-40
  CrossrefPubMedGoogle Scholar
• 773 Matsui DM. Therapeutic drug monitoring in pregnancy. Ther Drug Monit 2012; 34: 507-511
  CrossrefPubMedGoogle Scholar
• 774 Matthaei J, Brockmoller J, Tzvetkov MV. et al. Heritability of metoprolol and torsemide pharmacokinetics. Clin Pharmacol Ther 2015; 98: 611-621
  CrossrefPubMedGoogle Scholar
• 775 Mattila MA, Larni HM. Flunitrazepam: A review of its pharmacological properties and therapeutic use. Drugs 1980; 20: 353-374
  CrossrefPubMedGoogle Scholar
• 776 Maurer HH, Sauer C, Theobald DS. Toxicokinetics of drugs of abuse: current knowledge of the isoenzymes involved in the human metabolism of tetrahydrocannabinol, cocaine, heroin, morphine, and codeine. Ther Drug Monit 2006; 28: 447-453
  CrossrefPubMedGoogle Scholar
• 777 Mauri MC, Laini V, Boscati L. et al. Long-term treatment of chronic schizophrenia with risperidone: A study with plasma levels. Eur Psychiatry 2001; 16: 57-63
  CrossrefPubMedGoogle Scholar
• 778 Mauri MC, Maffini M, Di Pace C. et al. "Long-acting" olanzapine in maintenance therapy of schizophrenia: A study with plasma levels. Int J Psychiatry Clin Pract 2015; 19: 99-105
  CrossrefPubMedGoogle Scholar
• 779 Mauri MC, Paletta S, Maffini M. et al. Clinical pharmacology of atypical antipsychotics: An update. EXCLI J 2014; 13: 1163-1191
  PubMedGoogle Scholar
• 780 Mauri MC, Steinhilber CP, Marino R. et al. Clinical outcome and olanzapine plasma levels in acute schizophrenia. Eur Psychiatry 2005; 20: 55-60
  CrossrefPubMedGoogle Scholar
• 781 Mauri MC, Volonteri LS, Colasanti A. et al. Clinical pharmacokinetics of atypical antipsychotics: A critical review of the relationship between plasma concentrations and clinical response. Clin Pharmacokinet 2007; 46: 359-388
  CrossrefPubMedGoogle Scholar
• 782 May TW, Korn-Merker E, Rambeck B. Clinical pharmacokinetics of oxcarbazepine. Clin Pharmacokinet 2003; 42: 1023-1042
  CrossrefPubMedGoogle Scholar
• 783 May TW, Korn-Merker E, Rambeck B. et al. Pharmacokinetics of sulthiame in epileptic patients. Ther Drug Monit 1994; 16: 251-257
  CrossrefPubMedGoogle Scholar
• 784 May TW, Rambeck B, Jurgens U. Serum concentrations of topiramate in patients with epilepsy: Influence of dose, age, and comedication. Ther Drug Monit 2002; 24: 366-374
  CrossrefPubMedGoogle Scholar
• 785 May TW, Rambeck B, Neb R. et al. Serum concentrations of pregabalin in patients with epilepsy: The influence of dose, age, and comedication. Ther Drug Monit 2007; 29: 789-794
  CrossrefPubMedGoogle Scholar
• 786 Mayo BC, Biggs SR, Chasseaud LF. et al. The metabolic fate of Sormodren (bornaprine hydrochloride) in animals and humans. Xenobiotica 1980; 10: 873-888
  CrossrefPubMedGoogle Scholar
• 787 Mazur A, Lichti CF, Prather PL. et al. Characterization of human hepatic and extrahepatic UDP-glucuronosyltransferase enzymes involved in the metabolism of classic cannabinoids. Drug Metab Dispos 2009; 37: 1496-1504
  CrossrefPubMedGoogle Scholar
• 788 McAlpine DE, Biernacka JM, Mrazek DA. et al. Effect of cytochrome P450 enzyme polymorphisms on pharmacokinetics of venlafaxine. Ther Drug Monit 2011; 33: 14-20
  CrossrefPubMedGoogle Scholar
• 789 McCarthy MJ, Leckband SG, Kelsoe JR. Pharmacogenetics of lithium response in bipolar disorder. Pharmacogenomics 2010; 11: 1439-1465
  CrossrefPubMedGoogle Scholar
• 790 McDonald MG, Au NT, Rettie AE. P450-Based drug-drug interactions of amiodarone and its metabolites: Diversity of inhibitory mechanisms. Drug Metab Dispos 2015; 43: 1661-1669
  CrossrefPubMedGoogle Scholar
• 791 McIntyre IM, Mallett P, Stabley R. Postmortem distribution of trazodone concentrations. Forensic Sci Int 2015; 251: 195-201
  CrossrefPubMedGoogle Scholar
• 792 McKenzie ME, Roswell-Harris D. A controlled trial of prothipendyl (tolnate) in mentally subnormal patients. Br J Psychiatry 1966; 112: 95-100
  CrossrefPubMedGoogle Scholar
• 793 Medori R, Mannaert E, Gründer G. Plasma antipsychotic concentration and receptor occupancy, with special focus on risperidone long-acting injectable. Eur Neuropsychopharmacol 2006; 16: 233-240
  CrossrefPubMedGoogle Scholar
• 794 Mehler-Wex C, Kolch M, Kirchheiner J. et al. Drug monitoring in child and adolescent psychiatry for improved efficacy and safety of psychopharmacotherapy. Child Adolesc Psychiatry Ment Health 2009; 3: 14
  CrossrefPubMedGoogle Scholar
• 795 Meijer WE, Bouvy ML, Heerdink ER. et al. Spontaneous lapses in dosing during chronic treatment with selective serotonin reuptake inhibitors. Br J Psychiatry 2001; 179: 519-522
  CrossrefPubMedGoogle Scholar
• 796 Meineke I, Kress I, Poser W. et al. Therapeutic drug monitoring of mirtazapine and its metabolite desmethylmirtazapine by HPLC with fluorescence detection. Ther Drug Monit 2004; 26: 277-283
  CrossrefPubMedGoogle Scholar
• 797 Meisenzahl EM, Schmitt G, Gründer G. et al. Striatal D2/D3 receptor occupancy, clinical response and side effects with amisulpride: An iodine-123-iodobenzamide SPET study. Pharmacopsychiatry 2008; 41: 169-175
  Article in Thieme ConnectPubMedGoogle Scholar
• 798 Menke A, Klengel T, Binder EB. Epigenetics, depression and antidepressant treatment. Curr Pharm Des 2012; 18: 5879-5889
  CrossrefPubMedGoogle Scholar
• 799 Meyer-Barner M, Meineke I, Schreeb KH. et al. Pharmacokinetics of doxepin and desmethyldoxepin: An evaluation with the population approach. Eur J Clin Pharmacol 2002; 58: 253-257
  CrossrefPubMedGoogle Scholar
• 800 Meyer JH. Imaging the serotonin transporter during major depressive disorder and antidepressant treatment. J Psychiatry Neurosci 2007; 32: 86-102
  PubMedGoogle Scholar
• 801 Meyer JH, Wilson AA, Sagrati S. et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: An [11C]DASB positron emission tomography study. Am J Psychiatry 2004; 161: 826-835
  CrossrefPubMedGoogle Scholar
• 802 Meyer MR, Schutz A, Maurer HH. Contribution of human esterases to the metabolism of selected drugs of abuse. Toxicol Lett 2015; 232: 159-166
  CrossrefPubMedGoogle Scholar
• 803 Meyer RP, Gehlhaus M, Knoth R. et al. Expression and function of cytochrome p450 in brain drug metabolism. Curr Drug Metab 2007; 8: 297-306
  CrossrefPubMedGoogle Scholar
• 804 Michaud V, Mouksassi MS, Labbe L. et al. Inhibitory effects of propafenone on the pharmacokinetics of caffeine in humans. Ther Drug Monit 2006; 28: 779-783
  CrossrefPubMedGoogle Scholar
• 805 Michelson D, Read HA, Ruff DD. et al. CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry 2007; 46: 242-251
  CrossrefPubMedGoogle Scholar
• 806 Mihara K, Otani K, Suzuki A. et al. Relationship between the CYP2D6 genotype and the steady-state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine. Psychopharmacology (Berl) 1997; 133: 95-98
  CrossrefPubMedGoogle Scholar
• 807 Mihara K, Yasui-Furukori N, Kondo T. et al. Relationship between plasma concentrations of trazodone and its active metabolite, m-chlorophenylpiperazine, and its clinical effect in depressed patients. Ther Drug Monit 2002; 24: 563-566
  CrossrefPubMedGoogle Scholar
• 808 Mikami A, Ohtani H, Hori S. et al. Pharmacokinetic model incorporating mechanism-based inactivation of CYP2D6 can explain both non-linear kinetics and drug interactions of paroxetine. Int J Clin Pharmacol Ther 2013; 51: 374-382
  CrossrefPubMedGoogle Scholar
• 809 Miller DS. Regulation of ABC transporters blood-brain barrier: The good, the bad, and the ugly. Adv Cancer Res 2015; 125: 43-70
  PubMedGoogle Scholar
• 810 Milosheska D, Grabnar I, Vovk T. Dried blood spots for monitoring and individualization of antiepileptic drug treatment. Eur J Pharm Sci 2015; 75: 25-39
  CrossrefPubMedGoogle Scholar
• 811 Mimaki T. Clinical pharmacology and therapeutic drug monitoring of zonisamide. Ther Drug Monit 1998; 20: 593-597
  CrossrefPubMedGoogle Scholar
• 812 Mitchell TB, White JM, Somogyi AA. et al. Comparative pharmacodynamics and pharmacokinetics of methadone and slow-release oral morphine for maintenance treatment of opioid dependence. Drug Alcohol Depend 2003; 72: 85-94
  CrossrefPubMedGoogle Scholar
• 813 Miura H. Zonisamide monotherapy with once-daily dosing in children with cryptogenic localization-related epilepsies: Clinical effects and pharmacokinetic studies. Seizure 2004; 13 Suppl 1: S17-S23 discussion S24-15
  CrossrefPubMedGoogle Scholar
• 814 Miura M, Ohkubo T. Identification of human cytochrome P450 enzymes involved in the major metabolic pathway of fluvoxamine. Xenobiotica 2007; 37: 169-179
  CrossrefPubMedGoogle Scholar
• 815 Molden E, Lunde H, Lunder N. et al. Pharmacokinetic variability of aripiprazole and the active metabolite dehydroaripiprazole in psychiatric patients. Ther Drug Monit 2006; 28: 744-749
  CrossrefPubMedGoogle Scholar
• 816 Montgomery S, McAuley R, Montgomery DB. Relationship between mianserin plasma levels and antidepressant effect in a double-blind trial comparing a single night-time and divided daily dose regimens. Br J Clin Pharmacol 1978; 5 (Suppl. 01) 71S-76S
  CrossrefPubMedGoogle Scholar
• 817 Moody DE, Chang Y, Huang W. et al. The in vivo response of novel buprenorphine metabolites, M1 and M3, to antiretroviral inducers and inhibitors of buprenorphine metabolism. Basic Clin Pharmacol Toxicol 2009; 105: 211-215
  CrossrefPubMedGoogle Scholar
• 818 Morgan DD, Robinson JD, Mendenhall CL. Clinical pharmacokinetics of chlordiazepoxide in patients with alcoholic hepatitis. Eur J Clin Pharmacol 1981; 19: 279-285
  CrossrefPubMedGoogle Scholar
• 819 Morris RG, Black AB, Harris AL. et al. Lamotrigine and therapeutic drug monitoring: Retrospective survey following the introduction of a routine service. Br J Clin Pharmacol 1998; 46: 547-551
  CrossrefPubMedGoogle Scholar
• 820 Morris RG, Lee MY, Cleanthous X. et al. Long-term follow-up using a higher target range for lamotrigine monitoring. Ther Drug Monit 2004; 26: 626-632
  CrossrefPubMedGoogle Scholar
• 821 Morselli PL, Baruzzi A, Gerna M. et al. Carbamazepine and carbamazepine-10, 11-epoxide concentrations in human brain. Br J Clin Pharmacol 1977; 4: 535-540
  CrossrefPubMedGoogle Scholar
• 822 Mossner R, Schuhmacher A, Kuhn KU. et al. Functional serotonin 1A receptor variant influences treatment response to atypical antipsychotics in schizophrenia. Pharmacogenet Genomics 2009; 19: 91-94
  CrossrefPubMedGoogle Scholar
• 823 Mrazek DA. Psychiatric pharmacogenomic testing in clinical practice. Dialogues Clin Neurosci 2010; 12: 69-76
  PubMedGoogle Scholar
• 824 Müller-Isberner R, Freese R, Jockel D. et al. Forensic psychiatric assessment and treatment in Germany. Legal framework, recent developments, and current practice. Int J Law Psychiatry 2000; 23: 467-480
  CrossrefPubMedGoogle Scholar
• 825 Müller H, Eusterschulte B, Havemann-Reinecke U. et al. Forensische Aspekte des therapeutischen Drug-Monitorings (TDM) in der Psychiatrie. Psychopharmakotherapie 2009; 16: 52-56
  PubMedGoogle Scholar
• 826 Müller MJ, Dragicevic A, Fric M. et al. Therapeutic drug monitoring of tricyclic antidepressants: How does it work under clinical conditions?. Pharmacopsychiatry 2003; 36: 98-104
  Article in Thieme ConnectPubMedGoogle Scholar
• 827 Müller MJ, Eich FX, Regenbogen B. et al. Amisulpride doses and plasma levels in different age groups of patients with schizophrenia or schizoaffective disorder. J Psychopharmacol 2009; 23: 278-286
  CrossrefPubMedGoogle Scholar
• 828 Müller MJ, Härtter S, Kohler D. et al. Serum levels of sulpiride enantiomers after oral treatment with racemic sulpiride in psychiatric patients: a pilot study. Pharmacopsychiatry 2001; 34: 27-32
  Article in Thieme ConnectPubMedGoogle Scholar
• 829 Müller MJ, Regenbogen B, Härtter S. et al. Therapeutic drug monitoring for optimizing amisulpride therapy in patients with schizophrenia. J Psychiatr Res 2007; 41: 673-679
  CrossrefPubMedGoogle Scholar
• 830 Müller T. Pharmacokinetic considerations for the use of levodopa in the treatment of Parkinson disease: Focus on levodopa/carbidopa/entacapone for treatment of levodopa-associated motor complications. Clin Neuropharmacol 2013; 36: 84-91
  CrossrefPubMedGoogle Scholar
• 831 Myung W, Jang JH, Yoon H. et al. Therapeutic drug monitoring of mirtazapine in a routine outpatient setting in Asian psychiatric patients. Pharmacopsychiatry 2014; 47: 210-214
  Article in Thieme ConnectPubMedGoogle Scholar
• 832 Nagasaka Y, Oda K, Iwatsubo T. et al. Effects of aripiprazole and its active metabolite dehydroaripiprazole on the activities of drug efflux transporters expressed both in the intestine and at the blood-brain barrier. Biopharm Drug Dispos 2012; 33: 304-315
  CrossrefPubMedGoogle Scholar
• 833 Nagy CF, Kumar D, Cullen EI. et al. Steady-state pharmacokinetics and safety of donepezil HCl in subjects with moderately impaired renal function. Br J Clin Pharmacol 2004; 58 (Suppl. 01) 18-24
  CrossrefPubMedGoogle Scholar
• 834 Naik H, Chan S, Vakilynejad M. et al. A population pharmacokinetic-pharmacodynamic meta-analysis of vortioxetine in patients with major depressive disorder. Basic Clin Pharmacol Toxicol 2016; 118: 344-355
  CrossrefPubMedGoogle Scholar
• 835 Naito H, Wachi M, Nishida M. Clinical effects and plasma concentrations of long-term clonazepam monotherapy in previously untreated epileptics. Acta Neurol Scand 1987; 76: 58-63
  CrossrefPubMedGoogle Scholar
• 836 Nakajima S, Caravaggio F, Mamo DC. et al. Dopamine D(2)/(3) receptor availability in the striatum of antipsychotic-free older patients with schizophrenia-A [(1)(1)C]-raclopride PET study. Schizophr Res 2015; 164: 263-267
  CrossrefPubMedGoogle Scholar
• 837 Nakajima S, Uchida H, Bies RR. et al. Dopamine D2/3 receptor occupancy following dose reduction is predictable with minimal plasma antipsychotic concentrations: An open-label clinical trial. Schizophr Bull 2016; 42: 212-219
  PubMedGoogle Scholar
• 838 Nakamura A, Mihara K, Nagai G. et al. Prediction of an optimal dose of lamotrigine for augmentation therapy in treatment-resistant depressive disorder from plasma lamotrigine concentration at week 2. Ther Drug Monit 2016; 38: 379-382
  CrossrefPubMedGoogle Scholar
• 839 Nakamura K, Yokoi T, Inoue K. et al. CYP2D6 is the principal cytochrome P450 responsible for metabolism of the histamine H1 antagonist promethazine in human liver microsomes. Pharmacogenetics 1996; 6: 449-457
  CrossrefPubMedGoogle Scholar
• 840 Nakamura T, Kubota T, Iwakaji A. et al. Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment). Drug Des Devel Ther 2016; 10: 327-338
  PubMedGoogle Scholar
• 841 Narimatsu S, Kariya S, Isozaki S. et al. Involvement of CYP2D6 in oxidative metabolism of cinnarizine and flunarizine in human liver microsomes. Biochem Biophys Res Commun 1993; 193: 1262-1268
  CrossrefPubMedGoogle Scholar
• 842 Nazirizadeh Y, Vogel F, Bader W. et al. Serum concentrations of paliperidone versus risperidone and clinical effects. Eur J Clin Pharmacol 2010; 66: 797-803
  CrossrefPubMedGoogle Scholar
• 843 Neels HM, Sierens AC, Naelaerts K. et al. Therapeutic drug monitoring of old and newer anti-epileptic drugs. Clin Chem Lab Med 2004; 42: 1228-1255
  PubMedGoogle Scholar
• 844 Nemoda Z, Angyal N, Tarnok Z. et al. Carboxylesterase 1 gene polymorphism and methylphenidate response in ADHD. Neuropharmacology 2009; 57: 731-733
  CrossrefPubMedGoogle Scholar
• 845 Nesvag R, Hendset M, Refsum H. et al. Serum concentrations of risperidone and 9-OH risperidone following intramuscular injection of long-acting risperidone compared with oral risperidone medication. Acta Psychiatr Scand 2006; 114: 21-26
  CrossrefPubMedGoogle Scholar
• 846 Neuhaus W, Mandikova J, Pawlowitsch R. et al. Blood-brain barrier in vitro models as tools in drug discovery: Assessment of the transport ranking of antihistaminic drugs. Pharmazie 2012; 67: 432-439
  PubMedGoogle Scholar
• 847 Nguyen TT, Benech H, Pruvost A. et al. A limited sampling strategy based on maximum a posteriori Bayesian estimation for a five-probe phenotyping cocktail. Eur J Clin Pharmacol 2016; 72: 39-51
  CrossrefPubMedGoogle Scholar
• 848 Nichols AI, Focht K, Jiang Q. et al. Pharmacokinetics of venlafaxine extended release 75 mg and desvenlafaxine 50 mg in healthy CYP2D6 extensive and poor metabolizers: A randomized, open-label, two-period, parallel-group, crossover study. Clin Drug Investig 2011; 31: 155-167
  CrossrefPubMedGoogle Scholar
• 849 Nicolas JM, Collart P, Gerin B. et al. In vitro evaluation of potential drug interactions with levetiracetam, a new antiepileptic agent. Drug Metab Dispos 1999; 27: 250-254
  PubMedGoogle Scholar
• 850 Nikisch G, Baumann P, Oneda B. et al. Cytochrome P450 and ABCB1 genetics: Association with quetiapine and norquetiapine plasma and cerebrospinal fluid concentrations and with clinical response in patients suffering from schizophrenia. A pilot study. J Psychopharmacol 2011; 25: 896-907
  CrossrefPubMedGoogle Scholar
• 851 Nikisch G, Baumann P, Wiedemann G. et al. Quetiapine and norquetiapine in plasma and cerebrospinal fluid of schizophrenic patients treated with quetiapine: Correlations to clinical outcome and HVA, 5-HIAA, and MHPG in CSF. J Clin Psychopharmacol 2010; 30: 496-503
  CrossrefPubMedGoogle Scholar
• 852 Nikisch G, Mathe AA, Czernik A. et al. Stereoselective metabolism of citalopram in plasma and cerebrospinal fluid of depressive patients: Relationship with 5-HIAA in CSF and clinical response. J Clin Psychopharmacol 2004; 24: 283-290
  CrossrefPubMedGoogle Scholar
• 853 Nikolaus S, Larisch R, Beu M. et al. In vivo measurement of D2 receptor density and affinity for 18F-(3-N-methyl)benperidol in the rat striatum with a PET system for small laboratory animals. J Nucl Med 2003; 44: 618-624
  PubMedGoogle Scholar
• 854 Nilausen DO, Zuiker RG, van Gerven J. The perception and pharmacokinetics of a 20-mg dose of escitalopram orodispersible tablets in a relative bioavailability study in healthy men. Clin Ther 2011; 33: 1492-1502
  PubMedGoogle Scholar
• 855 Nilsson EB, Rimmele SM, Schmidt EK. et al. Pharmacokinetics and relative bioavailability of opipramol in the new INSIDON–sustained release preparation. Fortschr Neurol Psychiatr 1998; 66 (Suppl. 01) S13-S16
  Article in Thieme ConnectPubMedGoogle Scholar
• 856 Nilsson MI, Meresaar U, Anggard E. Clinical pharmacokinetics of methadone. Acta Anaesthesiol Scand Suppl 1982; 74: 66-69
  PubMedGoogle Scholar
• 857 Nishikage H, Nakanishi T, Takamitsu Y. et al. Sequential changes in the plasma concentration of risperidone following intentional overdose. Clin Neuropharmacol 2002; 25: 307-309
  CrossrefPubMedGoogle Scholar
• 858 Nishikawa N, Nagai M, Moritoyo T. et al. Plasma amantadine concentrations in patients with Parkinson’s disease. Parkinsonism Relat Disord 2009; 15: 351-353
  CrossrefPubMedGoogle Scholar
• 859 Nishimura Y, Kurata N, Sakurai E. et al. Inhibitory effect of antituberculosis drugs on human cytochrome P450-mediated activities. J Pharmacol Sci 2004; 96: 293-300
  CrossrefPubMedGoogle Scholar
• 860 Niwa T, Imagawa Y, Yamazaki H. Drug interactions between nine antifungal agents and drugs metabolized by human cytochromes P450. Curr Drug Metab 2014; 15: 651-679
  PubMedGoogle Scholar
• 861 Nnadi CU, Malhotra AK. Clinical and pharmacogenetic studies of iloperidone. Per Med 2008; 5: 367-375
  CrossrefPubMedGoogle Scholar
• 862 Noetzli M, Guidi M, Ebbing K. et al. Population pharmacokinetic study of memantine: Effects of clinical and genetic factors. Clin Pharmacokinet 2013; 52: 211-223
  CrossrefPubMedGoogle Scholar
• 863 Noetzli M, Guidi M, Ebbing K. et al. Population pharmacokinetic approach to evaluate the effect of CYP2D6, CYP3A, ABCB1, POR and NR1I2 genotypes on donepezil clearance. Br J Clin Pharmacol 2014; 78: 135-144
  CrossrefPubMedGoogle Scholar
• 864 Nogami T, Takano H, Arakawa R. et al. Occupancy of serotonin and norepinephrine transporter by milnacipran in patients with major depressive disorder: A positron emission tomography study with [(11)C]DASB and (S,S)-[(18)F]FMeNER-D(2). Int J Neuropsychopharmacol 2013; 16: 937-943
  CrossrefPubMedGoogle Scholar
• 865 Norman T, Chiu E, James RH. et al. Single oral dose pharmacokinetics of tiapride in patients with Huntington’s disease. Eur J Clin Pharmacol 1987; 32: 583-586
  CrossrefPubMedGoogle Scholar
• 866 Nozawa M, Ohnuma T, Matsubara Y. et al. The relationship between the response of clinical symptoms and plasma olanzapine concentration, based on pharmacogenetics: Juntendo University Schizophrenia Projects (JUSP). Ther Drug Monit 2008; 30: 35-40
  CrossrefPubMedGoogle Scholar
• 867 Nutt JG, Fellman JH. Pharmacokinetics of levodopa. Clin Neuropharmacol 1984; 7: 35-49
  CrossrefPubMedGoogle Scholar
• 868 Nyberg S, Nordstrom AL, Halldin C. et al. Positron emission tomography studies on D2 dopamine receptor occupancy and plasma antipsychotic drug levels in man. Int Clin Psychopharmacol 1995; 10 (Suppl. 03) 81-85
  PubMedGoogle Scholar
• 869 Nyholm D. Pharmacokinetic optimisation in the treatment of Parkinson’s disease: An update. Clin Pharmacokinet 2006; 45: 109-136
  CrossrefPubMedGoogle Scholar
• 870 Nyholm D, Ehrnebo M, Lewander T. et al. Frequent administration of levodopa/carbidopa microtablets vs levodopa/carbidopa/entacapone in healthy volunteers. Acta Neurol Scand 2013; 127: 124-132
  CrossrefPubMedGoogle Scholar
• 871 Nyholm D, Odin P, Johansson A. et al. Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson’s disease patients. AAPS J 2013; 15: 316-323
  CrossrefPubMedGoogle Scholar
• 872 O’Connor S, Ayres A, Cortellini L. et al. Process improvement methods increase the efficiency, accuracy, and utility of a neurocritical care research repository. Neurocrit Care 2012; 17: 90-96
  CrossrefPubMedGoogle Scholar
• 873 O’Dushlaine C, Ripke S, Ruderfer DM. et al. Rare copy number variation in treatment-resistant major depressive disorder. Biol Psychiatry 2014; 76: 536-541
  CrossrefPubMedGoogle Scholar
• 874 O’Mahony D, Gallagher PF. Inappropriate prescribing in the older population: Need for new criteria. Age Ageing 2008; 37: 138-141
  CrossrefPubMedGoogle Scholar
• 875 O’Mahony D, O’Sullivan D, Byrne S. et al. STOPP/START criteria for potentially inappropriate prescribing in older people: Version 2. Age Ageing 2015; 44: 213-218
  CrossrefPubMedGoogle Scholar
• 876 Obach RS, Cox LM, Tremaine LM. Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: An in vitro study. Drug Metab Dispos 2005; 33: 262-270
  CrossrefPubMedGoogle Scholar
• 877 Ochs HR, Greenblatt DJ, Friedman H. et al. Bromazepam pharmacokinetics: Influence of age, gender, oral contraceptives, cimetidine, and propranolol. Clin Pharmacol Ther 1987; 41: 562-570
  CrossrefPubMedGoogle Scholar
• 878 Oda S, Fukami T, Yokoi T. et al. A comprehensive review of UDP-glucuronosyltransferase and esterases for drug development. Drug Metab Pharmacokinet 2015; 30: 30-51
  CrossrefPubMedGoogle Scholar
• 879 Ogilvie BW, Yerino P, Kazmi F. et al. The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: Implications for coadministration with clopidogrel. Drug Metab Dispos 2011; 39: 2020-2033
  CrossrefPubMedGoogle Scholar
• 880 Ohman D, Cherma MD, Norlander B. et al. Determination of serum reboxetine enantiomers in patients on chronic medication with racemic reboxetine. Ther Drug Monit 2003; 25: 174-182
  CrossrefPubMedGoogle Scholar
• 881 Ohman D, Norlander B, Peterson C. et al. Bioanalysis of racemic reboxetine and its desethylated metabolite in a therapeutic drug monitoring setting using solid phase extraction and HPLC. Ther Drug Monit 2001; 23: 27-34
  CrossrefPubMedGoogle Scholar
• 882 Ohno Y, Hisaka A, Ueno M. et al. General framework for the prediction of oral drug interactions caused by CYP3A4 induction from in vivo information. Clin Pharmacokinet 2008; 47: 669-680
  CrossrefPubMedGoogle Scholar
• 883 Okudaira T, Kotegawa T, Imai H. et al. Effect of the treatment period with erythromycin on cytochrome P450 3A activity in humans. J Clin Pharmacol 2007; 47: 871-876
  CrossrefPubMedGoogle Scholar
• 884 Olesen OV, Linnet K. Contributions of five human cytochrome P450 isoforms to the N-demethylation of clozapine in vitro at low and high concentrations. J Clin Pharmacol 2001; 41: 823-832
  PubMedGoogle Scholar
• 885 Olesen OV, Linnet K. Hydroxylation and demethylation of the tricyclic antidepressant nortriptyline by cDNA-expressed human cytochrome P-450 isozymes. Drug Metab Dispos 1997; 25: 740-744
  PubMedGoogle Scholar
• 886 Olesen OV, Linnet K. Identification of the human cytochrome P450 isoforms mediating in vitro N-dealkylation of perphenazine. Br J Clin Pharmacol 2000; 50: 563-571
  CrossrefPubMedGoogle Scholar
• 887 Ono S, Hatanaka T, Miyazawa S. et al. Human liver microsomal diazepam metabolism using cDNA-expressed cytochrome P450s: role of CYP2B6, 2C19 and the 3A subfamily. Xenobiotica 1996; 26: 1155-1166
  CrossrefPubMedGoogle Scholar
• 888 Orlando R, De Martin S, Andrighetto L. et al. Fluvoxamine pharmacokinetics in healthy elderly subjects and elderly patients with chronic heart failure. Br J Clin Pharmacol 2010; 69: 279-286
  CrossrefPubMedGoogle Scholar
• 889 Orsulak PJ. Therapeutic monitoring of antidepressant drugs: current methodology and applications. J Clin Psychiatry 1986; 47 Suppl: 39-52
  PubMedGoogle Scholar
• 890 Orsulak PJ. Therapeutic monitoring of antidepressant drugs: guidelines updated. Ther Drug Monit 1989; 11: 497-507
  CrossrefPubMedGoogle Scholar
• 891 Orsulak PJ, Schildkraut JJ. Guidelines for therapeutic monitoring of tricyclic antidepressant plasma levels. Ther Drug Monit 1979; 1: 199-208
  CrossrefPubMedGoogle Scholar
• 892 Ortiz de Montellano PR. Cytochrome P450-activated prodrugs. Future Med Chem 2013; 5: 213-228
  CrossrefPubMedGoogle Scholar
• 893 Osanai T, Ohkubo T, Yasui N. et al. Effect of itraconazole on the pharmacokinetics and pharmacodynamics of a single oral dose of brotizolam. Br J Clin Pharmacol 2004; 58: 476-481
  CrossrefPubMedGoogle Scholar
• 894 Ostad Haji E, Mann K, Dragicevic A. et al. Potential cost-effectiveness of therapeutic drug monitoring for depressed patients treated with citalopram. Ther Drug Monit 2013; 35: 396-401
  CrossrefPubMedGoogle Scholar
• 895 Ostad Haji E, Tadic A, Wagner S. et al. Association between citalopram serum levels and clinical improvement of patients with major depression. J Clin Psychopharmacol 2011; 31: 281-286
  CrossrefPubMedGoogle Scholar
• 896 Ostad Haji E, Tadic A, Wagner S. et al. Early improvement and serum concentrations of citalopram to predict antidepressant drug response of patients with major depression. Pharmacopsychiatry 2013; 46: 261-266
  Article in Thieme ConnectPubMedGoogle Scholar
• 897 Ostad Haji E, Wagner S, Fric M. et al. Quetiapine and norquetiapine serum concentrations and clinical effects in depressed patients under augmentation therapy with quetiapine. Ther Drug Monit 2013; 35: 539-545
  CrossrefPubMedGoogle Scholar
• 898 Ota T, Shinotoh H, Fukushi K. et al. Estimation of plasma IC50 of donepezil for cerebral acetylcholinesterase inhibition in patients with Alzheimer disease using positron emission tomography. Clin Neuropharmacol 2010; 33: 74-78
  CrossrefPubMedGoogle Scholar
• 899 Othman AA, Dutta S. Population pharmacokinetics of levodopa in subjects with advanced Parkinson’s disease: Levodopa-carbidopa intestinal gel infusion vs. oral tablets. Br J Clin Pharmacol 2014; 78: 94-105
  CrossrefPubMedGoogle Scholar
• 900 Palego L, Biondi L, Giannaccini G. et al. Clozapine, norclozapine plasma levels, their sum and ratio in 50 psychotic patients: Influence of patient-related variables. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 473-480
  CrossrefPubMedGoogle Scholar
• 901 Palmer EC, Binns LN, Carey H. Levomilnacipran: A new serotonin-norepinephrine reuptake inhibitor for the treatment of major depressive disorder. Ann Pharmacother 2014; 48: 1030-1039
  CrossrefPubMedGoogle Scholar
• 902 Panagiotidis G, Arthur HW, Lindh JD. et al. Depot haloperidol treatment in outpatients with schizophrenia on monotherapy: Impact of CYP2D6 polymorphism on pharmacokinetics and treatment outcome. Ther Drug Monit 2007; 29: 417-422
  CrossrefPubMedGoogle Scholar
• 903 Panchaud A, Weisskopf E, Winterfeld U. et al. Pharmacokinetic alterations in pregnancy and use of therapeutic drug monitoring. Therapie 2014; 69: 223-234
  CrossrefPubMedGoogle Scholar
• 904 Paris BL, Ogilvie BW, Scheinkoenig JA. et al. In vitro inhibition and induction of human liver cytochrome p450 enzymes by milnacipran. Drug Metab Dispos 2009; 37: 2045-2054
  CrossrefPubMedGoogle Scholar
• 905 Park JY, Kim KA, Park PW. et al. Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy subjects. Clin Pharmacol Ther 2006; 79: 590-599
  CrossrefPubMedGoogle Scholar
• 906 Park PW, Seo YH, Ahn JY. et al. Effect of CYP3A5*3 genotype on serum carbamazepine concentrations at steady-state in Korean epileptic patients. J Clin Pharm Ther 2009; 34: 569-574
  CrossrefPubMedGoogle Scholar
• 907 Parker DR, McIntyre IM. Case studies of postmortem quetiapine: therapeutic or toxic concentrations?. J Anal Toxicol 2005; 29: 407-412
  CrossrefPubMedGoogle Scholar
• 908 Pasina L, Djade CD, Lucca U. et al. Association of anticholinergic burden with cognitive and functional status in a cohort of hospitalized elderly: comparison of the anticholinergic cognitive burden scale and anticholinergic risk scale: Results from the REPOSI study. Drugs Aging 2013; 30: 103-112
  CrossrefPubMedGoogle Scholar
• 909 Patrick KS, Straughn AB, Minhinnett RR. et al. Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2007; 81: 346-353
  CrossrefPubMedGoogle Scholar
• 910 Patsalos PN. The clinical pharmacology profile of the new antiepileptic drug perampanel: A novel noncompetitive AMPA receptor antagonist. Epilepsia 2015; 56: 12-27
  CrossrefPubMedGoogle Scholar
• 911 Patsalos PN, Berry DJ. Therapeutic drug monitoring of antiepileptic drugs by use of saliva. Ther Drug Monit 2013; 35: 4-29
  CrossrefPubMedGoogle Scholar
• 912 Patsalos PN, Berry DJ, Bourgeois BF. et al. Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: A position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 2008; 49: 1239-1276
  CrossrefPubMedGoogle Scholar
• 913 Patteet L, Cappelle D, Maudens KE. et al. Advances in detection of antipsychotics in biological matrices. Clin Chim Acta 2015; 441: 11-22
  CrossrefPubMedGoogle Scholar
• 914 Patteet L, Maudens KE, Morrens M. et al. Determination of common antipsychotics in quantisal-collected oral fluid by UHPLC-MS/MS: Method validation and applicability for therapeutic drug monitoring. Ther Drug Monit 2016; 38: 87-97
  CrossrefPubMedGoogle Scholar
• 915 Patteet L, Maudens KE, Sabbe B. et al. High throughput identification and quantification of 16 antipsychotics and 8 major metabolites in serum using ultra-high performance liquid chromatography-tandem mass spectrometry. Clin Chim Acta 2014; 429: 51-58
  CrossrefPubMedGoogle Scholar
• 916 Patteet L, Maudens KE, Stove CP. et al. The use of dried blood spots for quantification of 15 antipsychotics and 7 metabolites with ultra-high performance liquid chromatography – tandem mass spectrometry. Drug Test Anal 2015; 7: 502-511
  CrossrefPubMedGoogle Scholar
• 917 Patteet L, Morrens M, Maudens KE. et al. Therapeutic drug monitoring of common antipsychotics. Ther Drug Monit 2012; 34: 629-651
  CrossrefPubMedGoogle Scholar
• 918 Paulzen M, Eap CB, Gründer G. et al. Pharmacokinetic interaction between valproic acid, meropenem, and risperidone. J Clin Psychopharmacol 2016; 36: 90-92
  CrossrefPubMedGoogle Scholar
• 919 Paulzen M, Groppe S, Tauber SC. et al. Venlafaxine and O-desmethylvenlafaxine concentrations in plasma and cerebrospinal fluid. J Clin Psychiatry 2015; 76: 25-31
  CrossrefPubMedGoogle Scholar
• 920 Paulzen M, Haen E, Stegmann B et al. Clinical response in a risperidone-medicated naturalistic sample: Patients’ characteristics and dose-dependent pharmacokinetic patterns. Eur Arch Psychiatry Clin Neurosci. 2016;
  PubMed
• 921 Paulzen M, Henkel K, Tauber S. et al. Plasma levels and cerebrospinal fluid penetration of venlafaxine in a patient with a nonfatal overdose during a suicide attempt. J Clin Psychopharmacol 2014; 34: 398-399
  CrossrefPubMedGoogle Scholar
• 922 Paz E, Bouzas L, Hermida J. et al. Evaluation of three dosing models for the prediction of steady-state trough clozapine concentrations. Clin Biochem 2008; 41: 603-606
  CrossrefPubMedGoogle Scholar
• 923 Pearce GA, Day RO. Compliance with criteria necessary for effective drug concentration monitoring. Ther Drug Monit 1990; 12: 250-257
  CrossrefPubMedGoogle Scholar
• 924 Pedersen OL, Gram LF, Kristensen CB. et al. Overdosage of antidepressants: clinical and pharmacokinetic aspects. Eur J Clin Pharmacol 1982; 23: 513-521
  CrossrefPubMedGoogle Scholar
• 925 Pellizzoni C, Poggesi I, Jorgensen NP. et al. Pharmacokinetics of reboxetine in healthy volunteers. Single against repeated oral doses and lack of enzymatic alterations. Biopharm Drug Dispos 1996; 17: 623-633
  CrossrefPubMedGoogle Scholar
• 926 Perez J, Chiron C, Musial C. et al. Stiripentol: Efficacy and tolerability in children with epilepsy. Epilepsia 1999; 40: 1618-1626
  CrossrefPubMedGoogle Scholar
• 927 Perlis RH, Fijal B, Dharia S. et al. Failure to replicate genetic associations with antidepressant treatment response in duloxetine-treated patients. Biol Psychiatry 2010; 67: 1110-1113
  CrossrefPubMedGoogle Scholar
• 928 Perry PJ. Therapeutic drug monitoring of antipsychotics. Psychopharmacol Bull 2001; 35: 19-29
  PubMedGoogle Scholar
• 929 Perry PJ, Browne JL, Alexander B. et al. Relationship of free nortriptyline levels to therapeutic response. Acta Psychiatr Scand 1985; 72: 120-125
  CrossrefPubMedGoogle Scholar
• 930 Perry PJ, Miller DD, Arndt SV. et al. Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry 1991; 148: 231-235
  PubMedGoogle Scholar
• 931 Perry PJ, Miller DD, Arndt SV. et al. Haloperidol dosing requirements: the contribution of smoking and nonlinear pharmacokinetics. J Clin Psychopharmacol 1993; 13: 46-51
  PubMedGoogle Scholar
• 932 Perry PJ, Pfohl BM, Holstad SG. The relationship between antidepressant response and tricyclic antidepressant plasma concentrations. A retrospective analysis of the literature using logistic regression analysis. Clin Pharmacokinet 1987; 13: 381-392
  CrossrefPubMedGoogle Scholar
• 933 Perry PJ, Sanger T, Beasley C. Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients. J Clin Psychopharmacol 1997; 17: 472-477
  CrossrefPubMedGoogle Scholar
• 934 Perry PJ, Zeilmann C, Arndt S. Tricyclic antidepressant concentrations in plasma: An estimate of their sensitivity and specificity as a predictor of response. J Clin Psychopharmacol 1994; 14: 230-240
  PubMedGoogle Scholar
• 935 Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 2006; 61: 246-255
  CrossrefPubMedGoogle Scholar
• 936 Perucca E, Cloyd J, Critchley D. et al. Rufinamide: Clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. Epilepsia 2008; 49: 1123-1141
  CrossrefPubMedGoogle Scholar
• 937 Petit P, Lonjon R, Cociglio M. et al. Carbamazepine and its 10,11-epoxide metabolite in acute mania: Clinical and pharmacokinetic correlates. Eur J Clin Pharmacol 1991; 41: 541-546
  CrossrefPubMedGoogle Scholar
• 938 Peyronneau MA, Delaforge M, Riviere R. et al. High affinity of ergopeptides for cytochromes P450 3A. Importance of their peptide moiety for P450 recognition and hydroxylation of bromocriptine. Eur J Biochem 1994; 223: 947-956
  CrossrefPubMedGoogle Scholar
• 939 Pichini S, Papaseit E, Joya X. et al. Pharmacokinetics and therapeutic drug monitoring of psychotropic drugs in pediatrics. Ther Drug Monit 2009; 31: 283-318
  CrossrefPubMedGoogle Scholar
• 940 Pierce DM, Franklin RA, Harry TV. et al. Pharmacodynamic correlates of modified absorption: Studies with lormetazepam. Br J Clin Pharmacol 1984; 18: 31-35
  CrossrefPubMedGoogle Scholar
• 941 Pilla Reddy V, Kozielska M, Johnson M. et al. Population pharmacokinetic-pharmacodynamic modeling of haloperidol in patients with schizophrenia using positive and negative syndrome rating scale. J Clin Psychopharmacol 2013; 33: 731-739
  CrossrefPubMedGoogle Scholar
• 942 Pilleri M, Antonini A. Novel levodopa formulations in the treatment of Parkinson’s disease. Expert Rev Neurother 2014; 14: 143-149
  CrossrefPubMedGoogle Scholar
• 943 Piotrovsky V, Van Peer A, Van Osselaer N. et al. Galantamine population pharmacokinetics in patients with Alzheimer’s disease: modeling and simulations. J Clin Pharmacol 2003; 43: 514-523
  CrossrefPubMedGoogle Scholar
• 944 Plesnicar BK, Zalar B, Breskvar K. et al. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment. J Psychopharmacol 2006; 20: 829-833
  CrossrefPubMedGoogle Scholar
• 945 Poggesi I, Benedetti MS, Whomsley R. et al. Pharmacokinetics in special populations. Drug Metab Rev 2009; 41: 422-454
  CrossrefPubMedGoogle Scholar
• 946 Poppe C, Müller ST, Greil W. et al. Pharmacotherapy for obsessive compulsive disorder in clinical practice – Data of 842 inpatients from the International AMSP Project between 1994 and 2012. J Affect Disord 2016; 200: 89-96
  CrossrefPubMedGoogle Scholar
• 947 Potgieter GE, Groenewoud G, Jordaan PJ. et al. Pharmacokinetics of pipamperone from three different tablet formulations. Arzneimittelforschung 2002; 52: 430-434
  Article in Thieme ConnectPubMedGoogle Scholar
• 948 Pounder DJ, Jones GR. Post-mortem drug redistribution–a toxicological nightmare. Forensic Sci Int 1990; 45: 253-263
  CrossrefPubMedGoogle Scholar
• 949 Pozzi M, Cattaneo D, Baldelli S. et al. Therapeutic drug monitoring of second-generation antipsychotics in pediatric patients: An observational study in real-life settings. Eur J Clin Pharmacol 2016; 72: 285-293
  CrossrefPubMedGoogle Scholar
• 950 Prakash C, Kamel A, Cui D. et al. Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions. Br J Clin Pharmacol 2000; 49 (Suppl. 01) 35S-42S
  CrossrefPubMedGoogle Scholar
• 951 Preskorn S, Ereshefsky L, Chiu YY. et al. Effect of food on the pharmacokinetics of lurasidone: Results of two randomized, open-label, crossover studies. Hum Psychopharmacol 2013; 28: 495-505
  CrossrefPubMedGoogle Scholar
• 952 Preskorn S, Patroneva A, Silman H. et al. Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers. J Clin Psychopharmacol 2009; 29: 39-43
  CrossrefPubMedGoogle Scholar
• 953 Preskorn SH. CNS drug development. Part I: The early period of CNS drugs. J Psychiatr Pract 2010; 16: 334-339
  CrossrefPubMedGoogle Scholar
• 954 Preskorn SH. CNS drug development: Part II: Advances from the 1960s to the 1990s. J Psychiatr Pract 2010; 16: 413-415
  CrossrefPubMedGoogle Scholar
• 955 Preskorn SH. Patients who do not respond to the "usual" dose: Why Terry fell off the dose-response curve. J Psychiatr Pract 2009; 15: 460-466
  CrossrefPubMedGoogle Scholar
• 956 Preskorn SH. Pharmacokinetics and therapeutics of acute intramuscular ziprasidone. Clin Pharmacokinet 2005; 44: 1117-1133
  CrossrefPubMedGoogle Scholar
• 957 Preskorn SH. Practical application of therapeutic drug monitoring: A tale of two patients. J Psychiatr Pract 2008; 14: 301-306
  CrossrefPubMedGoogle Scholar
• 958 Preskorn SH. Therapeutic Drug Monitoring (TDM) in psychiatry (part I): Why studies attempting to correlate drug concentration and antidepressant response don’t work. J Psychiatr Pract 2014; 20: 133-137
  CrossrefPubMedGoogle Scholar
• 959 Preskorn SH. Tricyclic antidepressant plasma level monitoring: An improvement over the dose-response approach. J Clin Psychiatry 1986; 47: 24-30
  PubMedGoogle Scholar
• 960 Preskorn SH, Burke MJ, Fast GA. Therapeutic drug monitoring. Principles and practice. Psychiatr Clin North Am 1993; 16: 611-645
  CrossrefPubMedGoogle Scholar
• 961 Preskorn SH, Fast GA. Therapeutic drug monitoring for antidepressants: Efficacy, safety, and cost effectiveness. J Clin Psychiatry 1991; 52 Suppl: 23-33
  PubMedGoogle Scholar
• 962 Preskorn SH, Fast GA. Tricyclic antidepressant-induced seizures and plasma drug concentration. J Clin Psychiatry 1992; 53: 160-162
  PubMedGoogle Scholar
• 963 Preskorn SH, Fleck RJ, Schroeder DH. Therapeutic drug monitoring of bupropion. Am J Psychiatry 1990; 147: 1690-1691
  CrossrefPubMedGoogle Scholar
• 964 Preskorn SH, Jerkovich GS. Central nervous system toxicity of tricyclic antidepressants: Phenomenology, course, risk factors, and role of therapeutic drug monitoring. J Clin Psychopharmacol 1990; 10: 88-95
  CrossrefPubMedGoogle Scholar
• 965 Proft F, Kopf J, Olmes D. et al. SLC6A2 and SLC6A4 variants interact with venlafaxine serum concentrations to influence therapy outcome. Pharmacopsychiatry 2014; 47: 245-250
  Article in Thieme ConnectPubMedGoogle Scholar
• 966 Puech A, Fleurot O, Rein W. Amisulpride. and atypical antipsychotic, in the treatment of acute episodes of schizophrenia: A dose-ranging study vs. haloperidol. The Amisulpride Study Group. Acta Psychiatr Scand 1998; 98: 65-72
  CrossrefPubMedGoogle Scholar
• 967 Pumariega AJ, Nelson R, Rotenberg L. Varenicline-induced mixed mood and psychotic episode in a patient with a past history of depression. CNS Spectr 2008; 13: 511-514
  CrossrefPubMedGoogle Scholar
• 968 Puozzo C, Albin H, Vincon G. et al. Pharmacokinetics of milnacipran in liver impairment. Eur J Drug Metab Pharmacokinet 1998; 23: 273-279
  CrossrefPubMedGoogle Scholar
• 969 Quinney SK, Haehner BD, Rhoades MB. et al. Interaction between midazolam and clarithromycin in the elderly. Br J Clin Pharmacol 2008; 65: 98-109
  CrossrefPubMedGoogle Scholar
• 970 Raaflaub J. On the pharmacokinetics of chlorprothixene in man. Experientia 1975; 31: 557-558
  CrossrefPubMedGoogle Scholar
• 971 Rabey JM, Oberman Z, Scharf M. et al. Bromocriptine blood levels after the concomitant administration of levodopa, amantadine and biperiden in Parkinson’s disease. Acta Neurol Scand 1990; 81: 411-415
  PubMedGoogle Scholar
• 972 Radtke RA. Pharmacokinetics of levetiracetam. Epilepsia 2001; 42 (Suppl. 04) 24-27
  CrossrefPubMedGoogle Scholar
• 973 Rao VA, Bishop M, Coppen A. Clinical state, plasma levels of haloperidol and prolactin: A correlation study in chronic schizophrenia. Br J Psychiatry 1980; 137: 518-521
  CrossrefPubMedGoogle Scholar
• 974 Rasmussen BB, Brosen K. Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors?. Ther Drug Monit 2000; 22: 143-154
  CrossrefPubMedGoogle Scholar
• 975 Rauschenbach R, Gieschen H, Husemann M. et al. Stable expression of human cytochrome P450 3A4 in V79 cells and its application for metabolic profiling of ergot derivatives. Eur J Pharmacol 1995; 293: 183-190
  CrossrefPubMedGoogle Scholar
• 976 Ravenstijn P, Remmerie B, Savitz A. et al. Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: A phase 1, single-dose, randomized, open-label study. J Clin Pharmacol 2016; 56: 330-339
  CrossrefPubMedGoogle Scholar
• 977 Ravva P, Gastonguay MR, Tensfeldt TG. et al. Population pharmacokinetic analysis of varenicline in adult smokers. Br J Clin Pharmacol 2009; 68: 669-681
  CrossrefPubMedGoogle Scholar
• 978 Ray A, Tennakoon L, Keller J. et al. ABCB1 (MDR1) predicts remission on P-gp substrates in chronic depression. Pharmacogenomics J 2015; 15: 332-339
  CrossrefPubMedGoogle Scholar
• 979 Rees JA. Clinical interpretation of pharmacokinetic data on dothiepin hydrochloride (Dosulepin, Prothiaden). J Int Med Res 1981; 9: 98-102
  CrossrefPubMedGoogle Scholar
• 980 Regenthal R, Krueger M, Koeppel C. et al. Drug levels: therapeutic and toxic serum/plasma concentrations of common drugs. J Clin Monit Comput 1999; 15: 529-544
  CrossrefPubMedGoogle Scholar
• 981 Reidenberg P, Glue P, Banfield CR. et al. Effects of felbamate on the pharmacokinetics of phenobarbital. Clin Pharmacol Ther 1995; 58: 279-287
  CrossrefPubMedGoogle Scholar
• 982 Reimold M, Solbach C, Noda S. et al. Occupancy of dopamine D(1), D (2) and serotonin (2A) receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol. Psychopharmacology (Berl) 2007; 190: 241-249
  PubMedGoogle Scholar
• 983 Reis M, Aamo T, Ahlner J. et al. Reference concentrations of antidepressants. A compilation of postmortem and therapeutic levels. J Anal Toxicol 2007; 31: 254-264
  CrossrefPubMedGoogle Scholar
• 984 Reis M, Aamo T, Spigset O. et al. Serum concentrations of antidepressant drugs in a naturalistic setting: Compilation based on a large therapeutic drug monitoring database. Ther Drug Monit 2009; 31: 42-56
  CrossrefPubMedGoogle Scholar
• 985 Reis M, Aberg-Wistedt A, Agren H. et al. Compliance with SSRI medication during 6 months of treatment for major depression: an evaluation by determination of repeated serum drug concentrations. J Affect Disord 2004; 82: 443-446
  PubMedGoogle Scholar
• 986 Reis M, Akerblad AC, Ekselius L. et al. Partial compliance as determined from plasma levels of sertraline and its metabolite in depressed patients in primary care. J Clin Psychopharmacol 2010; 30: 746-748
  CrossrefPubMedGoogle Scholar
• 987 Reis M, Cherma MD, Carlsson B. et al. Therapeutic drug monitoring of escitalopram in an outpatient setting. Ther Drug Monit 2007; 29: 758-766
  CrossrefPubMedGoogle Scholar
• 988 Reis M, Lundmark J, Bengtsson F. Therapeutic drug monitoring of racemic citalopram: A 5-year experience in Sweden, 1992-1997. Ther Drug Monit 2003; 25: 183-191
  CrossrefPubMedGoogle Scholar
• 989 Reis M, Lundmark J, Bjork H. et al. Therapeutic drug monitoring of racemic venlafaxine and its main metabolites in an everyday clinical setting. Ther Drug Monit 2002; 24: 545-553
  CrossrefPubMedGoogle Scholar
• 990 Reis M, Olsson G, Carlsson B. et al. Serum levels of citalopram and its main metabolites in adolescent patients treated in a naturalistic clinical setting. J Clin Psychopharmacol 2002; 22: 406-413
  CrossrefPubMedGoogle Scholar
• 991 Reis M, Prochazka J, Sitsen A. et al. Inter- and intraindividual pharmacokinetic variations of mirtazapine and its N-demethyl metabolite in patients treated for major depressive disorder: A 6-month therapeutic drug monitoring study. Ther Drug Monit 2005; 27: 469-477
  CrossrefPubMedGoogle Scholar
• 992 Remington G, Mamo D, Labelle A. et al. A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. Am J Psychiatry 2006; 163: 396-401
  CrossrefPubMedGoogle Scholar
• 993 Renwick AB, Mistry H, Ball SE. et al. Metabolism of Zaleplon by human hepatic microsomal cytochrome P450 isoforms. Xenobiotica 1998; 28: 337-348
  CrossrefPubMedGoogle Scholar
• 994 Riant P, Urien S, Albengres E. et al. Effects of the binding of imipramine to erythrocytes and plasma proteins on its transport through the rat blood-brain barrier. J Neurochem 1988; 51: 421-425
  CrossrefPubMedGoogle Scholar
• 995 Richens A, Banfield CR, Salfi M. et al. Single and multiple dose pharmacokinetics of felbamate in the elderly. Br J Clin Pharmacol 1997; 44: 129-134
  CrossrefPubMedGoogle Scholar
• 996 Richter T, Murdter TE, Heinkele G. et al. Potent mechanism-based inhibition of human CYP2B6 by clopidogrel and ticlopidine. J Pharmacol Exp Ther 2004; 308: 189-197
  CrossrefPubMedGoogle Scholar
• 997 Riedel M, Schwarz MJ, Strassnig M. et al. Risperidone plasma levels, clinical response and side-effects. Eur Arch Psychiatry Clin Neurosci 2005; 255: 261-268
  CrossrefPubMedGoogle Scholar
• 998 Rivas N, Buelga DS, Elger CE. et al. Population pharmacokinetics of lamotrigine with data from therapeutic drug monitoring in German and Spanish patients with epilepsy. Ther Drug Monit 2008; 30: 483-489
  PubMedGoogle Scholar
• 999 Rivera-Calimlim L, Castaneda L, Lasagna L. Effects of mode of management on plasma chlorpromazine in psychiatric patients. Clin Pharmacol Ther 1973; 14: 978-986
  CrossrefPubMedGoogle Scholar
• 1000 Roberts JK, Cook SF, Stockmann C. et al. A Population pharmacokinetic analysis of dextroamphetamine in the plasma and hair of healthy adults. Clin Drug Investig 2015; 35: 633-643
  CrossrefPubMedGoogle Scholar
• 1001 Roberts RL, Joyce PR, Mulder RT. et al. A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression. Pharmacogenomics J 2002; 2: 191-196
  CrossrefPubMedGoogle Scholar
• 1002 Robertson P, DeCory HH, Madan A. et al. In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil. Drug Metab Dispos 2000; 28: 664-671
  PubMedGoogle Scholar
• 1003 Robertson Jr. P, Hellriegel ET. Clinical pharmacokinetic profile of modafinil. Clin Pharmacokinet 2003; 42: 123-137
  CrossrefPubMedGoogle Scholar
• 1004 Robertson SM, Maldarelli F, Natarajan V. et al. Efavirenz induces CYP2B6-mediated hydroxylation of bupropion in healthy subjects. J Acquir Immune Defic Syndr 2008; 49: 513-519
  CrossrefPubMedGoogle Scholar
• 1005 Rocha JF, Falcao A, Santos A. et al. Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations. Eur J Clin Pharmacol 2014; 70: 1059-1071
  CrossrefPubMedGoogle Scholar
• 1006 Rocha JF, Santos A, Falcao A. et al. Effect of moderate liver impairment on the pharmacokinetics of opicapone. Eur J Clin Pharmacol 2014; 70: 279-286
  CrossrefPubMedGoogle Scholar
• 1007 Rochat B, Kosel M, Boss G. et al. Stereoselective biotransformation of the selective serotonin reuptake inhibitor citalopram and its demethylated metabolites by monoamine oxidases in human liver. Biochem Pharmacol 1998; 56: 15-23
  CrossrefPubMedGoogle Scholar
• 1008 Roelofsen EE, Wilhelm AJ, Sinjewel A. et al. Toxicokinetics of dothiepin: 2 case reports. Ther Drug Monit 2008; 30: 638-641
  CrossrefPubMedGoogle Scholar
• 1009 Roesch B, Corcoran M, Haffey M. et al. Pharmacokinetics of coadministration of guanfacine extended release and methylphenidate extended release. Drugs R D 2013; 13: 53-61
  CrossrefPubMedGoogle Scholar
• 1010 Roesch B, Corcoran ME, Fetterolf J. et al. Pharmacokinetics of coadministered guanfacine extended release and lisdexamfetamine dimesylate. Drugs R D 2013; 13: 119-128
  CrossrefPubMedGoogle Scholar
• 1011 Rogers HL, Bhattaram A, Zineh I. et al. CYP2D6 genotype information to guide pimozide treatment in adult and pediatric patients: Basis for the U.S. Food and Drug Administration’s new dosing recommendations. J Clin Psychiatry 2012; 73: 1187-1190
  CrossrefPubMedGoogle Scholar
• 1012 Rogers SL, Doody RS, Mohs RC. et al. Donepezil improves cognition and global function in Alzheimer disease: A 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Arch Intern Med 1998; 158: 1021-1031
  CrossrefPubMedGoogle Scholar
• 1013 Rogers SL, Friedhoff LT. The efficacy and safety of donepezil in patients with Alzheimer’s disease: Results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. The Donepezil Study Group. Dementia 1996; 7: 293-303
  PubMedGoogle Scholar
• 1014 Rolan P, Sargentini-Maier ML, Pigeolet E. et al. The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men. Br J Clin Pharmacol 2008; 66: 71-75
  CrossrefPubMedGoogle Scholar
• 1015 Roman M, Kronstrand R, Lindstedt D. et al. Quantitation of seven low-dosage antipsychotic drugs in human postmortem blood using LC-MS-MS. J Anal Toxicol 2008; 32: 147-155
  CrossrefPubMedGoogle Scholar
• 1016 Ronfeld RA, Tremaine LM, Wilner KD. Pharmacokinetics of sertraline and its N-demethyl metabolite in elderly and young male and female volunteers. Clin Pharmacokinet 1997; 32 (Suppl. 01) 22-30
  CrossrefPubMedGoogle Scholar
• 1017 Rook EJ, Huitema AD, van den Brink W. et al. Population pharmacokinetics of heroin and its major metabolites. Clin Pharmacokinet 2006; 45: 401-417
  CrossrefPubMedGoogle Scholar
• 1018 Rosenzweig P, Canal M, Patat A. et al. A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers. Hum Psychopharmacol 2002; 17: 1-13
  CrossrefPubMedGoogle Scholar
• 1019 Rotzinger S, Fang J, Baker GB. Trazodone is metabolized to m-chlorophenylpiperazine by CYP3A4 from human sources. Drug Metab Dispos 1998; 26: 572-575
  PubMedGoogle Scholar
• 1020 Rougemont M, Ulrich S, Hiemke C. et al. French summaries of product characteristics: Content in relation to therapeutic monitoring of psychotropic drugs. Fundam Clin Pharmacol 2010; 24: 377-384
  CrossrefPubMedGoogle Scholar
• 1021 Ruan CJ, Li AN, Dong F. et al. Single- and multiple-dose milnacipran pharmacokinetics in healthy han chinese volunteers. Clin Pharmacokinet 2016; 55: 889-896
  CrossrefPubMedGoogle Scholar
• 1022 Rudolph JL, Salow MJ, Angelini MC. et al. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med 2008; 168: 508-513
  CrossrefPubMedGoogle Scholar
• 1023 Rudorfer MV, Potter WZ. The Role of Metabolites of Antidepressants in the Treatment of Depression. CNS Drugs 1997; 7: 273-312
  CrossrefPubMedGoogle Scholar
• 1024 Ruike Z, Junhua C, Wenxing P. In vitro and in vivo evaluation of the effects of duloxetine on P-gp function. Hum Psychopharmacol 2010; 25: 553-559
  CrossrefPubMedGoogle Scholar
• 1025 Ruottinen HM, Rinne UK. Effect of one month’s treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients. Clin Neuropharmacol 1996; 19: 222-233
  CrossrefPubMedGoogle Scholar
• 1026 Sachse J, Härtter S, Hiemke C. Automated determination of ziprasidone by HPLC with column switching and spectrophotometric detection. Ther Drug Monit 2005; 27: 158-162
  CrossrefPubMedGoogle Scholar
• 1027 Sachse J, Härtter S, Weigmann H. et al. Automated determination of amisulpride by liquid chromatography with column switching and spectrophotometric detection. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 784: 405-410
  CrossrefPubMedGoogle Scholar
• 1028 Sachse J, Koller J, Härtter S. et al. Automated analysis of quetiapine and other antipsychotic drugs in human blood by high performance-liquid chromatography with column-switching and spectrophotometric detection. J Chromatogr B Analyt Technol Biomed Life Sci 2006; 830: 342-348
  CrossrefPubMedGoogle Scholar
• 1029 Sagar KA, Smyth MR. Bioavailability studies of oral dosage forms containing levodopa and carbidopa using column-switching chromatography followed by electrochemical detection. Analyst 2000; 125: 439-445
  CrossrefPubMedGoogle Scholar
• 1030 Sage JI, Mark MH. Pharmacokinetics of continuous-release carbidopa/levodopa. Clin Neuropharmacol 1994; 17 (Suppl. 02) S1-S6
  PubMedGoogle Scholar
• 1031 Sainati SM, Hubbard JW, Chi E. et al. Safety, tolerability, and effect of food on the pharmacokinetics of iloperidone (HP 873), a potential atypical antipsychotic. J Clin Pharmacol 1995; 35: 713-720
  CrossrefPubMedGoogle Scholar
• 1032 Saint-Marcoux F, Sauvage FL, Marquet P. Current role of LC-MS in therapeutic drug monitoring. Anal Bioanal Chem 2007; 388: 1327-1349
  CrossrefPubMedGoogle Scholar
• 1033 Saivin S, Hulot T, Chabac S. et al. Clinical pharmacokinetics of acamprosate. Clin Pharmacokinet 1998; 35: 331-345
  CrossrefPubMedGoogle Scholar
• 1034 Sajatovic M, Velligan DI, Weiden PJ. et al. Measurement of psychiatric treatment adherence. J Psychosom Res 2010; 69: 591-599
  CrossrefPubMedGoogle Scholar
• 1035 Sakka SG, Kuethe F, Demme U. et al. Intoxication with a tricyclic antidepressant. Anaesthesist 2007; 56: 581-586
  CrossrefPubMedGoogle Scholar
• 1036 Sakolsky DJ, Perel JM, Emslie GJ. et al. Antidepressant exposure as a predictor of clinical outcomes in the Treatment of Resistant Depression in Adolescents (TORDIA) study. J Clin Psychopharmacol 2011; 31: 92-97
  CrossrefPubMedGoogle Scholar
• 1037 Salazar DE, Frackiewicz EJ, Dockens R. et al. Pharmacokinetics and tolerability of buspirone during oral administration to children and adolescents with anxiety disorder and normal healthy adults. J Clin Pharmacol 2001; 41: 1351-1358
  CrossrefPubMedGoogle Scholar
• 1038 Sallee FR, Pollock BG. Clinical pharmacokinetics of imipramine and desipramine. Clin Pharmacokinet 1990; 18: 346-364
  CrossrefPubMedGoogle Scholar
• 1039 Sallee FR, Pollock BG, Stiller RL. et al. Pharmacokinetics of pimozide in adults and children with Tourette’s syndrome. J Clin Pharmacol 1987; 27: 776-781
  CrossrefPubMedGoogle Scholar
• 1040 Salva P, Costa J. Clinical pharmacokinetics and pharmacodynamics of zolpidem. Therapeutic implications. Clin Pharmacokinet 1995; 29: 142-153
  CrossrefPubMedGoogle Scholar
• 1041 Samer CF, Lorenzini KI, Rollason V. et al. Applications of CYP450 testing in the clinical setting. Mol Diagn Ther 2013; 17: 165-184
  CrossrefPubMedGoogle Scholar
• 1042 Sargentini-Maier ML, Espie P, Coquette A. et al. Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjects. Drug Metab Dispos 2008; 36: 36-45
  CrossrefPubMedGoogle Scholar
• 1043 Sarginson JE, Lazzeroni LC, Ryan HS. et al. ABCB1 (MDR1) polymorphisms and antidepressant response in geriatric depression. Pharmacogenet Genomics 2010; 20: 467-475
  CrossrefPubMedGoogle Scholar
• 1044 Saruwatari J, Ogusu N, Shimomasuda M. et al. Effects of CYP2C19 and P450 oxidoreductase polymorphisms on the population pharmacokinetics of clobazam and N-desmethylclobazam in japanese patients with epilepsy. Ther Drug Monit 2014; 36: 302-309
  CrossrefPubMedGoogle Scholar
• 1045 Sattler A, Schaefer M, May TW. et al. Fluctuation of lacosamide serum concentrations during the day and occurrence of adverse drug reactions--first clinical experience. Epilepsy Res 2011; 95: 207-212
  CrossrefPubMedGoogle Scholar
• 1046 Sauer JM, Ring BJ, Witcher JW. Clinical pharmacokinetics of atomoxetine. Clin Pharmacokinet 2005; 44: 571-590
  CrossrefPubMedGoogle Scholar
• 1047 Sauvage FL, Gaulier JM, Lachatre G. et al. Pitfalls and prevention strategies for liquid chromatography-tandem mass spectrometry in the selected reaction-monitoring mode for drug analysis. Clin Chem 2008; 54: 1519-1527
  CrossrefPubMedGoogle Scholar
• 1048 Schafer A, Hiemke C, Baumann P. Consensus guideline for therapeutic drug monitoring in psychiatry (2004): Bibliometric analysis of citations for the period 2004-2011. Nord J Psychiatry 2016; 70: 202-207
  CrossrefPubMedGoogle Scholar
• 1049 Schall U, Pries E, Katta T. et al. Pharmacokinetic and pharmacodynamic interactions in an outpatient maintenance therapy of intravenous heroin users with levomethadone. Addict Biol 1996; 1: 105-113
  CrossrefPubMedGoogle Scholar
• 1050 Scharfetter J, Fischer P. QTc prolongation induced by intravenous sedation with Haloperidol, Prothipendyl and Lorazepam. Neuropsychiatr 2014; 28: 1-5
  CrossrefPubMedGoogle Scholar
• 1051 Schatzberg AF, DeBattista C, Lazzeroni LC. et al. ABCB1 Genetic effects on antidepressant outcomes: A report from the iSPOT-D trial. Am J Psychiatry 2015; 172: 751-759
  CrossrefPubMedGoogle Scholar
• 1052 Schifano F. Misuse and abuse of pregabalin and gabapentin: cause for concern?. CNS Drugs 2014; 28: 491-496
  CrossrefPubMedGoogle Scholar
• 1053 Schoemaker R, Wade JR, Stockis A. Brivaracetam population pharmacokinetics and exposure-response modeling in adult subjects with partial-onset seizures. J Clin Pharmacol 2016; 56: 1591-1602
  CrossrefPubMedGoogle Scholar
• 1054 Schoretsanitis G, Haen E, Gründer G. et al. Pharmacokinetic drug-drug interactions of mood stabilizers and risperidone in patients under combined treatment. J Clin Psychopharmacol 2016; 36: 554-561
  CrossrefPubMedGoogle Scholar
• 1055 Schoretsanitis G, Haen E, Stegmann B et al. Effect of smoking on risperidone pharmacokinetics - A multifactorial approach to better predict the influence on drug metabolism. Schizophr Res 2017; 185: 51–57
  PubMed
• 1056 Schoretsanitis G, Stegmann B, Hiemke C. et al. Pharmacokinetic patterns of risperidone-associated adverse drug reactions. Eur J Clin Pharmacol 2016; 72: 1091-1098
  CrossrefPubMedGoogle Scholar
• 1057 Schubert I, Kupper-Nybelen J, Ihle P. et al. Prescribing potentially inappropriate medication (PIM) in Germany’s elderly as indicated by the PRISCUS list. An analysis based on regional claims data. Pharmacoepidemiol Drug Saf 2013; 22: 719-727
  CrossrefPubMedGoogle Scholar
• 1058 Schulz M, Iwersen-Bergmann S, Andresen H. et al. Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobiotics. Crit Care 2012; 16: R136
  CrossrefPubMedGoogle Scholar
• 1059 Schulze TG, Alda M, Adli M. et al. The International Consortium on Lithium Genetics (ConLiGen): An initiative by the NIMH and IGSLI to study the genetic basis of response to lithium treatment. Neuropsychobiology 2010; 62: 72-78
  CrossrefPubMedGoogle Scholar
• 1060 Schwartz JB. The current state of knowledge on age, sex, and their interactions on clinical pharmacology. Clin Pharmacol Ther 2007; 82: 87-96
  CrossrefPubMedGoogle Scholar
• 1061 Schwartz MA, Postma E. Metabolism of flurazepam, a benzodiazepine, in man and dog. J Pharm Sci 1970; 59: 1800-1806
  CrossrefPubMedGoogle Scholar
• 1062 Schwarz V, Reis O, Glaser T. et al. Therapeutic drug monitoring of zuclopenthixol in a double-blind placebo-controlled discontinuation study in adults with intellectual disabilities and aggressive behaviour. Pharmacopsychiatry 2014; 47: 29-32
  Article in Thieme ConnectPubMedGoogle Scholar
• 1063 Schwarzenbach F, Netillard C, Demoly P. et al. Antidepressant response and fluvoxamine plasma concentrations: A pilot study. Pharm World Sci 2003; 25: 27-29
  CrossrefPubMedGoogle Scholar
• 1064 Scordo MG, Spina E, Dahl ML. et al. Influence of CYP2C9, 2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine. Basic Clin Pharmacol Toxicol 2005; 97: 296-301
  CrossrefPubMedGoogle Scholar
• 1065 The Scottish First Episode Schizophrenia Study II. Treatment: Pimozide versus flupenthixol. The scottish schizophrenia research group. Br J Psychiatry 1987; 150: 334–338
  PubMed
• 1066 Segman RH, Heresco-Levy U, Finkel B. et al. Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia. Mol Psychiatry 2001; 6: 225-229
  CrossrefPubMedGoogle Scholar
• 1067 Segman RH, Heresco-Levy U, Finkel B. et al. Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: additive contribution of 5-HT2Cser and DRD3gly alleles to susceptibility. Psychopharmacology (Berl) 2000; 152: 408-413
  CrossrefPubMedGoogle Scholar
• 1068 Seiler W, Wetzel H, Hillert A. et al. Pharmacokinetics and bioavailability of benperidol in schizophrenic patients after intravenous and two different kinds of oral application. Psychopharmacology (Berl) 1994; 116: 457-463
  CrossrefPubMedGoogle Scholar
• 1069 Self TH, Chrisman CR, Baciewicz AM. et al. Isoniazid drug and food interactions. Am J Med Sci 1999; 317: 304-311
  CrossrefPubMedGoogle Scholar
• 1070 Seree EJ, Pisano PJ, Placidi M. et al. Identification of the human and animal hepatic cytochromes P450 involved in clonazepam metabolism. Fundam Clin Pharmacol 1993; 7: 69-75
  CrossrefPubMedGoogle Scholar
• 1071 Serretti A, Kato M, De Ronchi D. et al. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry 2007; 12: 247-257
  CrossrefPubMedGoogle Scholar
• 1072 Service JA, Waring WS. QT Prolongation and delayed atrioventricular conduction caused by acute ingestion of trazodone. Clin Toxicol (Phila) 2008; 46: 71-73
  CrossrefPubMedGoogle Scholar
• 1073 Shams M, Hiemke C, Härtter S. Therapeutic drug monitoring of the antidepressant mirtazapine and its N-demethylated metabolite in human serum. Ther Drug Monit 2004; 26: 78-84
  CrossrefPubMedGoogle Scholar
• 1074 Shams ME, Arneth B, Hiemke C. et al. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. J Clin Pharm Ther 2006; 31: 493-502
  CrossrefPubMedGoogle Scholar
• 1075 Shang DW, Li LJ, Wang XP. et al. Population pharmacokinetic/pharmacodynamic model of clozapine for characterizing the relationship between accumulated exposure and PANSS scores in patients with schizophrenia. Ther Drug Monit 2014; 36: 378-386
  CrossrefPubMedGoogle Scholar
• 1076 Sharma S, Joshi S, Chadda RK. Therapeutic drug monitoring of lithium in patients with bipolar affective disorder: Experiences from a tertiary care hospital in India. Am J Ther 2009; 16: 393-397
  CrossrefPubMedGoogle Scholar
• 1077 Sharma S, Joshi S, Mukherji S. et al. Therapeutic drug monitoring: appropriateness and clinical utility in neuropsychiatry practice. Am J Ther 2009; 16: 11-16
  CrossrefPubMedGoogle Scholar
• 1078 Sheehan JJ, Reilly KR, Fu DJ. et al. Comparison of the peak-to-trough fluctuation in plasma concentration of long-acting injectable antipsychotics and their oral equivalents. Innov Clin Neurosci 2012; 9: 17-23
  PubMedGoogle Scholar
• 1079 Shimoda K, Jerling M, Bottiger Y. et al. Pronounced differences in the dispositon of clomipramine between Japanese and Swedish patients. J Clin Psychopharmacol 1999; 19: 393-400
  CrossrefPubMedGoogle Scholar
• 1080 Shin C, Han C, Pae CU. et al. Precision medicine for psychopharmacology: a general introduction. Expert Rev Neurother 2016; 16: 831-839
  CrossrefPubMedGoogle Scholar
• 1081 Shin JG, Soukhova N, Flockhart DA. Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: Preferential inhibition of CYP2D6. Drug Metab Dispos 1999; 27: 1078-1084
  PubMedGoogle Scholar
• 1082 Shinderman M, Maxwell S, Brawand-Amey M. et al. Cytochrome P4503A4 metabolic activity, methadone blood concentrations, and methadone doses. Drug Alcohol Depend 2003; 69: 205-211
  CrossrefPubMedGoogle Scholar
• 1083 Shiraga T, Kaneko H, Iwasaki K. et al. Identification of cytochrome P450 enzymes involved in the metabolism of zotepine, an antipsychotic drug, in human liver microsomes. Xenobiotica 1999; 29: 217-229
  CrossrefPubMedGoogle Scholar
• 1084 Shiran MR, Hassanzadeh-Khayyat M, Iqbal MZ. et al. Can saliva replace plasma for the monitoring of methadone?. Ther Drug Monit 2005; 27: 580-586
  CrossrefPubMedGoogle Scholar
• 1085 Shram MJ, Quinn AM, Chen N. et al. Differences in the in vitro and in vivo pharmacokinetic profiles of once-daily modified-release methylphenidate formulations in Canada: Examination of current bioequivalence criteria. Clin Ther 2012; 34: 1170-1181
  CrossrefPubMedGoogle Scholar
• 1086 Shua-Haim J, Smith J, Picard F. et al. Steady-state pharmacokinetics of rivastigmine in patients with mild to moderate Alzheimer’s disease not affected by co-administration of memantine: An open-label, crossover, single-centre study. Clin Drug Investig 2008; 28: 361-374
  CrossrefPubMedGoogle Scholar
• 1087 Sidhu J, Priskorn M, Poulsen M. et al. Steady-state pharmacokinetics of the enantiomers of citalopram and its metabolites in humans. Chirality 1997; 9: 686-692
  CrossrefPubMedGoogle Scholar
• 1088 Sigurdsson HP, Hefner G, Ben-Omar N. et al. Steady-state serum concentrations of venlafaxine in patients with late-life depression. Impact of age, sex and BMI. J Neural Transm (Vienna) 2015; 122: 721-729
  CrossrefPubMedGoogle Scholar
• 1089 Simmons SA, Perry PJ, Rickert ED. et al. Cost-benefit analysis of prospective pharmacokinetic dosing of nortriptyline in depressed inpatients. J Affect Disord 1985; 8: 47-53
  CrossrefPubMedGoogle Scholar
• 1090 Simons FE, Watson WT, Chen XY. et al. The pharmacokinetics and pharmacodynamics of hydroxyzine in patients with primary biliary cirrhosis. J Clin Pharmacol 1989; 29: 809-815
  CrossrefPubMedGoogle Scholar
• 1091 Simons KJ, Watson WT, Martin TJ. et al. Diphenhydramine: pharmacokinetics and pharmacodynamics in elderly adults, young adults, and children. J Clin Pharmacol 1990; 30: 665-671
  CrossrefPubMedGoogle Scholar
• 1092 Sindrup SH, Brosen K, Gram LF. Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: Nonlinearity and relation to the sparteine oxidation polymorphism. Clin Pharmacol Ther 1992; 51: 288-295
  CrossrefPubMedGoogle Scholar
• 1093 Siva N. Tackling the booming trade in counterfeit drugs. Lancet 2010; 376: 1725-1726
  CrossrefPubMedGoogle Scholar
• 1094 Sjoqvist F. Development of clinical pharmacology as a medical speciality in Europe – the roles of WHO, IUPHAR and EACPT. Basic Clin Pharmacol Toxicol 2014; 115: 172-178
  CrossrefPubMedGoogle Scholar
• 1095 Skinner MD, Lahmek P, Pham H. et al. Disulfiram efficacy in the treatment of alcohol dependence: A meta-analysis. PLoS One 2014; 9: e87366
  CrossrefPubMedGoogle Scholar
• 1096 Skinner MH, Kuan HY, Pan A. et al. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers. Clin Pharmacol Ther 2003; 73: 170-177
  CrossrefPubMedGoogle Scholar
• 1097 Skinner MH, Kuan HY, Skerjanec A. et al. Effect of age on the pharmacokinetics of duloxetine in women. Br J Clin Pharmacol 2004; 57: 54-61
  PubMedGoogle Scholar
• 1098 Skogh E, Bengtsson F, Nordin C. Could discontinuing smoking be hazardous for patients administered clozapine medication? A case report. Ther Drug Monit 1999; 21: 580-582
  CrossrefPubMedGoogle Scholar
• 1099 Skogh E, Reis M, Dahl ML. et al. Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in the naturalistic clinical setting. Ther Drug Monit 2002; 24: 518-526
  CrossrefPubMedGoogle Scholar
• 1100 Small JG, Hirsch SR, Arvanitis LA. et al. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch Gen Psychiatry 1997; 54: 549-557
  CrossrefPubMedGoogle Scholar
• 1101 Smith JC, Curry SC. Prolonged toxicity after amitriptyline overdose in a patient deficient in CYP2D6 activity. J Med Toxicol 2011; 7: 220-223
  CrossrefPubMedGoogle Scholar
• 1102 Smith RB, Divoll M, Gillespie WR. et al. Effect of subject age and gender on the pharmacokinetics of oral triazolam and temazepam. J Clin Psychopharmacol 1983; 3: 172-176
  PubMedGoogle Scholar
• 1103 Smith RB, Kroboth PD, Vanderlugt JT. et al. Pharmacokinetics and pharmacodynamics of alprazolam after oral and IV administration. Psychopharmacology (Berl) 1984; 84: 452-456
  CrossrefPubMedGoogle Scholar
• 1104 Smith SW. Chiral toxicology: it’s the same thing...only different. Toxicol Sci 2009; 110: 4-30
  CrossrefPubMedGoogle Scholar
• 1105 Snoeck E, Van Peer A, Sack M. et al. Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man. Psychopharmacology (Berl) 1995; 122: 223-229
  CrossrefPubMedGoogle Scholar
• 1106 Sogaard B, Mengel H, Rao N. et al. The pharmacokinetics of escitalopram after oral and intravenous administration of single and multiple doses to healthy subjects. J Clin Pharmacol 2005; 45: 1400-1406
  CrossrefPubMedGoogle Scholar
• 1107 Soldin OP, Mattison DR. Sex differences in pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 2009; 48: 143-157
  CrossrefPubMedGoogle Scholar
• 1108 Someya T, Muratake T, Hirokane G. et al. Interindividual variation in bromperidol metabolism and relationship to therapeutic effects. J Clin Psychopharmacol 2000; 20: 175-180
  CrossrefPubMedGoogle Scholar
• 1109 Sondergaard Khinchi M, Nielsen KA, Dahl M. et al. Lamotrigine therapeutic thresholds. Seizure 2008; 17: 391-395
  CrossrefPubMedGoogle Scholar
• 1110 Song L, Du Q, Jiang X. et al. Effect of CYP1A2 polymorphism on the pharmacokinetics of agomelatine in Chinese healthy male volunteers. J Clin Pharm Ther 2014; 39: 204-209
  CrossrefPubMedGoogle Scholar
• 1111 Soni SD. Fluspirilene in the treatment of non-hospitalized schizophrenic patients. Curr Med Res Opin 1977; 4: 645-649
  CrossrefPubMedGoogle Scholar
• 1112 Sorgel F, Mahr G, Granneman GR. et al. Effects of 2 quinolone antibacterials, temafloxacin and enoxacin, on theophylline pharmacokinetics. Clin Pharmacokinet 1992; 22 (Suppl. 01) 65-74
  CrossrefPubMedGoogle Scholar
• 1113 Spanarello S, La Ferla T. The pharmacokinetics of long-acting antipsychotic medications. Curr Clin Pharmacol 2014; 9: 310-317
  CrossrefPubMedGoogle Scholar
• 1114 Sparshatt A, Taylor D, Patel MX. et al. Amisulpride – dose, plasma concentration, occupancy and response: Implications for therapeutic drug monitoring. Acta Psychiatr Scand 2009; 120: 416-428
  CrossrefPubMedGoogle Scholar
• 1115 Sparshatt A, Taylor D, Patel MX. et al. A systematic review of aripiprazole–dose, plasma concentration, receptor occupancy, and response: implications for therapeutic drug monitoring. J Clin Psychiatry 2010; 71: 1447-1456
  CrossrefPubMedGoogle Scholar
• 1116 Spencer TJ, Biederman J, Ciccone PE. et al. PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short- and long-acting oral methylphenidate. Am J Psychiatry 2006; 163: 387-395
  CrossrefPubMedGoogle Scholar
• 1117 Spencer TJ, Bonab AA, Dougherty DD. et al. A PET study examining pharmacokinetics and dopamine transporter occupancy of two long-acting formulations of methylphenidate in adults. Int J Mol Med 2010; 25: 261-265
  PubMedGoogle Scholar
• 1118 Spies M, Knudsen GM, Lanzenberger R. et al. The serotonin transporter in psychiatric disorders: insights from PET imaging. Lancet Psychiatry 2015; 2: 743-755
  CrossrefPubMedGoogle Scholar
• 1119 Spigset O, Hagg S, Stegmayr B. et al. Citalopram pharmacokinetics in patients with chronic renal failure and the effect of haemodialysis. Eur J Clin Pharmacol 2000; 56: 699-703
  CrossrefPubMedGoogle Scholar
• 1120 Spina E, Avenoso A, Facciola G. et al. Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia. Psychopharmacology (Berl) 2001; 153: 238-243
  CrossrefPubMedGoogle Scholar
• 1121 Spina E, Birgersson C, von Bahr C. et al. Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes. Clin Pharmacol Ther 1984; 36: 677-682
  CrossrefPubMedGoogle Scholar
• 1122 Spina E, Pisani F, Perucca E. Clinically significant pharmacokinetic drug interactions with carbamazepine. An update. Clin Pharmacokinet 1996; 31: 198-214
  CrossrefPubMedGoogle Scholar
• 1123 Spinewine A, Schmader KE, Barber N. et al. Appropriate prescribing in elderly people: How well can it be measured and optimised?. Lancet 2007; 370: 173-184
  CrossrefPubMedGoogle Scholar
• 1124 Spivak AM, Andrade A, Eisele E. et al. A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy. Clin Infect Dis 2014; 58: 883-890
  CrossrefPubMedGoogle Scholar
• 1125 Sproule BA, Hardy BG, Shulman KI. Differential pharmacokinetics of lithium in elderly patients. Drugs Aging 2000; 16: 165-177
  CrossrefPubMedGoogle Scholar
• 1126 Spyker DA, Riesenberg RA, Cassella JV. Multiple dose pharmacokinetics of inhaled loxapine in subjects on chronic, stable antipsychotic regimens. J Clin Pharmacol 2015; 55: 985-994
  CrossrefPubMedGoogle Scholar
• 1127 Sramek JJ, Cutler NR. The impact of gender on antidepressants. Curr Top Behav Neurosci 2011; 8: 231-249
  PubMedGoogle Scholar
• 1128 Sridharan K, Sivaramakrishnan G. Interaction of Citrus Juices with Cyclosporine: Systematic Review and Meta-Analysis. Eur J Drug Metab Pharmacokinet 2016; 41: 665-673
  CrossrefPubMedGoogle Scholar
• 1129 Stamm TJ, Becker D, Sondergeld LM. et al. Prediction of antidepressant response to venlafaxine by a combination of early response assessment and therapeutic drug monitoring. Pharmacopsychiatry 2014; 47: 174-179
  Article in Thieme ConnectPubMedGoogle Scholar
• 1130 Stassen H, Anghelescu IG, Angst J. et al. Predicting response to psychopharmacological treatment: Survey of recent results. Pharmacopsychiatry 2011; 44: 263-272
  Article in Thieme ConnectPubMedGoogle Scholar
• 1131 Stassen HH, Angst J, Hell D. et al. Is there a common resilience mechanism underlying antidepressant drug response? Evidence from 2848 patients. J Clin Psychiatry 2007; 68: 1195-1205
  CrossrefPubMedGoogle Scholar
• 1132 Stead AH, Moffat AC. A collection of therapeutic, toxic and fatal blood drug concentrations in man. Hum Toxicol 1983; 2: 437-464
  PubMedGoogle Scholar
• 1133 Stegmann B, Dorfelt A, Haen E. Quantification of Methylphenidate, Dexamphetamine, and Atomoxetine in Human Serum and Oral Fluid by HPLC With Fluorescence Detection. Ther Drug Monit 2016; 38: 98-107
  CrossrefPubMedGoogle Scholar
• 1134 Steimer W. Besondere Bedeutung der Präanalytik und Interpretatoion bei der Bestimmung von Arzneimittelkonzentrationen. DBI 2004; 24: 147-157
  PubMedGoogle Scholar
• 1135 Steimer W, Potter JM. Pharmacogenetic screening and therapeutic drugs. Clin Chim Acta 2002; 315: 137-155
  CrossrefPubMedGoogle Scholar
• 1136 Steimer W, Zopf K, von Amelunxen S. et al. Amitriptyline or not, that is the question: pharmacogenetic testing of CYP2D6 and CYP2C19 identifies patients with low or high risk for side effects in amitriptyline therapy. Clin Chem 2005; 51: 376-385
  CrossrefPubMedGoogle Scholar
• 1137 Stenkrona P, Halldin C, Lundberg J. 5-HTT and 5-HT(1A) receptor occupancy of the novel substance vortioxetine (Lu AA21004). A PET study in control subjects. Eur Neuropsychopharmacol 2013; 23: 1190-1198
  CrossrefPubMedGoogle Scholar
• 1138 Stepanova D, Beran RG. The benefits of antiepileptic drug (AED) blood level monitoring to complement clinical management of people with epilepsy. Epilepsy Behav 2015; 42: 7-9
  CrossrefPubMedGoogle Scholar
• 1139 Stepanova D, Beran RG. Measurement of levetiracetam drug levels to assist with seizure control and monitoring of drug interactions with other anti-epileptic medications (AEMs). Seizure 2014; 23: 371-376
  CrossrefPubMedGoogle Scholar
• 1140 Stephenson A, Anderson GM, Rochon P. Off-label prescribing in older people: The need for increased awareness and caution. Drugs Aging 2012; 29: 435-436
  CrossrefPubMedGoogle Scholar
• 1141 Stieffenhofer V, Hiemke C. Pharmacogenetics, therapeutic drug monitoring and non compliance. Ther Umsch 2010; 67: 309-315
  CrossrefPubMedGoogle Scholar
• 1142 Stieffenhofer V, Saglam H, Schmidtmann I. et al. Clozapine plasma level monitoring for prediction of rehospitalization schizophrenic outpatients. Pharmacopsychiatry 2011; 44: 55-59
  Article in Thieme ConnectPubMedGoogle Scholar
• 1143 Stingl J, Viviani R. Polymorphism in CYP2D6 and CYP2C19, members of the cytochrome P450 mixed-function oxidase system, in the metabolism of psychotropic drugs. J Intern Med 2015; 277: 167-177
  CrossrefPubMedGoogle Scholar
• 1144 Stingl JC, Bartels H, Viviani R. et al. Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: A quantitative systematic review. Pharmacol Ther 2014; 141: 92-116
  CrossrefPubMedGoogle Scholar
• 1145 Stingl JC, Brockmoller J, Viviani R. Genetic variability of drug-metabolizing enzymes: The dual impact on psychiatric therapy and regulation of brain function. Mol Psychiatry 2013; 18: 273-287
  CrossrefPubMedGoogle Scholar
• 1146 Stock B, Spiteller G. Metabolism of antiparkinson drugs. An example of competitive hydroxylation. Arzneimittelforschung 1979; 29: 610-615
  PubMedGoogle Scholar
• 1147 Stockis A, Watanabe S, Rouits E. et al. Brivaracetam single and multiple rising oral dose study in healthy Japanese participants: Influence of CYP2C19 genotype. Drug Metab Pharmacokinet 2014; 29: 394-399
  CrossrefPubMedGoogle Scholar
• 1148 Stollberger C, Huber JO, Finsterer J. Antipsychotic drugs and QT prolongation. Int Clin Psychopharmacol 2005; 20: 243-251
  CrossrefPubMedGoogle Scholar
• 1149 Stormer E, Brockmoller J, Roots I. et al. Cytochrome P-450 enzymes and FMO3 contribute to the disposition of the antipsychotic drug perazine in vitro. Psychopharmacology (Berl) 2000; 151: 312-320
  CrossrefPubMedGoogle Scholar
• 1150 Stormer E, von Moltke LL, Shader RI. et al. Metabolism of the antidepressant mirtazapine in vitro: Contribution of cytochromes P-450 1A2, 2D6, and 3A4. Drug Metab Dispos 2000; 28: 1168-1175
  PubMedGoogle Scholar
• 1151 Stout SM, Cimino NM. Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: A systematic review. Drug Metab Rev 2014; 46: 86-95
  CrossrefPubMedGoogle Scholar
• 1152 Suhara T, Takano A, Sudo Y. et al. High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography. Arch Gen Psychiatry 2003; 60: 386-391
  CrossrefPubMedGoogle Scholar
• 1153 Sutfin TA, Perini GI, Molnar G. et al. Multiple-dose pharmacokinetics of imipramine and its major active and conjugated metabolites in depressed patients. J Clin Psychopharmacol 1988; 8: 48-53
  PubMedGoogle Scholar
• 1154 Sutton D, Butler AM, Nadin L. et al. Role of CYP3A4 in human hepatic diltiazem N-demethylation: Inhibition of CYP3A4 activity by oxidized diltiazem metabolites. J Pharmacol Exp Ther 1997; 282: 294-300
  PubMedGoogle Scholar
• 1155 Suzuki A, Otani K, Ishida M. et al. No interaction between desipramine and bromperidol. Prog Neuropsychopharmacol Biol Psychiatry 1996; 20: 1265-1271
  CrossrefPubMedGoogle Scholar
• 1156 Suzuki A, Otani K, Ishida M. et al. Increased plasma concentrations of bromperidol and its reduced metabolite with levomepromazine, but not with thioridazine. Ther Drug Monit 1997; 19: 261-264
  CrossrefPubMedGoogle Scholar
• 1157 Suzuki T, Mihara K, Nakamura A. et al. Effects of genetic polymorphisms of CYP2D6, CYP3A5, and ABCB1 on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia. Ther Drug Monit 2014; 36: 651-655
  CrossrefPubMedGoogle Scholar
• 1158 Suzuki Y, Fukui N, Sawamura K. et al. Concentration-response relationship for fluvoxamine using remission as an endpoint: A receiver operating characteristics curve analysis in major depression. J Clin Psychopharmacol 2008; 28: 325-328
  CrossrefPubMedGoogle Scholar
• 1159 Svirbely JR, Speicher CE. The importance of request and report forms in the interpretation of therapeutic drug monitoring data. Ther Drug Monit 1980; 2: 211-216
  CrossrefPubMedGoogle Scholar
• 1160 Sweet RA, Pollock BG, Kirshner M. et al. Pharmacokinetics of single- and multiple-dose bupropion in elderly patients with depression. J Clin Pharmacol 1995; 35: 876-884
  CrossrefPubMedGoogle Scholar
• 1161 Sweet RA, Pollock BG, Mulsant BH. et al. Pharmacologic profile of perphenazine’s metabolites. J Clin Psychopharmacol 2000; 20: 181-187
  CrossrefPubMedGoogle Scholar
• 1162 Szegedi A, Jansen WT, van Willigenburg AP. et al. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: A meta-analysis including 6562 patients. J Clin Psychiatry 2009; 70: 344-353
  CrossrefPubMedGoogle Scholar
• 1163 Szymura-Oleksiak J, Wyska E, Wasieczko A. Pharmacokinetic interaction between imipramine and carbamazepine in patients with major depression. Psychopharmacology (Berl) 2001; 154: 38-42
  CrossrefPubMedGoogle Scholar
• 1164 Takahashi LH, Huie K, Spyker DA. et al. Effect of smoking on the pharmacokinetics of inhaled loxapine. Ther Drug Monit 2014; 36: 618-623
  CrossrefPubMedGoogle Scholar
• 1165 Takano A, Halldin C, Farde L. SERT and NET occupancy by venlafaxine and milnacipran in nonhuman primates: A PET study. Psychopharmacology (Berl) 2013; 226: 147-153
  CrossrefPubMedGoogle Scholar
• 1166 Takano A, Suhara T, Ichimiya T. et al. Time course of in vivo 5-HTT transporter occupancy by fluvoxamine. J Clin Psychopharmacol 2006; 26: 188-191
  CrossrefPubMedGoogle Scholar
• 1167 Takano A, Suzuki K, Kosaka J. et al. A dose-finding study of duloxetine based on serotonin transporter occupancy. Psychopharmacology (Berl) 2006; 185: 395-399
  CrossrefPubMedGoogle Scholar
• 1168 Takekita Y, Fabbri C, Kato M. et al. HTR1A Polymorphisms and Clinical Efficacy of Antipsychotic Drug Treatment in Schizophrenia: A Meta-Analysis. Int J Neuropsychopharmacol 2016; 19
  PubMedGoogle Scholar
• 1169 Tan L, Yu JT, Sun YP. et al. The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients. Clin Neurol Neurosurg 2010; 112: 320-323
  CrossrefPubMedGoogle Scholar
• 1170 Tanaka E, Kurata N, Yasuhara H. How useful is the "cocktail approach" for evaluating human hepatic drug metabolizing capacity using cytochrome P450 phenotyping probes in vivo?. J Clin Pharm Ther 2003; 28: 157-165
  CrossrefPubMedGoogle Scholar
• 1171 Tanaka E, Misawa S. Pharmacokinetic interactions between acute alcohol ingestion and single doses of benzodiazepines, and tricyclic and tetracyclic antidepressants – an update. J Clin Pharm Ther 1998; 23: 331-336
  CrossrefPubMedGoogle Scholar
• 1172 Tanaka O, Kondo T, Otani K. et al. Single oral dose kinetics of zotepine and its relationship to prolactin response and side effects. Ther Drug Monit 1998; 20: 117-119
  CrossrefPubMedGoogle Scholar
• 1173 Tapaninen T, Backman JT, Kurkinen KJ. et al. Itraconazole, a P-glycoprotein and CYP3A4 inhibitor, markedly raises the plasma concentrations and enhances the renin-inhibiting effect of aliskiren. J Clin Pharmacol 2011; 51: 359-367
  CrossrefPubMedGoogle Scholar
• 1174 Taright N, Mentre F, Mallet A. et al. Nonparametric estimation of population characteristics of the kinetics of lithium from observational and experimental data: Individualization of chronic dosing regimen using a new Bayesian approach. Ther Drug Monit 1994; 16: 258-269
  CrossrefPubMedGoogle Scholar
• 1175 Tasker TC, Kaye CM, Zussman BD. et al. Paroxetine plasma levels: lack of correlation with efficacy or adverse events. Acta Psychiatr Scand Suppl 1989; 350: 152-155
  PubMedGoogle Scholar
• 1176 Tateishi T, Watanabe M, Kumai T. et al. CYP3A is responsible for N-dealkylation of haloperidol and bromperidol and oxidation of their reduced forms by human liver microsomes. Life Sci 2000; 67: 2913-2920
  CrossrefPubMedGoogle Scholar
• 1177 Taurines R, Burger R, Wewetzer C. et al. The relation between dosage, serum concentrations, and clinical outcome in children and adolescents treated with sertraline: A naturalistic study. Ther Drug Monit 2013; 35: 84-91
  CrossrefPubMedGoogle Scholar
• 1178 Taylor D. Antidepressant drugs and cardiovascular pathology: A clinical overview of effectiveness and safety. Acta Psychiatr Scand 2008; 118: 434-442
  CrossrefPubMedGoogle Scholar
• 1179 Taylor D. Psychopharmacology and adverse effects of antipsychotic long-acting injections: A review. Br J Psychiatry Suppl 2009; 52: S13-S19
  PubMedGoogle Scholar
• 1180 Taylor G, Houston JB, Shaffer J. et al. Pharmacokinetics of promethazine and its sulphoxide metabolite after intravenous and oral administration to man. Br J Clin Pharmacol 1983; 15: 287-293
  CrossrefPubMedGoogle Scholar
• 1181 Taylor MJ, Sen S, Bhagwagar Z. Antidepressant response and the serotonin transporter gene-linked polymorphic region. Biol Psychiatry 2010; 68: 536-543
  CrossrefPubMedGoogle Scholar
• 1182 Temesvari M, Kobori L, Paulik J. et al. Estimation of drug-metabolizing capacity by cytochrome P450 genotyping and expression. J Pharmacol Exp Ther 2012; 341: 294-305
  CrossrefPubMedGoogle Scholar
• 1183 Tetrault JM, McCance-Katz EF, Moody DE. et al. The impact of recent cocaine use on plasma levels of methadone and buprenorphine in patients with and without HIV-infection. J Subst Abuse Treat 2015; 51: 70-74
  CrossrefPubMedGoogle Scholar
• 1184 Thanacoody RH, Daly AK, Reilly JG. et al. Factors affecting drug concentrations and QT interval during thioridazine therapy. Clin Pharmacol Ther 2007; 82: 555-565
  CrossrefPubMedGoogle Scholar
• 1185 Theisen FM, Haberhausen M, Schulz E. et al. Serum levels of olanzapine and its N-desmethyl and 2-hydroxymethyl metabolites in child and adolescent psychiatric disorders: Effects of dose, diagnosis, age, sex, smoking, and comedication. Ther Drug Monit 2006; 28: 750-759
  CrossrefPubMedGoogle Scholar
• 1186 Theunissen EL, Street D, Hojer AM. et al. A randomized trial on the acute and steady-state effects of a new antidepressant, vortioxetine (Lu AA21004), on actual driving and cognition. Clin Pharmacol Ther 2013; 93: 493-501
  CrossrefPubMedGoogle Scholar
• 1187 Thieme D, Rolf B, Sachs H. et al. Correlation of inter-individual variations of amitriptyline metabolism examined in hairs with CYP2C19 and CYP2D6 polymorphisms. Int J Legal Med 2008; 122: 149-155
  CrossrefPubMedGoogle Scholar
• 1188 Tianmei S, Knadler MP, Lim MT. et al. Pharmacokinetics and tolerability of duloxetine following oral administration to healthy Chinese subjects. Clin Pharmacokinet 2007; 46: 767-775
  CrossrefPubMedGoogle Scholar
• 1189 Timmer CJ, Sitsen JM, Delbressine LP. Clinical pharmacokinetics of mirtazapine. Clin Pharmacokinet 2000; 38: 461-474
  CrossrefPubMedGoogle Scholar
• 1190 Tiseo PJ, Rogers SL, Friedhoff LT. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following evening administration. Br J Clin Pharmacol 1998; 46 (Suppl. 01) 13-18
  CrossrefPubMedGoogle Scholar
• 1191 Titier K, Canal M, Deridet E. et al. Determination of myocardium to plasma concentration ratios of five antipsychotic drugs: Comparison with their ability to induce arrhythmia and sudden death in clinical practice. Toxicol Appl Pharmacol 2004; 199: 52-60
  CrossrefPubMedGoogle Scholar
• 1192 Toennes SW, Maurer HH. Microsoft Excel in pharmacokinetics – an easy way to solve kinetic problems in clinical toxicology, legal medicine or doping control. In: Sachs H, Bernhard W, Jeger A. (eds.) Proceedings of the 34th International TIAFT Meeting, Interlaken. 11–15 August 1996. Leipzig: Molina; 1997: 201–204
  PubMed
• 1193 Tokairin T, Fukasawa T, Yasui-Furukori N. et al. Inhibition of the metabolism of brotizolam by erythromycin in humans: In vivo evidence for the involvement of CYP3A4 in brotizolam metabolism. Br J Clin Pharmacol 2005; 60: 172-175
  CrossrefPubMedGoogle Scholar
• 1194 Tokunaga H, Kudo K, Imamura T. et al. Plasma concentrations of antipsychotic drugs in psychiatric inpatients. Nihon Hoigaku Zasshi 1997; 51: 417-422
  PubMedGoogle Scholar
• 1195 Tolbert D, Bekersky I, Chu HM. et al. An integrative population pharmacokinetics approach to the characterization of the effect of hepatic impairment on clobazam pharmacokinetics. J Clin Pharmacol 2016; 56: 213-222
  CrossrefPubMedGoogle Scholar
• 1196 Tomita T, Yasui-Furukori N, Nakagami T. et al. Therapeutic reference range for plasma concentrations of paroxetine in patients with major depressive disorders. Ther Drug Monit 2014; 36: 480-485
  CrossrefPubMedGoogle Scholar
• 1197 Tompson DJ, Crean CS. Clinical pharmacokinetics of retigabine/ezogabine. Curr Clin Pharmacol 2013; 8: 319-331
  CrossrefPubMedGoogle Scholar
• 1198 Tompson DJ, Vearer D. Steady-state pharmacokinetic properties of a 24-hour prolonged-release formulation of ropinirole: Results of two randomized studies in patients with Parkinson’s disease. Clin Ther 2007; 29: 2654-2666
  CrossrefPubMedGoogle Scholar
• 1199 Tomson T. Landmark CJ, Battino D. Antiepileptic drug treatment in pregnancy: Changes in drug disposition and their clinical implications. Epilepsia 2013; 54: 405-414
  CrossrefPubMedGoogle Scholar
• 1200 Topinkova E, Baeyens JP, Michel JP. et al. Evidence-based strategies for the optimization of pharmacotherapy in older people. Drugs Aging 2012; 29: 477-494
  CrossrefPubMedGoogle Scholar
• 1201 Topiwala A, Fazel S. The pharmacological management of violence in schizophrenia: a structured review. Expert Rev Neurother 2011; 11: 53-63
  CrossrefPubMedGoogle Scholar
• 1202 Tornio A, Neuvonen PJ, Backman JT. The CYP2C8 inhibitor gemfibrozil does not increase the plasma concentrations of zopiclone. Eur J Clin Pharmacol 2006; 62: 645-651
  CrossrefPubMedGoogle Scholar
• 1203 Totah RA, Sheffels P, Roberts T. et al. Role of CYP2B6 in stereoselective human methadone metabolism. Anesthesiology 2008; 108: 363-374
  CrossrefPubMedGoogle Scholar
• 1204 Touw DJ, Neef C, Thomson AH. et al. Cost-effectiveness of therapeutic drug monitoring: A systematic review. Ther Drug Monit 2005; 27: 10-17
  CrossrefPubMedGoogle Scholar
• 1205 Traugott KA, Maxwell PR, Green K. et al. Effects of therapeutic drug monitoring criteria in a computerized prescriber-order-entry system on the appropriateness of vancomycin level orders. Am J Health Syst Pharm 2011; 68: 347-352
  CrossrefPubMedGoogle Scholar
• 1206 Trivedi MH, Rush AJ, Gaynes BN. et al. Maximizing the adequacy of medication treatment in controlled trials and clinical practice: STAR(*)D measurement-based care. Neuropsychopharmacology 2007; 32: 2479-2489
  CrossrefPubMedGoogle Scholar
• 1207 Tsai MH, Lin KM, Hsiao MC. et al. Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response. Pharmacogenomics 2010; 11: 537-546
  CrossrefPubMedGoogle Scholar
• 1208 Tuerck D, Appel-Dingemanse S, Maboudian M. et al. Dose-proportional pharmacokinetics of d-threo-methylphenidate after a repeated-action release dosage form. J Clin Pharmacol 2007; 47: 64-69
  CrossrefPubMedGoogle Scholar
• 1209 Tuerck D, Wang Y, Maboudian M. et al. Similar bioavailability of dexmethylphenidate extended (bimodal) release, dexmethyl-phenidate immediate release and racemic methylphenidate extended (bimodal) release formulations in man. Int J. Clin Pharmacol Ther 2007; 45: 662-668
  CrossrefPubMedGoogle Scholar
• 1210 Turbott J, Norman TR, Burrows GD. et al. Pharmacokinetics of nortriptyline in elderly volunteers. Commun Psychopharmacol 1980; 4: 225-231
  PubMedGoogle Scholar
• 1211 Turpeinen M, Koivuviita N, Tolonen A. et al. Effect of renal impairment on the pharmacokinetics of bupropion and its metabolites. Br J Clin Pharmacol 2007; 64: 165-173
  CrossrefPubMedGoogle Scholar
• 1212 Uchida H, Mamo DC, Mulsant BH. et al. Increased antipsychotic sensitivity in elderly patients: Evidence and mechanisms. J Clin Psychiatry 2009; 70: 397-405
  CrossrefPubMedGoogle Scholar
• 1213 Uchida H, Suzuki T, Graff-Guerrero A. et al. Therapeutic window for striatal dopamine D(2/3) receptor occupancy in older patients with schizophrenia: A pilot PET study. Am J Geriatr Psychiatry 2014; 22: 1007-1016
  CrossrefPubMedGoogle Scholar
• 1214 Ufer M, von Stulpnagel C, Muhle H. et al. Impact of ABCC2 genotype on antiepileptic drug response in Caucasian patients with childhood epilepsy. Pharmacogenet Genomics 2011; 21: 624-630
  CrossrefPubMedGoogle Scholar
• 1215 Uhr M, Grauer MT, Holsboer F. Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption. Biol Psychiatry 2003; 54: 840-846
  CrossrefPubMedGoogle Scholar
• 1216 Uhr M, Steckler T, Yassouridis A. et al. Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption. Neuropsychopharmacology 2000; 22: 380-387
  CrossrefPubMedGoogle Scholar
• 1217 Uhr M, Tontsch A, Namendorf C. et al. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron 2008; 57: 203-209
  CrossrefPubMedGoogle Scholar
• 1218 Ujiie Y, Fukasawa T, Yasui-Furukori N. et al. Rifampicin markedly decreases plasma concentration and hypnotic effect of brotizolam. Ther Drug Monit 2006; 28: 299-302
  CrossrefPubMedGoogle Scholar
• 1219 Ulrich S, Baumann B, Wolf R. et al. Therapeutic drug monitoring of clozapine and relapse–a retrospective study of routine clinical data. Int J Clin Pharmacol Ther 2003; 41: 3-13
  CrossrefPubMedGoogle Scholar
• 1220 Ulrich S, Danos P, Baumann B. et al. Serum concentration of chlormethiazole and therapeutic effect in acute alcohol withdrawal syndrome: An open clinical trial. Ther Drug Monit 2002; 24: 446-454
  CrossrefPubMedGoogle Scholar
• 1221 Ulrich S, Hiemke C, Laux G. et al. Value and actuality of the prescription information for therapeutic drug monitoring of psychopharmaceuticals: A comparison with the medico-scientific evidence. Pharmacopsychiatry 2007; 40: 121-127
  Article in Thieme ConnectPubMedGoogle Scholar
• 1222 Ulrich S, Lauter J. Comprehensive survey of the relationship between serum concentration and therapeutic effect of amitriptyline in depression. Clin Pharmacokinet 2002; 41: 853-876
  CrossrefPubMedGoogle Scholar
• 1223 Ulrich S, Sandmann U, Genz A. Serum concentrations of haloperidol pyridinium metabolites and the relationship with tardive dyskinesia and parkinsonism: A cross-section study in psychiatric patients. Pharmacopsychiatry 2005; 38: 171-177
  Article in Thieme ConnectPubMedGoogle Scholar
• 1224 Ulrich S, Wurthmann C, Brosz M. et al. The relationship between serum concentration and therapeutic effect of haloperidol in patients with acute schizophrenia. Clin Pharmacokinet 1998; 34: 227-263
  CrossrefPubMedGoogle Scholar
• 1225 Unholzer S, Haen E. Retrospective analysis of therapeutic drug monitoring data for treatment of bipolar disorder with lamotrigine. Pharmacopsychiatry 2015; 48: 211-214
  Article in Thieme ConnectPubMedGoogle Scholar
• 1226 Unterecker S, Deckert J, Pfuhlmann B. No influence of body weight on serum levels of antidepressants. Ther Drug Monit 2011; 33: 730-734
  CrossrefPubMedGoogle Scholar
• 1227 Unterecker S, Pfuhlmann B, Kopf J. et al. Increase of heart rate and QTc by amitriptyline, but not by venlafaxine, is correlated to serum concentration. J Clin Psychopharmacol 2015; 35: 460-463
  PubMedGoogle Scholar
• 1228 Unterecker S, Riederer P, Proft F. et al. Effects of gender and age on serum concentrations of antidepressants under naturalistic conditions. J Neural Transm (Vienna) 2013; 120: 1237-1246
  CrossrefPubMedGoogle Scholar
• 1229 Valdes Jr R, Payne DA, Linder MW. (eds.) Laboratory medicine practice guidelines and recommendations for laboratory analysis and application of pharmacogenetics to clinical practice. Washington, DC: National Academy of Clinical Biochemistry; 2010
  Google Scholar
• 1230 van den Anker JN. Developmental pharmacology. Dev Disabil Res Rev 2010; 16: 233-238
  CrossrefPubMedGoogle Scholar
• 1231 van der Lee MJ, Blenke AA, Rongen GA. et al. Interaction study of the combined use of paroxetine and fosamprenavir-ritonavir in healthy subjects. Antimicrob Agents Chemother 2007; 51: 4098-4104
  CrossrefPubMedGoogle Scholar
• 1232 van der Weide J, Steijns LS, van Weelden MJ. The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirement. Pharmacogenetics 2003; 13: 169-172
  CrossrefPubMedGoogle Scholar
• 1233 van der Weide J, van Baalen-Benedek EH, Kootstra-Ros JE. Metabolic ratios of psychotropics as indication of cytochrome P450 2D6/2C19 genotype. Ther Drug Monit 2005; 27: 478-483
  CrossrefPubMedGoogle Scholar
• 1234 van Gerven JM, Uchida E, Uchida N. et al. Pharmacodynamics and pharmacokinetics of a single oral dose of nitrazepam in healthy volunteers: an interethnic comparative study between Japanese and European volunteers. J Clin Pharmacol 1998; 38: 1129-1136
  PubMedGoogle Scholar
• 1235 van Gorp F, Whyte IM, Isbister GK. Clinical and ECG effects of escitalopram overdose. Ann Emerg Med 2009; 54: 404-408
  CrossrefPubMedGoogle Scholar
• 1236 van Hasselt FM, Coehorst Y, Wilffert B. et al. Influencing CYP enzymes to boost psychiatric treatment: A review on clinical evidence. Pharmacopsychiatry 2013; 46: 43-46
  Article in Thieme ConnectPubMedGoogle Scholar
• 1237 Van Putten T, Marder SR, Wirshing WC. et al. Neuroleptic plasma levels. Schizophr Bull 1991; 17: 197-216
  CrossrefPubMedGoogle Scholar
• 1238 van Rongen A, Kervezee L, Brill M. et al. Population Pharmacokinetic Model Characterizing 24-Hour Variation in the Pharmacokinetics of Oral and Intravenous Midazolam in Healthy Volunteers. CPT Pharmacometrics Syst Pharmacol 2015; 4: 454-464
  CrossrefPubMedGoogle Scholar
• 1239 van Steveninck AL, Wallnofer AE, Schoemaker RC. et al. A study of the effects of long-term use on individual sensitivity to temazepam and lorazepam in a clinical population. Br J Clin Pharmacol 1997; 44: 267-275
  CrossrefPubMedGoogle Scholar
• 1240 Vandenberghe F, Guidi M, Choong E. et al. Genetics-Based Population Pharmacokinetics and Pharmacodynamics of Risperidone in a Psychiatric Cohort. Clin Pharmacokinet 2015; 54: 1259-1272
  CrossrefPubMedGoogle Scholar
• 1241 VanderZwaag C, McGee M, McEvoy JP. et al. Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges. Am J Psychiatry 1996; 153: 1579-1584
  CrossrefPubMedGoogle Scholar
• 1242 Varsaldi F, Miglio G, Scordo MG. et al. Impact of the CYP2D6 polymorphism on steady-state plasma concentrations and clinical outcome of donepezil in Alzheimer’s disease patients. Eur J Clin Pharmacol 2006; 62: 721-726
  CrossrefPubMedGoogle Scholar
• 1243 Vasudev K, Das S, Goswami U. et al. Pharmacokinetics of valproic acid in patients with bipolar disorder. J Psychopharmacol 2001; 15: 187-190
  CrossrefPubMedGoogle Scholar
• 1244 Vasudev K, Goswami U, Kohli K. Carbamazepine and valproate monotherapy: Feasibility, relative safety and efficacy, and therapeutic drug monitoring in manic disorder. Psychopharmacology (Berl) 2000; 150: 15-23
  CrossrefPubMedGoogle Scholar
• 1245 Veefkind AH, Haffmans PM, Hoencamp E. Venlafaxine serum levels and CYP2D6 genotype. Ther Drug Monit 2000; 22: 202-208
  CrossrefPubMedGoogle Scholar
• 1246 Velligan DI, Lam YW, Glahn DC. et al. Defining and assessing adherence to oral antipsychotics: A review of the literature. Schizophr Bull 2006; 32: 724-742
  PubMedGoogle Scholar
• 1247 Velligan DI, Weiden PJ, Sajatovic M. et al. Assessment of adherence problems in patients with serious and persistent mental illness: recommendations from the Expert Consensus Guidelines. J Psychiatr Pract 2010; 16: 34-45
  CrossrefPubMedGoogle Scholar
• 1248 Venkatakrishnan K, Culm KE, Ehrenberg BL. et al. Kinetics and dynamics of intravenous adinazolam, N-desmethyl adinazolam, and alprazolam in healthy volunteers. J Clin Pharmacol 2005; 45: 529-537
  CrossrefPubMedGoogle Scholar
• 1249 Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Nortriptyline E-10-hydroxylation in vitro is mediated by human CYP2D6 (high affinity) and CYP3A4 (low affinity): Implications for interactions with enzyme-inducing drugs. J Clin Pharmacol 1999; 39: 567-577
  CrossrefPubMedGoogle Scholar
• 1250 Vermeir M, Naessens I, Remmerie B. et al. Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans. Drug Metab Dispos 2008; 36: 769-779
  CrossrefPubMedGoogle Scholar
• 1251 Vernaleken I, Fellows C, Janouschek H. et al. Striatal and extrastriatal D2/D3-receptor-binding properties of ziprasidone: a positron emission tomography study with [18F]Fallypride and [11C]raclopride (D2/D3-receptor occupancy of ziprasidone). J Clin Psychopharmacol 2008; 28: 608-617
  CrossrefPubMedGoogle Scholar
• 1252 Vernaleken I, Janouschek H, Raptis M. et al. Dopamine D2/3 receptor occupancy by quetiapine in striatal and extrastriatal areas. Int J Neuropsychopharmacol 2010; 13: 951-960
  CrossrefPubMedGoogle Scholar
• 1253 Vernaleken I, Siessmeier T, Buchholz HG. et al. High striatal occupancy of D2-like dopamine receptors by amisulpride in the brain of patients with schizophrenia. Int J Neuropsychopharmacol 2004; 7: 421-430
  CrossrefPubMedGoogle Scholar
• 1254 Verster JC, Roth T. Blood drug concentrations of benzodiazepines correlate poorly with actual driving impairment. Sleep Med Rev 2013; 17: 153-159
  CrossrefPubMedGoogle Scholar
• 1255 Verthein U, Ullmann R, Lachmann A. et al. The effects of racemic D,L-methadone and L-methadone in substituted patients–a randomized controlled study. Drug Alcohol Depend 2005; 80: 267-271
  CrossrefPubMedGoogle Scholar
• 1256 Ververs FF, Voorbij HA, Zwarts P. et al. Effect of cytochrome P450 2D6 genotype on maternal paroxetine plasma concentrations during pregnancy. Clin Pharmacokinet 2009; 48: 677-683
  CrossrefPubMedGoogle Scholar
• 1257 Veselinovic T, Paulzen M, Gründer G. Cariprazine, a new, orally active dopamine D2/3 receptor partial agonist for the treatment of schizophrenia, bipolar mania and depression. Expert Rev Neurother 2013; 13: 1141-1159
  CrossrefPubMedGoogle Scholar
• 1258 Vevelstad M, Pettersen S, Tallaksen C. et al. O-demethylation of codeine to morphine inhibited by low-dose levomepromazine. Eur J Clin Pharmacol 2009; 65: 795-801
  CrossrefPubMedGoogle Scholar
• 1259 Vezmar S, Miljkovic B, Vucicevic K. et al. Pharmacokinetics and efficacy of fluvoxamine and amitriptyline in depression. J Pharmacol Sci 2009; 110: 98-104
  CrossrefPubMedGoogle Scholar
• 1260 Viala A, Ba B, Durand A. et al. Comparative study of the pharmacokinetics of zuclopenthixol decanoate and fluphenazine decanoate. Psychopharmacology (Berl) 1988; 94: 293-297
  PubMedGoogle Scholar
• 1261 Vickers S, Stuart EK, Hucker HB. Further studies on the metabolism of carbidopa, (minus)-L-alpha-hydrazino-3,4-dihydroxy-alpha-methylbenzenepropanoic acid monohydrate, in the human, Rhesus monkey, dog, and rat. J Med Chem 1975; 18: 134-138
  CrossrefPubMedGoogle Scholar
• 1262 Videla S, Cebrecos J, Lahjou M. et al. Pharmacokinetic dose proportionality between two strengths (12.5 mg and 25 mg) of doxylamine hydrogen succinate film-coated tablets in fasting state: A single-dose, randomized, two-period crossover study in healthy volunteers. Drugs R D 2013; 13: 129-135
  CrossrefPubMedGoogle Scholar
• 1263 Viola MS, Bercellini MA, Saidon P. et al. [Pharmacokinetic variability of oxcarbazepine in epileptic patients]. Medicina (B Aires) 2000; 60: 914-918
  PubMedGoogle Scholar
• 1264 Vogel F, Gansmüller R, Leiblein T. et al. The use of ziprasidone in clinical practice: Analysis of pharmacokinetic and pharmacodynamic aspects from data of a drug monitoring survey. Eur Psychiatry 2009; 24: 143-148
  CrossrefPubMedGoogle Scholar
• 1265 Voineskos AN, Wilson AA, Boovariwala A. et al. Serotonin transporter occupancy of high-dose selective serotonin reuptake inhibitors during major depressive disorder measured with [11C]DASB positron emission tomography. Psychopharmacology (Berl) 2007; 193: 539-545
  CrossrefPubMedGoogle Scholar
• 1266 von Hentig N, Lotsch J. Cytochrome P450 3A inhibition by atazanavir and ritonavir, but not demography or drug formulation, influences saquinavir population pharmacokinetics in human immunodeficiency virus type 1-infected adults. Antimicrob Agents Chemother 2009; 53: 3524-3527
  CrossrefPubMedGoogle Scholar
• 1267 von Knorring L, Akerblad AC, Bengtsson F. et al. Cost of depression: effect of adherence and treatment response. Eur Psychiatry 2006; 21: 349-354
  CrossrefPubMedGoogle Scholar
• 1268 von Moltke LL, Greenblatt DJ, Giancarlo GM. et al. Escitalopram (S-citalopram) and its metabolites in vitro: Cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug Metab Dispos 2001; 29: 1102-1109
  PubMedGoogle Scholar
• 1269 Von Moltke LL, Greenblatt DJ, Granda BW. et al. Zolpidem metabolism in vitro: Responsible cytochromes, chemical inhibitors, and in vivo correlations. Br J Clin Pharmacol 1999; 48: 89-97
  CrossrefPubMedGoogle Scholar
• 1270 von Moltke LL, Greenblatt DJ, Grassi JM. et al. Protease inhibitors as inhibitors of human cytochromes P450: High risk associated with ritonavir. J Clin Pharmacol 1998; 38: 106-111
  CrossrefPubMedGoogle Scholar
• 1271 Vormfelde SV, Bitsch A, Meineke I. et al. Non-response to maprotiline caused by ultra-rapid metabolism that is different from CYP2D6?. Eur J Clin Pharmacol 1997; 52: 387-390
  CrossrefPubMedGoogle Scholar
• 1272 Vuille F, Amey M, Baumann P. Use of plasma level monitoring of antidepressants in clinical practice. Towards an analysis of clinical utility. Pharmacopsychiatry 1991; 24: 190-195
  Article in Thieme ConnectPubMedGoogle Scholar
• 1273 Waade RB, Christensen H, Rudberg I. et al. Influence of comedication on serum concentrations of aripiprazole and dehydroaripiprazole. Ther Drug Monit 2009; 31: 233-238
  CrossrefPubMedGoogle Scholar
• 1274 Waldschmitt C, Vogel F, Pfuhlmann B. et al. Duloxetine serum concentrations and clinical effects. Data from a therapeutic drug monitoring (TDM) survey. Pharmacopsychiatry 2009; 42: 189-193
  Article in Thieme ConnectPubMedGoogle Scholar
• 1275 Wan J, Xia H, He N. et al. The elimination of diazepam in Chinese subjects is dependent on the mephenytoin oxidation phenotype. Br J Clin Pharmacol 1996; 42: 471-474
  CrossrefPubMedGoogle Scholar
• 1276 Wang JH, Liu ZQ, Wang W. et al. Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19. Clin Pharmacol Ther 2001; 70: 42-47
  CrossrefPubMedGoogle Scholar
• 1277 Wang JS, Zhu HJ, Markowitz JS. et al. Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology (Berl) 2006; 187: 415-423
  CrossrefPubMedGoogle Scholar
• 1278 Wang JS, Zhu HJ, Markowitz JS. et al. Antipsychotic drugs inhibit the function of breast cancer resistance protein. Basic Clin Pharmacol Toxicol 2008; 103: 336-341
  CrossrefPubMedGoogle Scholar
• 1279 Wang P, Yin T, Ma HY. et al. First analysis of the association between CYP3A4/5, ABCB1 genetic polymorphisms and oxcarbazepine metabolism and transport in chinese epileptic patients with oxcarbazepine monotherapy and bitherapy. J Pharm Pharm Sci 2015; 18: 256-265
  CrossrefPubMedGoogle Scholar
• 1280 Wang P, Yin T, Ma HY. et al. Effects of CYP3A4/5 and ABCB1 genetic polymorphisms on carbamazepine metabolism and transport in Chinese patients with epilepsy treated with carbamazepine in monotherapy and bitherapy. Epilepsy Res 2015; 117: 52-57
  CrossrefPubMedGoogle Scholar
• 1281 Wang Q, Zhao L, Liang M. et al. Effects of UGT2B7 genetic polymorphisms on serum concentrations of valproic acid in chinese children with epilepsy comedicated with lamotrigine. Ther Drug Monit 2016; 38: 343-349
  CrossrefPubMedGoogle Scholar
• 1282 Wang Y, Zhang H, Meng L. et al. Influence of CYP2C19 on the relationship between pharmacokinetics and intragastric pH of omeprazole administered by successive intravenous infusions in Chinese healthy volunteers. Eur J Clin Pharmacol 2010; 66: 563-569
  CrossrefPubMedGoogle Scholar
• 1283 Ward ME, Musa MN, Bailey L. Clinical pharmacokinetics of lithium. J Clin Pharmacol 1994; 34: 280-285
  CrossrefPubMedGoogle Scholar
• 1284 Wattmo C, Jedenius E, Blennow K. et al. Dose and plasma concentration of galantamine in Alzheimer’s disease – clinical application. Alzheimers Res Ther 2013; 5: 2
  CrossrefPubMedGoogle Scholar
• 1285 Weber J, McCormack PL, Asenapine CNS. Drugs 2009; 23: 781-792
  PubMed
• 1286 Weiden PJ, Kozma C, Grogg A. et al. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 2004; 55: 886-891
  CrossrefPubMedGoogle Scholar
• 1287 Weigmann H, Bierbrauer J, Härtter S. et al. Automated determination of clozapine and major metabolites in serum and urine. Ther Drug Monit 1997; 19: 480-488
  CrossrefPubMedGoogle Scholar
• 1288 Weigmann H, Härtter S, Hiemke C. Automated determination of clomipramine and its major metabolites in human and rat serum by high-performance liquid chromatography with on-line column-switching. J Chromatogr B Biomed Sci Appl 1998; 710: 227-233
  CrossrefPubMedGoogle Scholar
• 1289 Weigmann H, Härtter S, Maehrlein S. et al. Simultaneous determination of olanzapine, clozapine and demethylated metabolites in serum by on-line column-switching high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 2001; 759: 63-71
  CrossrefPubMedGoogle Scholar
• 1290 Weintraub D, Buchsbaum R, Spencer H. et al. Tolerability of Levetiracetam in 516 patients: analysis by dose and serum concentration. Epilepsia 2004; 45 (Suppl. 03) 68
  PubMedGoogle Scholar
• 1291 Weiss RD, Griffin ML, Potter JS. et al. Who benefits from additional drug counseling among prescription opioid-dependent patients receiving buprenorphine-naloxone and standard medical management?. Drug Alcohol Depend 2014; 140: 118-122
  CrossrefPubMedGoogle Scholar
• 1292 Weiss U, Marksteiner J, Kemmler G. et al. Effects of age and sex on olanzapine plasma concentrations. J Clin Psychopharmacol 2005; 25: 570-574
  CrossrefPubMedGoogle Scholar
• 1293 Wen B, Ma L, Zhu M. Bioactivation of the tricyclic antidepressant amitriptyline and its metabolite nortriptyline to arene oxide intermediates in human liver microsomes and recombinant P450s. Chem Biol Interact 2008; 173: 59-67
  CrossrefPubMedGoogle Scholar
• 1294 Wen B, Zhou M. Metabolic activation of the phenothiazine antipsychotics chlorpromazine and thioridazine to electrophilic iminoquinone species in human liver microsomes and recombinant P450s. Chem Biol Interact 2009; 181: 220-226
  CrossrefPubMedGoogle Scholar
• 1295 Wenzel-Seifert K, Brandl R, Hiemke C. et al. Influence of concomitant medications on the total clearance and the risk for supra-therapeutic plasma concentrations of Citalopram. A population-based cohort study. Pharmacopsychiatry 2014; 47: 239-244
  Article in Thieme ConnectPubMedGoogle Scholar
• 1296 Wessels AM, Bies RR, Pollock BG. et al. Population pharmacokinetic modeling of ziprasidone in patients with schizophrenia from the CATIE study. J Clin Pharmacol 2011; 51: 1587-1591
  CrossrefPubMedGoogle Scholar
• 1297 White N, Litovitz T, Clancy C. Suicidal antidepressant overdoses: a comparative analysis by antidepressant type. J Med Toxicol 2008; 4: 238-250
  CrossrefPubMedGoogle Scholar
• 1298 Whitney Z, Boyda HN, Procyshyn RM. et al. Therapeutic drug levels of second generation antipsychotics in youth: a systematic review. J Child Adolesc Psychopharmacol 2015; 25: 234-245
  CrossrefPubMedGoogle Scholar
• 1299 Wienkers LC, Allievi C, Hauer MJ. et al. Cytochrome P-450-mediated metabolism of the individual enantiomers of the antidepressant agent reboxetine in human liver microsomes. Drug Metab Dispos 1999; 27: 1334-1340
  PubMedGoogle Scholar
• 1300 Wiesel FA, Alfredsson G, Ehrnebo M. et al. The pharmacokinetics of intravenous and oral sulpiride in healthy human subjects. Eur J Clin Pharmacol 1980; 17: 385-391
  CrossrefPubMedGoogle Scholar
• 1301 Wigal SB, Gupta S, Heverin E. et al. Pharmacokinetics and therapeutic effect of OROS methylphenidate under different breakfast conditions in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2011; 21: 255-263
  CrossrefPubMedGoogle Scholar
• 1302 Wilczynski S, Koprowski R, Blonska-Fajfrowska B. Directional reflectance analysis for identifying counterfeit drugs: Preliminary study. J Pharm Biomed Anal 2016; 124: 341-346
  CrossrefPubMedGoogle Scholar
• 1303 Wilhelm AJ, den Burger JC, Swart EL. Therapeutic drug monitoring by dried blood spot: Progress to date and future directions. Clin Pharmacokinet 2014; 53: 961-973
  CrossrefPubMedGoogle Scholar
• 1304 Wille SM, Cooreman SG, Neels HM. et al. Relevant issues in the monitoring and the toxicology of antidepressants. Crit Rev Clin Lab Sci 2008; 45: 25-89
  CrossrefPubMedGoogle Scholar
• 1305 Willmore LJ, Abelson MB, Ben-Menachem E. et al. Vigabatrin: 2008 update. Epilepsia 2009; 50: 163-173
  CrossrefPubMedGoogle Scholar
• 1306 Wilson JF. Survey of reference ranges and clinical measurements for psychoactive drugs in serum. Ther Drug Monit 2003; 25: 243-247
  CrossrefPubMedGoogle Scholar
• 1307 Wilting I, Heerdink ER, Mersch PP. et al. Association between lithium serum level, mood state, and patient-reported adverse drug reactions during long-term lithium treatment: A naturalistic follow-up study. Bipolar Disord 2009; 11: 434-440
  CrossrefPubMedGoogle Scholar
• 1308 Wimmer S, Neubert A, Rascher W. The Safety of Drug Therapy in Children. Dtsch Arztebl Int 2015; 112: 781-787
  CrossrefPubMedGoogle Scholar
• 1309 Winblad B, Grossberg G, Frolich L. et al. IDEAL: A 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease. Neurology 2007; 69: S14-S22
  CrossrefPubMedGoogle Scholar
• 1310 Wincor MZ, Munjack DJ, Palmer R. Alprazolam levels and response in panic disorder: Preliminary results. J Clin Psychopharmacol 1991; 11: 48-51
  PubMedGoogle Scholar
• 1311 Windhager E, Kim SW, Saria A. et al. Perinatal use of aripiprazole: plasma levels, placental transfer, and child outcome in 3 new cases. J Clin Psychopharmacol 2014; 34: 637-641
  CrossrefPubMedGoogle Scholar
• 1312 Winter HR, Earley WR, Hamer-Maansson JE. et al. Steady-state pharmacokinetic, safety, and tolerability profiles of quetiapine, norquetiapine, and other quetiapine metabolites in pediatric and adult patients with psychotic disorders. J Child Adolesc Psychopharmacol 2008; 18: 81-98
  CrossrefPubMedGoogle Scholar
• 1313 Wire MB, Shelton MJ, Studenberg S. Fosamprenavir : Clinical pharmacokinetics and drug interactions of the amprenavir prodrug. Clin Pharmacokinet 2006; 45: 137-168
  CrossrefPubMedGoogle Scholar
• 1314 Wohkittel C, Gerlach M, Taurines R. et al. Relationship between clozapine dose, serum concentration, and clinical outcome in children and adolescents in clinical practice. J Neural Transm (Vienna) 2016; 123: 1021-1031
  CrossrefPubMedGoogle Scholar
• 1315 Wojcikowski J, Basinska A, Daniel WA. The cytochrome P450-catalyzed metabolism of levomepromazine: A phenothiazine neuroleptic with a wide spectrum of clinical application. Biochem Pharmacol 2014; 90: 188-195
  CrossrefPubMedGoogle Scholar
• 1316 Wojcikowski J, Boksa J, Daniel WA. Main contribution of the cytochrome P450 isoenzyme 1A2 (CYP1A2) to N-demethylation and 5-sulfoxidation of the phenothiazine neuroleptic chlorpromazine in human liver–A comparison with other phenothiazines. Biochem Pharmacol 2010; 80: 1252-1259
  CrossrefPubMedGoogle Scholar
• 1317 Wojcikowski J, Daniel WA. Perazine at therapeutic drug concentrations inhibits human cytochrome P450 isoenzyme 1A2 (CYP1A2) and caffeine metabolism–an in vitro study. Pharmacol Rep 2009; 61: 851-858
  CrossrefPubMedGoogle Scholar
• 1318 Wojcikowski J, Pichard-Garcia L, Maurel P. et al. Contribution of human cytochrome p-450 isoforms to the metabolism of the simplest phenothiazine neuroleptic promazine. Br J Pharmacol 2003; 138: 1465-1474
  CrossrefPubMedGoogle Scholar
• 1319 Wolff K, Hay AW, Raistrick D. et al. Steady-state pharmacokinetics of methadone in opioid addicts. Eur J Clin Pharmacol 1993; 44: 189-194
  CrossrefPubMedGoogle Scholar
• 1320 Wolking S, Schaeffeler E, Lerche H. et al. Impact of Genetic Polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on Drug Disposition and Potential Clinical Implications: Update of the Literature. Clin Pharmacokinet 2015; 54: 709-735
  CrossrefPubMedGoogle Scholar
• 1321 Wong SL, Granneman GR. Modeling of sertindole pharmacokinetic disposition in healthy volunteers in short term dose-escalation studies. J Pharm Sci 1998; 87: 1629-1631
  CrossrefPubMedGoogle Scholar
• 1322 Wong SL, Menacherry S, Mulford D. et al. Pharmacokinetics of sertindole and dehydrosertindole in volunteers with normal or impaired renal function. Eur J Clin Pharmacol 1997; 52: 223-227
  CrossrefPubMedGoogle Scholar
• 1323 Wong YN, King SP, Simcoe D. et al. Open-label, single-dose pharmacokinetic study of modafinil tablets: Influence of age and gender in normal subjects. J Clin Pharmacol 1999; 39: 281-288
  PubMedGoogle Scholar
• 1324 Wong YN, Simcoe D, Hartman LN. et al. A double-blind, placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers. J Clin Pharmacol 1999; 39: 30-40
  CrossrefPubMedGoogle Scholar
• 1325 World Haelth Organization. Adherence to long term therapy: evidence for action. 2003; http://www.who.int/hiv/pub/prev_care/ lttherapies/en/ [assessed May 13 2016]
  PubMed
• 1326 Wright CE, Sisson TL, Ichhpurani AK. et al. Steady-state pharmacokinetic properties of pramipexole in healthy volunteers. J Clin Pharmacol 1997; 37: 520-525
  CrossrefPubMedGoogle Scholar
• 1327 Wu MJ, Ing TS, Soung LS. et al. Amantadine hydrochloride pharmacokinetics in patients with impaired renal function. Clin Nephrol 1982; 17: 19-23
  PubMedGoogle Scholar
• 1328 Wu MK, Chung W, Wu CK. et al. The severe complication of Stevens-Johnson syndrome induced by long-term clozapine treatment in a male schizophrenia patient: A case report. Neuropsychiatr Dis Treat 2015; 11: 1039-1041
  PubMedGoogle Scholar
• 1329 Wynalda MA, Wienkers LC. Assessment of potential interactions between dopamine receptor agonists and various human cytochrome P450 enzymes using a simple in vitro inhibition screen. Drug Metab Dispos 1997; 25: 1211-1214
  PubMedGoogle Scholar
• 1330 Xiang Q, Zhao X, Zhou Y. et al. Effect of CYP2D6, CYP3A5, and MDR1 genetic polymorphisms on the pharmacokinetics of risperidone and its active moiety. J Clin Pharmacol 2010; 50: 659-666
  CrossrefPubMedGoogle Scholar
• 1331 Xu M, Zhou Y, Ni Y. et al. Tolerability and pharmacokinetic comparison of oral, intramuscular, and intravenous administration of levosulpiride after single and multiple dosing in healthy chinese volunteers. Clin Ther 2015; 37: 2458-2467
  CrossrefPubMedGoogle Scholar
• 1332 Xu P, Li HD, Zhang BK. et al. Pharmacokinetics and tolerability of modafinil tablets in Chinese subjects. J Clin Pharm Ther 2008; 33: 429-437
  CrossrefPubMedGoogle Scholar
• 1333 Xu RA, Gu EM, Zhou Q. et al. Effects of 22 novel CYP2D6 variants found in Chinese population on the metabolism of dapoxetine. Drug Des Devel Ther 2016; 10: 687-696
  PubMedGoogle Scholar
• 1334 Yao C, Raoufinia A, Gold M. et al. Steady-state pharmacokinetics of galantamine are not affected by addition of memantine in healthy subjects. J Clin Pharmacol 2005; 45: 519-528
  CrossrefPubMedGoogle Scholar
• 1335 Yasui-Furukori N, Nakagami T, Kaneda A. et al. Inverse correlation between clinical response to paroxetine and plasma drug concentration in patients with major depressive disorders. Hum Psychopharmacol 2011; 26: 602-608
  CrossrefPubMedGoogle Scholar
• 1336 Yasui-Furukori N, Saito M, Nakagami T. et al. Clinical response to risperidone in relation to plasma drug concentrations in acutely exacerbated schizophrenic patients. J Psychopharmacol 2010; 24: 987-994
  CrossrefPubMedGoogle Scholar
• 1337 Yasui-Furukori N, Saito M, Nakagami T. et al. Association between multidrug resistance 1 (MDR1) gene polymorphisms and therapeutic response to bromperidol in schizophrenic patients: A preliminary study. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 286-291
  CrossrefPubMedGoogle Scholar
• 1338 Yeung PK, Hubbard JW, Korchinski ED. et al. Pharmacokinetics of chlorpromazine and key metabolites. Eur J Clin Pharmacol 1993; 45: 563-569
  CrossrefPubMedGoogle Scholar
• 1339 Yin OQ, Wing YK, Cheung Y. et al. Phenotype-genotype relationship and clinical effects of citalopram in Chinese patients. J Clin Psychopharmacol 2006; 26: 367-372
  CrossrefPubMedGoogle Scholar
• 1340 Yonkers KA, Kando JC, Cole JO. et al. Gender differences in pharmacokinetics and pharmacodynamics of psychotropic medication. Am J Psychiatry 1992; 149: 587-595
  CrossrefPubMedGoogle Scholar
• 1341 Yu DK, Dimmitt DC, Lanman RC. et al. Pharmacokinetics of dothiepin in humans: A single dose dose-proportionality study. J Pharm Sci 1986; 75: 582-585
  CrossrefPubMedGoogle Scholar
• 1342 Yu Y, Zhang Q, Xu W. et al. Population pharmacokinetic modeling of oxcarbazepine active metabolite in Chinese patients with epilepsy. Eur J Drug Metab Pharmacokinet 2016; 41: 345-351
  CrossrefPubMedGoogle Scholar
• 1343 Zand R, Nelson SD, Slattery JT. et al. Inhibition and induction of cytochrome P4502E1-catalyzed oxidation by isoniazid in humans. Clin Pharmacol Ther 1993; 54: 142-149
  CrossrefPubMedGoogle Scholar
• 1344 Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 2013; 138: 103-141
  CrossrefPubMedGoogle Scholar
• 1345 Zernig G, Hiemke C, Havemann-Reinecke U. et al. Empfehlungen für die gutachterliche Bewertung von Medikamentenspiegeln in der Psychiatrie im gerichtsanhängigen Schadensfall. Psychopharmakotherapie 2009; 16: 57-64
  PubMedGoogle Scholar
• 1346 Zernig G, Lechner T, Kramer-Reinstadler K. et al. What the clinician still has to be reminded of. Ther Drug Monit 2004; 26: 582
  CrossrefPubMedGoogle Scholar
• 1347 Zernig G, Ng K, Hiemke C. et al. Therapeutic drug monitoring-based clozapine dosing recommendations. Ther Drug Monit 2007; 29: 130-131
  CrossrefPubMedGoogle Scholar
• 1348 Zhao Q, Iyer GR, Verhaeghe T. et al. Pharmacokinetics and safety of galantamine in subjects with hepatic impairment and healthy volunteers. J Clin Pharmacol 2002; 42: 428-436
  CrossrefPubMedGoogle Scholar
• 1349 Zhaoxu L, Jingcheng T, Jinnan Z. Rifabutin autoinduction is caused by involvement of cytochrome P450 and cholinesterase. Pharmazie 2008; 63: 156-159
  PubMedGoogle Scholar
• 1350 Zhou D, Bui KH, Li J. et al. Population pharmacokinetic modeling of quetiapine after administration of seroquel and seroquel XR formulations to Western and Chinese patients with schizophrenia, schizoaffective disorder, or bipolar disorder. J Clin Pharmacol 2015; 55: 1248-1255
  CrossrefPubMedGoogle Scholar
• 1351 Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet 2009; 48: 689-723
  CrossrefPubMedGoogle Scholar
• 1352 Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin Pharmacokinet 2009; 48: 761-804
  CrossrefPubMedGoogle Scholar
• 1353 Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 2009; 41: 89-295
  CrossrefPubMedGoogle Scholar
• 1354 Zhu HJ, Wang JS, Donovan JL. et al. Interactions of attention-deficit/hyperactivity disorder therapeutic agents with the efflux transporter P-glycoprotein. Eur J Pharmacol 2008; 578: 148-158
  CrossrefPubMedGoogle Scholar
• 1355 Zingmark PH, Ekblom M, Odergren T. et al. Population pharmacokinetics of clomethiazole and its effect on the natural course of sedation in acute stroke patients. Br J Clin Pharmacol 2003; 56: 173-183
  CrossrefPubMedGoogle Scholar
• 1356 Zullig LL, Peterson ED, Bosworth HB. Ingredients of successful interventions to improve medication adherence. JAMA 2013; 310: 2611-2612
  CrossrefPubMedGoogle Scholar
• 1357 Zullino DF, Delessert D, Eap CB. et al. Tobacco and cannabis smoking cessation can lead to intoxication with clozapine or olanzapine. Int Clin Psychopharmacol 2002; 17: 141-143
  CrossrefPubMedGoogle Scholar
• 1358 Zweben A, Pettinati HM, Weiss RD. et al. Relationship between medication adherence and treatment outcomes: the COMBINE study. Alcohol Clin Exp Res 2008; 32: 1661-1669
  CrossrefPubMedGoogle Scholar